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Resumen 
Las macromoléculas biológicas:  las proteínas, los ácidos nucleicos y los 
hidratos de carbono son los motores principales de la célula viva. La esencia de 
la vida está regulada por las interacciones que se dan entre estas entidades, con 
distintos niveles de complejidad. El conocimiento de su estructura 
tridimensional, su dinámica y la manera en que se relacionan entre ellas y con 
otras moléculas más pequeñas es imprescindible para entender en profundidad 
el funcionamiento de la compleja maquinaria celular. 
Los hidratos de carbono son de las moléculas más variables y complejas 
de los sistemas biológicos. La glicosilación de proteínas y lípidos tiene la 
capacidad inigualable de generar una amplia gama de estructuras diferentes. El 
conocimiento de la comunicación intermolecular, a escala atómica y molecular, 
entre los hidratos de carbono y sus receptores debería llevar al entendimiento y 
modulación de las señales biológicas en eventos fisiológicos y patológicos. 
Existen varias herramientas para obtener información a escala atómica de 
la comunicación de este tipo de moléculas: la espectroscopía de Resonancia 
Magnética Nuclear (RMN), la difracción de rayos X y la crio-microscopía 
electrónica (cryo-EM). También coexisten una legión de técnicas que 
proporcionan información estructural menos detallada, como otras 
espectroscopías (IR, UV, Raman), la microscopía electrónica (EM), o los 
métodos basados en transferencia de energía de resonancia (FRET).  
En este trabajo, empleamos la espectroscopia de Resonancia Magnética 
Nuclear (RMN) para obtener información, a distintas escalas, sobre diferentes 
procesos de reconocimiento molecular entre hidratos de carbono y proteínas con 
interés biomédico. En particular, nos hemos centrado en cáncer (mucina-1 
(MUC1)) estudiando el mecanismo de glicosilación de mucinas por GalNAc-
transferasas (GalNAc-Ts) y en infecciones bacterianas (receptor Toll-like 4 
(TLR4)). 
  iv 
 
Capítulo 1 
En la introducción de esta tesis he proporcionado una visión general de 
las bases de RMN, centrada en la descripción de los métodos de RMN que se 
usan para seguir eventos de reconocimiento molecular.  
El reconocimiento molecular por RMN puede hacerse del punto de vista 
del ligando y/o del receptor. Los experimentos de RMN enfocados en la 
observación de las señales del ligando revelan información clave sobre el 
epítopo de unión del ligando. Uno de los experimentos de RMN más relevantes 
dentro de esta clase es el experimento de diferencia de transferencia de 
saturación (STD-NMR) que se basa en la transferencia de magnetización entre 
el receptor, que es objeto de irradiación selectiva, y aquellos ligandos que, en 
exceso y en régimen de intercambio rápido, se unen a él. 
Entre los métodos basados en la observación de las señales del receptor, 
regularmente proteínas, podemos destacar los experimentos basados en la 
correlación heteronuclear de cuanto simple 1H/15N (1H/15N-HSQC). El HSQC 
proporciona información a nivel atómico para definir con precisión los aminos 
ácidos del sitio de unión. 
 
Objetivos 
El objetivo general de la tesis es aplicar métodos de RMN basados en 
ligandos y receptores para estudiar la interacción de una variedad de hidratos de 
carbono con receptores de interés biológico y / o biomédico. Por lo tanto, un 
objetivo específico ha sido avanzar en la comprensión de las características 
estructurales que gobiernan las interacciones de los hidratos de carbono así 
como determinar de sus epítopos de reconocimiento. 
  v 
Los objetivos específicos se han centrado en: 
- Comprender el mecanismo de acción de GalNAc-Ts. 
- Evaluar las interacciones de diferentes moléculas naturales y sintéticas 
con péptidos antimicrobianos y la proteína MD-2, en el contexto de la 
comprensión de la inmunidad innata relacionada con TLR4. 
 
Capítulo 2 
La gran familia de GalNAc-Ts es responsable de una modificación 
postraduccional de muchas proteínas de la superficie celular. Existen cambios 
de expresión de GalNAc-Ts en las células en el caso de procesos tumorales. 
Así, el ajuste fino de la expresión de GalNAc-Ts regula la glicosilación con O-
GalNAc en ciertas proteínas. Desde esta perspectiva, y usando una combinación 
de métodos de RMN y de modelado molecular, hemos analizado la 
especificidad y dinámica de diversas GalNAc-Ts en el proceso de O-
glicosilación para desentrañar el mecanismo de acción de estas enzimas y 
definir los determinantes moleculares para el reconocimiento de sustrato. 
Así, hemos descubierto que el reconocimiento de GalNAc-Ts sigue un 
mecanismo de ajuste inducido en el que el UDP-GalNAc es absolutamente 
necesario.  También hemos determinado las bases moleculares de las 
preferencias de GalNAc-glicosilación a largo y corto rango para la GalNAc-T4. 
Además, hemos demostrado que las enzimas GalNAc-T2 -T3 y -T4 
tienen un proceso de glicosilación altamente ordenado, en que todas las 
repeticiones en tándem se glicosilan de una manera gradual. La acción 
combinada del dominio de la lectina y el dominio catalítico de esas enzimas es 
esencial para conseguir modificar todos los lugares de glicosilación de MUC1. 
  vi 
Estos estudios son un paso importante para conseguir el diseño racional 
de inhibidores que sirvan para regular la expresión de GalNAc-Ts en 
enfermedades, especialmente en cáncer. 
 
Capítulo 3 
El otro apartado importante de esta tesis se ha centrado en el receptor 
Toll-like 4 (TLR4). TLR4 se expresa en la superficie de las células inmunitarias 
y reconoce específicamente endotoxinas de las bacterias, o sea, 
lipopolisacáridos (LPS) o lipooligosacáridos (LOS), el núcleo molecular de las 
paredes de las bacterias gram-negativas. 
 La modulación de receptores de inmunidad innata por agonistas y/o 
antagonistas con pequeñas moléculas sintéticas permiten controlar la actividad 
biológica del TLR4. Estas moléculas representan una herramienta poderosa 
para estudiar TLR4 y son de gran interés farmacológico como agentes 
antisépticos y antiinflamatorios (antagonistas) o como adyuvantes de vacunas 
(agonistas). El conocimiento de los aspectos moleculares del reconocimiento de 
LPS por CD14 (cluster de diferenciación 14) y por el complejo TLR4/MD-2 
(proteína de diferenciación mieloide 2) es esencial para comprender las 
diferentes respuestas mediadas por TLR4 a diferentes variantes de LPS o a 
moléculas sintéticas. 
En esta tesis nos involucramos en el estudio de estos eventos de 
reconocimiento molecular y caracterización de las estructuras supramoleculares 
de estas moléculas naturales y sintéticas mayoritariamente por métodos RMN y 
de microscopía electrónica. En particular, caracterizamos la interacción entre 
FP7 (antagonista sintético de TLR4) y péptidos antimicrobianos (AMPs) así 
como la agregación de diferentes glicolípidos, naturales y miméticos, por 
técnicas de RMN y TEM (microscopía electrónica de transmisión). 
  vii 
A lo largo de esta Tesis, los aspectos formativos han incluido el uso de 
experimentos de RMN para diseccionar los detalles moleculares de estos 
procesos de reconocimiento biomolecular. Así, se han empleado métodos de 
RMN basados en el ligando y en el receptor, en combinación con una variedad 
de técnicas experimentales y teóricas. Se han usado multitud de herramientas 
biofísicas, bioquímicas, de biología molecular, así como diversas metodologías 
computacionales para complementar los datos de RMN y así obtener una 
descripción más completa de los eventos de interacción. 
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Resumo 
Os hidratos de carbono estão entre as moléculas mais variadas e 
complexas dos sistemas biológicos. O processo de glicosilação é a modificação 
mais complexa de proteínas e lípidos, com uma capacidade inigualável de gerar 
uma ampla gama de estruturas diferentes. O reconhecimento molecular de 
hidratos de carbono por recetores específicos traduz-se em sinais biológicos em 
eventos fisiológicos e patológicos. 
Neste trabalho, aplicamos a espectroscopia de Ressonância Magnética 
Nuclear (RMN) para obter informações estruturais de diferentes processos de 
reconhecimento molecular entre hidratos de carbono e diversas proteínas com 
relevância biomédica. Com principal destaque nos principais aspetos do 
mecanismo de glicosilação da proteína MUC1 pela família de enzimas GalNAc-
Transferases (GalNAc-Ts). Os alvos estudados ao longo desta tese têm impacto 
no cancro (mucina-1 (MUC1)) e infeções bacterianas (recetor Toll-like 4 
(TLR4)).  
 
Capítulo 1 
A introdução desta tese contém uma visão geral das bases de RMN, no 
entanto, focou-se sobretudo em descrever as metodologias de RMN aplicadas 
ao estudo de eventos de reconhecimento molecular. 
Objetivo 
O objetivo global desta tese foi avançar na compreensão das 
características estruturais que conduzem as interações de hidratos de carbono e 
sobretudo na determinação dos seus epítopos de reconhecimento. 
Como objetivos específicos propusemo-nos a: 
  x 
- Compreender o mecanismo de glicosilação orquestrado pelas GalNAc-
Ts. 
- Avaliar as interações de diferentes moléculas naturais e sintéticas com 
peptídeos antimicrobianos e a proteína MD-2, no contexto da compreensão da 
imunidade inata relacionada ao TLR4. 
 
Capítulo 2 
A grande família das enzimas GalNAc-Ts é responsável por iniciar a 
modificação de pós-tradução de muitas proteínas da superfície celular. 
Alterações na expressão das GalNAc-Ts ocorrem em eventos de neoplasia 
celular, conduzindo a uma glicosilação aberrante das proteínas. Assim, o ajuste 
fino da expressão das GalNAc-Ts poderá permitir regular o processo de O-
glicosilação.  Nesta perspetiva, estudámos as especificidades e a dinâmica do 
mecanismo das GalNAc-Ts aquando a O-glicosilação por métodos de RMN, 
em conjunto com estudos de modelação molecular, para desvendar o 
mecanismo de ação de GalNAc-Ts e definir os determinantes moleculares 
necessários ao reconhecimento do substrato por essas enzimas.  
Neste trabalho, fornecemos evidências de que o processo de 
reconhecimento de GalNAc-Ts segue um mecanismo de ajuste induzido para o 
qual o UDP-GalNAc é absolutamente necessário.  
Além do mais a base molecular para as preferências de glicosilação a 
longa e curta distância foram identificadas. O processo de glicosilação a longa 
distância é orientado por um linker flexível que fornece capacidade de rotação 
ao domínio de lectina; enquanto para a glicosilação a curta distância existe no 
domínio catalítico um sítio de ligação que é responsável pelo reconhecimento 
do resíduo de GalNAc adjacente ao sítio a glicosilar. 
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Este estudo também fornece a evidência de que as enzimas GalNAc-T2 -
T3 e -T4 tem um processo de glicosilação altamente ordenado, em que todas as 
repetições em tandem da proteína MUC1 são totalmente O-glicosiladas, de um 
modo gradual. Dentro deste trabalho, demonstramos evidências de que é muito 
importante a ação concertada entre o domínio de lectina e o domínio catalítico 
destas enzimas para uma catálise eficiente de todos os locais de glicosilação da 
proteína MUC1.  
Capítulo 3 
O outro tópico desta tese é o recetor Toll-like 4 (TLR4), o qual é expresso 
na superfície das células imunes inatas e reconhece especificamente 
endotoxinas bacterianas. Em particular este recetor reconhece o 
lipopolissacarídeo (LPS) ou seu lipoligossacarídeo de versão incompleta 
(LOS), os principais componentes moleculares das paredes celulares de 
bactérias gram-negativas. A modulação dos recetores da imunidade inata por 
agonistas e/ou antagonistas, por exemplo através de pequenas moléculas 
sintéticas, permite controlar a atividade biológica do recetor TLR4. Sendo assim 
estas pequenas moléculas sintéticas representam uma ferramenta poderosa para 
estudar o sistema de TLR4 e são de grande interesse farmacológico como 
agentes antissépticos e anti-inflamatórios (antagonistas) ou como adjuvantes de 
vacinas (agonistas). O conhecimento dos aspetos moleculares do 
reconhecimento de LPS por CD14 (cluster de diferenciação 14) e pelo 
complexo TLR4/MD-2 (recetor Toll-like 4/proteína de diferenciação mieloide 
2) é essencial para compreender as diferentes respostas mediadas pelo TLR4 a 
diferentes variantes de LPS / lípido A ou pequenas moléculas sintéticas. 
 Nesta tese dedicamo-nos ao estudo destes eventos de reconhecimento 
molecular e à caracterização das estruturas supramoleculares destas moléculas 
naturais e sintéticas maioritariamente usando técnicas de RMN e de 
microscopia eletrónica. Em particular, caracterizámos a interação entre FP7 
(antagonista sintético de TLR4) e peptídeos antimicrobianos (AMPs) bem como 
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a agregação de diferentes glicolipídios, naturais e miméticos, por técnicas de 
RMN e TEM (microscopia eletrônica de transmissão). 
 
Ao longo desta Tese, a RMN foi a técnica central para elucidar os detalhes 
moleculares, estruturais e mecanísticos, dos processos de reconhecimento 
biomolecular em estudo.  
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Abstract  
Glycans are among the most varied and complex molecules in biological 
systems. The glycosylation process is the most complex and widespread 
modification of proteins and lipids, with an unsurpassed capacity to generate a 
wide array of different structures. Recognition of glycans by specific receptors 
translates the glycome into unprecedented biological signals in physiological 
and pathological events.  
In this work, we applied Nuclear Magnetic Resonance (NMR) spectroscopy 
to gain structural insights of different molecular recognition processes between 
glycans and diverse proteins with biomedical relevance. As key highlight, key 
aspects of the glycosylation mechanism of MUC1 by GalNAc-Transferases 
(GalNAc-Ts) have been unraveled, paying special attention to the site-
specificity of the process. Furthermore, our targets have an important impact in 
disease, particularly, in cancer (mucin-1) and in bacterial infections (Toll-like 
receptor 4).  
Throughout this Thesis, state-of-the-art NMR experiments have been 
applied to dissect the molecular details of these biomolecular recognition 
processes. Thus, ligand-based and receptor-based methods have been used, in 
combination with a variety of additional experimental and theoretical 
techniques. Thus, biophysical, biochemical, molecular biology and 
computational methodologies have complemented the NMR data in order to 
attain a complete description of the interaction events.  
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1.1 General Introduction  
Nuclear magnetic resonance spectroscopy (NMR spectroscopy), based on 
the discovery and development of Nuclear Magnetic Resonance by the end of 
1930s-beginning of 1940s,1,2 consists in a powerful and widely recognized research 
technique that makes use of the interaction between nuclear spins (I ≠ 0) and 
electromagnetic radio frequency (RF) pulses to permit the “visualization” and 
consequent study of molecules at atomic scale.3 This development has been 
awarded with three Nobel prizes in physics (one in 1944 for Rabi, and two in 1952 
for Bloch and Purcell)4 in the last century. In this way, as the research progressed, 
it became possible to determine physicochemical properties of the atoms and 
molecules, as well as detailed information about structure, dynamics, reactions 
state, and chemical environment, making use of different NMR parameters and 
using techniques governed by quantum theory.3 
Nowadays, NMR spectroscopy has seen an unprecedented growth and is now 
one of the most powerful and versatile tools, with increasing applications in 
chemistry, biology, medicine and materials science. The fundamentals and methods 
of NMR form a vast, complex and evolving discipline.   
 
1.1.1 Principles of NMR Spectroscopy3,4 
Nuclear Magnetic Resonance (NMR) spectroscopy detects nuclear-spin 
reorientation in an applied external magnetic field. For each kind of observed 
nuclei, the information provided by NMR depends on the electron environment in 
which the nuclei are immersed and on the positions of nuclei within molecules. 
Thus, NMR is a powerful tool for probing molecular structure and dynamics. The 
nuclei observable by NMR are those with a spin quantum number is different to 
zero (I≠ 0). In an external magnetic field (B0), a spin will prefer an alignment along 
with the external field rather than oppose it. This is due to an energy difference 
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(ΔE) between the two states that depends on the strength of B0 and the isotope-
specific gyromagnetic ratio (γ) (Figure 1.1) (equation 1).  
∆𝐸 = 𝛾ℏ𝐵0    
Equation 1  
Where ℏ is the reduced Planck constant. 
 
 
Figure 1.1 - Representation of the Zeeman effect in the energy states separation in NMR 
spectroscopy. 
 
The radio-frequency of the electromagnetic radiation that is emitted from 
transitions between the two states is called the Larmor frequency, which is equal to 
the ratio of ΔE and the Planck constant (ℏ) and can be given in units of angular 
frequency (ω0) or Hertz (ʋ0) (Equation 2). NMR spectroscopy is the technique that 
allows measuring the Larmor frequency of spins in a magnetic field, thus enabling 
investigation of molecular properties. 
𝜔0 =
∆𝐸
ℏ
= 𝛾𝐵0 
Equation 2  
ΔE
ms= -1/2
ms= +1/2
E
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To extract chemical information from a molecule, there are three 
fundamental concepts of solution NMR spectroscopy that are helpful, chemical 
shifts (i.e., the specific Larmor frequencies of spins), spin-spin couplings (i.e., spin 
interactions) and spin relaxation (i.e., the time dependency of an NMR signal).  
 
1.1.1.1 Chemical shift  
The magnetic field slightly differs for different spins, due to shielding effects 
from electron density around the specific nuclei. Therefore, spins will have shifted 
frequencies depending on their chemical environment (neighboring atoms and type 
of chemical bonding). Thus, each site experiences a slightly different magnetic field 
and has a different position in the NMR spectrum. Also, the chemical shifts will 
vary depending on the molecular orientation with respect to B0, due to the shielding 
of B0 caused by anisotropic electron density of the atomic orbitals, a phenomenon 
called chemical shift anisotropy (CSA). In solution, this effect is averaged to zero, 
so that only one frequency is observed for each chemically distinct site. 
 
1.1.1.2 Spin-spin couplings 
The NMR signal of a spin does not always appear as a single peak at a given 
chemical shift in an NMR spectrum. Instead, it is often observed as a split signal 
centered at the chemical shift. This phenomenon, the spin-spin coupling, arises 
from interactions between neighboring spins. The magnitude of the peak splitting 
is referred to as the coupling constant (J) and is equal for both spins involved in the 
interaction. The most obvious spin-spin coupling in solution NMR spectroscopy is 
the scalar coupling, which is mediated by electron interactions through covalent 
bonds. The strength of the interaction is measured by the scalar coupling constant, 
nJIS, in which n is the number of covalent bonds between the nuclei I and S and its 
magnitude is usually expressed in Hertz (Hz). The important nJIS have n until 4. 
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The J-coupling constant is also a source of information regarding the 
molecular shape, because of its dependence on bond geometry. The relationship 
can be described by Karplus-type equations (i.e., Equation 3), which differ 
depending on the nuclei involved in the bonds.  
𝐽(𝜃) = 𝐴𝑐𝑜𝑠2𝜃 + 𝐵𝑐𝑜𝑠2𝜃 + 𝑐 
Equation 3 
Where J is the 3J coupling constant, and A, B, and C are constants that depend on 
the specific coupled nuclei. θ is the dihedral angle.  
 
1.1.1.3 Spin relaxation 
An RF pulse applied onto a sample at equilibrium causes a perturbation on 
the nuclear spins removing them from the thermal stationary state. As consequence 
of this pulse, the system will try to return to the equilibrium, losing the excess 
energy. However, due to the low transition energies associated with magnetic 
resonance, the lifetime of the excited states may be extremely long (few seconds to 
minutes for small molecules). These long lifetimes are fundamental for NMR 
spectroscopy as they result in sharp lines (as a consequence of the Heisenberg 
uncertainty principle). 
In NMR, two relaxation parameters are defined:  
- T1, the spin-lattice or longitudinal relaxation time (R1 for spin-lattice 
relaxation rate, R1 = 1/T1);  
- T2, the spin-spin or transverse relaxation time (R2 for the spin-spin 
relaxation rate, R2 = 1/T2).  
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T1 measures the efficiency with which the excited nuclear spins return to 
their ground state by exchanging energy with their surroundings. T2 is a 
measurement of the efficiency with which spins exchange energy with each other. 
The more efficient this exchange, the shorter the relaxation time. In different 
experiments, these relaxation times can be studied to understand protein’s 
dynamics, transverse (T2) or longitudinal (T1), in the timescale of milliseconds (ms) 
to seconds (s), respectively (Figure 1.2). In solution, the resonance line widths are 
inversely proportional to the T2 relaxation time, which decreases with the increase 
in molecular size and tumbling time. 
 
 
Figure 1.2. Behavior of T1 and T2 as a function of the correlation time for spin ½ nuclei 
relaxing by the Dipole-Dipole mechanism.  
Dipole-dipole interaction is probably the most important mechanism of 
relaxation pathway for protons in molecules containing contiguous protons and for 
carbons with directly attached protons. This is also the source of the Nuclear 
Overhauser Effect (NOE). Dipolar coupling occurs when the magnetic field of one 
nuclear dipole affects the magnetic field at another nucleus. It depends on the 
distance between the nuclei and takes place through-space. Dipole-dipole 
relaxation is also dependent on the correlation time, τc. Small molecules tumble 
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very fast and have short τc, usually in the order of picoseconds. Large molecules, 
such as proteins, usually move slowly and have long τc, usually in the order of 
nanoseconds. In summary, several dynamic processes can be studied by NMR. The 
different time scales of NMR observable phenomena are graphically represented in 
Figure 1.3. 
 
 
Figure 1.3 - Time scales of some important molecular dynamic processes and 
multidimensional NMR methods available to study them. 
 
1.1.2 The Nuclear Overhauser Effect (NOE).  
The nuclear Overhauser effect (NOE) defines the correlation between 
protons close in space (up to 5 - 6 Ǻ distance) and is a consequence of dipole-dipole 
cross-relaxation in nuclear spin systems. Intra-proton distances can be estimated.5 
The NOE represents the change in intensity of a signal when the spin transitions of 
another nucleus cause a perturbation of its equilibrium populations. The two nuclei 
do not share a scalar, through bond, coupling; instead, they are sufficiently close in 
space to share a dipolar coupling. Thus, the NOE originates from dipolar cross-
relaxation between proton pairs and depends on the proton-proton distance and on 
the molecular motion of the inter-proton vector (Equation 4). 
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𝐼𝑁𝑂𝐸 ≈  (
1
𝑟6
) 𝑓(𝜏𝑐) 
Equation 4 
Where INOE is the NOE intensity, r is the proton-proton distance, and f is a 
function that depends, among others factors, on the correlation time (τc) that 
describes the motion of the inter-proton vector. 
τc is the correlation time (decay time of the correlation function). When 
considering isotropic molecular tumbling, τc is related with the time taken for the 
molecule to rotate by 1 radian about any axis. Therefore, rapidly tumbling 
molecules will have short correlation times, while slowly tumbling molecules will 
have long correlation times. Thus, the correlation time of a molecule is related with 
its molecular weight.  
Cross-relaxation rates for small molecules are positive while for large 
molecules, as proteins, are negative (Figure 1.4). For medium size molecules, such 
as small peptides, cross-relaxation rates can be positive or negative, which means 
very small (often not measurable) NOEs. This problem can be overcome by using 
the ROE technique (rotating frame NOE), in which cross-relaxation occurs in the 
transverse instead of in the longitudinal plane (Figure 1.4). 
 
 
Figure 1.4 - Maximum NOE and ROE in function with ωτc. 
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1.1.3 Diffusion ordered spectroscopy   
Diffusion ordered spectroscopy (DOSY) identifies the molecular 
components of a mixture and obtaines, at the same time, information on their size. 
This information may be accessed by measuring the self-diffusion coefficient, 
which measures the random translational motion of molecules, driven by their 
internal kinetic energy. Self-diffusion coefficients are related to the structural 
properties of a molecule by their dependence on the physical properties of the 
molecule (e.g. size, charge and shape). Furthermore, self-diffusion coefficients also 
depend on the characteristics of the surrounding medium (e.g. temperature and 
viscosity). 
For a spherical molecule moving in an unconstrained environment, the 
Stokes–Einstein law predicts a correlation between the hydrodynamic radius r and 
the self-diffusion coefficient (D) (Equation 5) 
𝐷 =
𝑘𝑇
6𝜋𝜂𝑟
 
Equation 5 
Where k is the Boltzmann constant, T is the temperature and η is the medium 
viscosity. 
The diffusion of molecules is measured by evaluating the attenuation of a 
spin echo signal using pulsed-field gradients (PFG).6 
 
1.1.4 NMR methods for the study of Protein-Ligand interactions: 
The binding of small ligands to large proteins usually follows a bimolecular 
association reaction, which can be described by one-site binding model:  
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Equation 6 
The Equation 6 represents a dynamic equilibrium involving three species: 
the free protein P, the free ligand L, and the receptor-ligand complex PL, with kon 
and koff being the on (association) and off (dissociation) rate constants. The 
unimolecular rate constant koff is inversely proportional to the mean lifetime B of 
the protein-ligand complex. The bimolecular rate constant kon measures the 
probability of encounter between free receptor and ligand.  
The binding affinity can be quantified by the temperature-dependent 
equilibrium dissociation constant (Equation 7):  
 
Equation 7 
 
Where [P], [L] and [PL] are the equilibrium concentrations of protein, ligand 
and the complex, respectively. [P] and [L] are also referred to as the free state and 
[PL] is varyingly referred to as ‘bound ligand’. KD has the units of concentration.  
When the receptor and ligand molecules are free, they retain their intrinsic 
NMR parameters (e.g. chemical shifts, relaxation rates, translational diffusion 
coefficients). However, in each other’s presence, their mutual binding affinity 
drives a two-state exchange process that can toggle both sets of molecules between 
the free and bound states (Figure 1.5). Besides providing structural information, 
NMR methods can supply a wide variety of transient and dynamic information on 
the complex. NMR methods can be divided in those detecting the ligand signals 
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(ligand-based experiments) and those detecting the receptor signals (receptor-based 
experiments).7,8 
1.1.4.1 Ligand-detected methods  
Generally, ligand-based NMR experiments assay for binding are employed 
by:  
i. Exploiting the differential mobility of the ligand in the free versus 
bound state: bound ligands will transiently experience the much 
slower rotational and translational mobility of the large receptor, 
leading to altered relaxation parameters and diffusion coefficients, 
respectively;  
ii. exploiting transfer of magnetization processes.9 
Ligands, small molecules, are characterized by small relaxation rates, 
positive 2D-NOESY cross-peaks, and large translational diffusion coefficients, D. 
In contrast, bound ligands share the NMR relaxation properties of the receptor, 
usually large molecules, with fast relaxation; negative 2D-NOESY cross-peaks, 
highly efficient spin-diffusion, and smaller molecular diffusion coefficients (D). 
These apparent differences are the basis of ligand-based methods, where changes 
in the ligand NMR parameters upon binding to the receptor can be exploited to 
detect and characterize the interaction (Figure 1.5). 
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Figure 1.5 - Illustration of the changes in different physical properties when a small 
ligand interacts with a large protein.  
 
1.1.4.1.1 Line Broadening in NMR  
The primary NMR methods for detection of ligand-protein interactions rely 
on measurement of T1/T2 relaxation rates of ligand resonances. Line broadening in 
the presence of the protein is often an indicator of protein–ligand interactions. The 
degreeof line broadening depends on many factors, including the transverse 
relaxation rate, the exchange rate, and the fractions of the ligand in the free and 
bound states. Ligands that bind to a macromolecular receptor experience an 
enhancement of their T2 relaxation: the molecular motion of the ligand dramatically 
changes becoming similar to that of the receptor with the selective shortening of 
the T2 relaxation times, which is translated into a broadening of certain protons of 
the ligand, which can even disappear.10  
 
1.1.4.1.2 Saturation Transfer Difference (STD) NMR 
The STD experiment is a popular and highly versatile screening method for 
the identification and characterization of protein-ligand interactions.7,9,11 The 
success of this technique is a consequence of its robustness and the fact that it is 
focused on the signals of the ligand, without any need of processing NMR 
Motion properties of L 
similar to those of R
ComplexReceptor Ligand
Fast Brownian motion
Small τc (ns scale)
Slow relaxation
Fast diffusion
Positive NOE
Slow Brownian motion
Large τc (ms –s  scale)
Fast relaxation
Slow diffusion
Negative NOE
koff
kon
 General Introduction 
 
 
 12 
information about the receptor, only using small amounts of non-labeled 
macromolecule.  
The STD NMR experiment is the difference between two different 1H-NMR 
spectra performed on the same ligand-receptor sample and relies on the 
magnetization exchange from the protein-bound state to the free state of the ligand. 
Basically, the first one (on-resonance spectrum) is a spectrum in which the protein 
is selectively saturated, by irradiating at a region of the spectrum that contains only 
resonances of the receptor (from 0 ppm to -2 ppm). The saturation is efficiently 
propagated across the entire protein through spin-diffusion and transferred to the 
binding compounds via intermolecular 1H-1H cross relaxation at the ligand-receptor 
interface. The second spectrum (off-resonance spectrum) is recorded as a reference 
or blank spectrum. Here, the chosen saturation region is free from ligand and 
protein signals (e.g. 100 ppm).  
The protein-to-ligand saturation transfer will affect the intensity of the ligand 
resonance signals in the spectrum obtained with selective receptor saturation (ISAT), 
and when compared to the spectrum acquired without saturation transfer (I0). Thus, 
the difference in intensity due to saturation transfer can be quantified (ISTD = I0 – 
ISAT) and constitutes an indication of binding (Figure 1.6). STD is ideally suited to 
receptors with large masses (>30 kDa). Receptors with large molecular masses 
display large rotational correlation time, τc that enhance spin diffusion and, 
consequently, saturation transfer within the receptor and to the ligand. 
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Figure 1.6 - Schematic representation of the STD experiment. When a protein becomes 
saturated, the intermolecular NOE is only transferred to those ligands, with shape and size 
that interact with the protein. The transference of saturation is detected by subtraction of 
on to off-resonance spectrum in order to obtain an NMR spectrum where only the signals 
from molecules that bind to the protein are present. Resonance signals from non-binders 
do not show up in the difference spectrum. Adapted from 12. 
 
Furthermore, for a given compound, the building blocks of the ligand in 
closest proximity to the receptor molecule receive higher amounts of 
magnetization, which are translated into stronger signals in the STD spectrum. 
Thus, the method can be also used to obtain detailed structural information on the 
binding epitope of the ligand (epitope mapping) (Figure 1.6).13 
Regarding group epitope mapping analysis, computing methods have been 
developed to predict and/or interpret STD data of reversibly forming ligand-
receptor complexes. In particular, CORCEMA (Complete relaxation and 
conformational exchange matrix) package14,15 predicts the expected STD intensities 
for a given model of a ligand-protein complex, and compares them quantitatively 
with the experimental STD data. This version is very useful for rapidly determining 
if a model for a given ligand-protein complex is compatible with the STD-NMR 
data obtained in solution.  
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Remarkably, it is also possible to measure KD if STD signals are recorded in 
the presence of a competitor inhibitor.14,16 Competition experiments can be 
performed for designed mixtures of both ligands by evaluation of the gradual decay 
of the STD signals from the reference in the presence of increasing concentrations 
of the inhibitor. Assuming a simple bimolecular association reaction for ligand L 
and a competitive inhibitor I to a receptor protein, the KD value of the ligand L can 
be determined from a known value of KI. However, more complicated situations 
such us those arising from binding of ligands to secondary binding sites should be 
taken into account. STD competition experiments have been also used for the 
detection of high-affinity ligands.14 
STD methods can be combined with any NMR pulse sequence generating a 
whole suite of concatenated STD NMR experiments such as STD-TOCSY or STD-
HSQC.15 The additional deconvolution of signals in a second dimension can be very 
helpful for mapping the binding epitope of ligands with complex 1D proton spectra.  
The major drawbacks associated with STD experiments are related to the 
potential self-association of the ligands, especially with aromatic molecules, and to 
the possibility of non-specific binding with the receptor. These potential problems 
can be circumvented by employing different ligand/receptor molar ratios, different 
saturation frequencies, and employing competitive binders (or inhibitors) of the 
interaction process, if they are available. 
 
1.1.4.1.3 WaterLOGSY 
The waterLOGSY (Water-Ligand Observed via Gradient SpectroscopY) 
technique, like STD, relies on excitation of the receptor-ligand complex through a 
selective RF pulse scheme. However, waterLOGSY experiment achieves this effect 
indirectly, by selective perturbation of the bulk water magnetization.17 The intended 
transfer of magnetization is therefore water →receptor → ligand. The 
magnetization of the water molecules is selectively saturated or inverted, and 
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during a long mixing time of up to several seconds, the magnetization is transferred, 
via 1H-1H cross-relaxation, to the ligand spins at the protein-ligand interface. 
 There are essentially two pathways by which this transfer of the 
magnetization occurs:  
i. Direct cross-relaxation from the water molecules tightly bound at 
the protein-ligand interface, 
ii. Chemical exchange between the water protons and the labile protons 
of amine and hydroxyl groups in the protein which in turn cross-
relax with the protons of the bound ligand.  
In either case, the perturbation of the bulk water magnetization is transferred 
to the binding compounds while residing in the receptor binding site. 
Distinguishing binding from nonbinding compounds in the waterLOGSY 
experiment is achieved by observation of the differential cross-relaxation properties 
of these ligands with water. Bound ligands interact directly or indirectly with 
inverted water spins with motional and relaxation properties of the receptor, with a 
slow tumbling rate and therefore, a long correlation time. This yields negative 
cross-relaxation rates, and inversion of the NOE signs for the bound ligand. For 
their part, non-interacting ligands receive the magnetization only in the free state, 
via water molecules involved in their solvation sphere, leading to positive cross-
relaxation rates and the sign of the NOE remains unaltered. As a consequence, 
binders and non-binders display waterLOGSY peak intensities of opposite sign, as 
in tr-NOESY (see below). 
 
1.1.4.1.4 Methods based on transferred NOE effects  
Transferred NOE methods are based on the changes in the rotational motion 
properties of a ligand upon binding to a large macromolecular receptor. For small 
molecules, characterized by a short correlation time, NOEs are positive. However, 
 General Introduction 
 
 
 16 
for large receptors, the correlation time is in the ns time scale and the associated 
NOEs are negative. Thus, this technique has become a classical method for 
studying the binding of ligands to large receptors and to deduce the conformation 
of the binding ligand in the protein site.9  
In trNOESY, low protein:ligand ratios are typically employed (from 1:5 to 
1:50, depending on the affinity and kinetic parameters). This implies that the NOEs 
observed for the ligand (tr-NOEs) will keep the information of its bound state, 
provided that the off-rate is fast in the relaxation time scale. Therefore, the signals 
of small ligands will experience a NOE sign change in the presence of the receptor, 
from positive (free state, small molecule, short correlation time) to negative (large 
complex, large correlation time), which will reflect the conformation of the ligand 
in the binding site. Technically, the tr-NOESY experiment consists of acquiring an 
ordinary NOESY spectrum for the ligand in presence of the protein. Normally, with 
lower mixing times is in the range of 50 to 100 ms, whereas for nonbinding 
molecules it is four- to ten-times longer. 
 
1.1.4.2 Receptor-detected methods: Chemical Shift Perturbations & 
HSQC  
For small proteins (~10 kDa) and peptides structure determination, 2D 
experiments, as COSY (COrrelation SpectroscopY) and TOCSY (TOtal 
Correlation SpectroscopY), are used to give information between protons, due to 
the scalar coupling through covalent bonds. NOESY experiments (Nuclear 
Overhauser Effect SpectroscopY) are the most important multidimensional 
experiments in structure determination since they correlate protons through space, 
allowing the determination of the distances between close protons.18 These 
methodologies can be used to determine the structure of proteins up to 10-15 kDa.18  
For large molecules, the number of hydrogen atoms is extremely high. The 
rotational correlation times of globular proteins and, therefore, the line widths of 
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the NMR resonances also increase linearly with the molecular mass. For these 
reasons, conventional assignment procedures based on sequential NOE correlations 
become very difficult, if not impossible. Heteronuclear experiments are then 
necessary and can solve these problems for proteins with molecular masses less 
than 30 kDa.18 However, isotopic labeling of the samples is required with NMR 
active isotopes 13C, 15N, and sometimes 2H.19  
In protein NMR, the Heteronuclear Single-Quantum Coherence (HSQC) 
experiment19 correlates the 15N or 13C nuclei with the attached 1H via the one-bond 
scalar coupling JN-H or JC-H, respectively. Thus, in the 1H/15N-HSQC one signal is 
expected for each amino acid residue with the exception of proline, which has no 
amide-hydrogen due to the cyclic nature of its backbone. In this sense, 1H/15N-
HSQC spectrum is the ‘fingerprint’ of the protein.  
One of the most frequently used receptor-based methods relies on monitoring 
the perturbation of the receptor 1H/15N-HSQC chemical shifts upon binding of the 
ligand. 
 
1.1.4.2.1 Chemical Shift Perturbations  
The chemical shift is an extremely sensitive parameter to environmental 
changes (pH, temperature, and folding states) and is able to reveal interaction 
processes. Moreover, nuclei located in the protein binding pocket usually show the 
largest effects. Thus, mapping chemical shift perturbations via heteronuclear shift-
correlation experiments is a straightforward NMR technique to detect binding and 
also to define the protein residues that are involved in the interaction.  
The 1H/15N-HSQC spectrum of the protein, considered as the NMR 
fingerprint, is acquired as a reference spectrum. Then, sequential 1H/15N-HSQC 
spectra are acquired for different amounts of ligand. The proximity of the ligand 
will modify the environment of the nuclei that are at the interface of the protein-
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ligand complex. Therefore, the residues involved in the binding will have a 
different chemical shift than in the unbound form. When the exchange rate between 
free and bound states is fast on the chemical shift time scale, the 1H/15N cross-peaks 
will move smoothly from their position in the free spectrum to those in the bound 
spectrum, with the frequency of the signal at any titration point being the weighted 
average of free and bound chemical shifts. When the exchange rate is slow on the 
chemical shift time scale, the free will signal gradually disappear and the bound 
signal will appear, as the intensities of the two peaks reflect the concentrations of 
the free and bound protein.20 The chemical shift perturbations allow identifying 
binding and to localize the binding site on the protein structure. Mapping 1H/15N 
chemical shift perturbations along the structure of the protein is usually applied to 
detect residues with larger chemical shift perturbations, which can be considered as 
part of the binding site (Figure 1.7).  
 
 
Figure 1.7 - Schematic representation of the chemical shift perturbation induced by the 
interaction of an unlabelled small ligand with a 15N-labelled protein as detected in the  
1H/15N-HSQC spectrum. Slow exchange (strong binding) after the addition of a sub-
stoichiometric quantity of ligand; two signals are observed one for the free (blue) and 
another for the bound (orange) protein. Fast exchange (weak binding), the scheme 
represents the superposition of 1H/15N-HSQC sequence obtained for increasing quantities 
of ligand in the order blue, dark red, green and orange; only one signal is observed in each 
spectrum with the shift (arrow) depending on the structural changes induced by the ligand 
at the specific residue. 
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Fast relaxation of the protein 1H/15N signals becomes an issue when dealing 
with high molecular weight macromolecules (> 35 kDa). Fortunately, the 
implementation of transverse relaxation optimized spectroscopy (TROSY) HSQC 
variant allows targeting larger protein receptors (up to 100 kDa) by selectively 
recording the most slowly relaxing signal component of the 15N-1H correlation.21  
Regarding specific labeling schemes, selective labeling methods have been 
also developed to improve or simplify NMR spectra of large proteins.  
 
1.1.4.3 Specific isotopic labeling to study protein by NMR 
 
1.1.4.3.1 13C-methyl labeled proteins 
A frequent, although expensive, approach is to use 13C-methyl labeled 
proteins, which contain 13C probes in the side chain of the protein, such as alanine, 
valine, isoleucine, leucine and methionine. For 13C-methyl labeled proteins, 2D 
1H/13C-HMQC experiments are typically used. These experiments have some 
advantages in comparison to 1H/15N-HSQC experiments. Specifically, methyl 
groups have three protons with a three-fold degeneracy and give rise to stronger 
signals. They also tend to resonate in a sparsely populated region of the 1H/13C 
correlation spectrum, reducing spectral overlap.22 
Several labeling schemes for amino acids, including alanine, isoleucine, 
leucine, methionine, and threonine, have been developed.22 These labeling 
strategies commonly involve metabolic pathways, metabolic precursors, and the 
amino acid’s propensity for isotopic scrambling at other sites in the protein. For 
example, in the case of leucine and valine, which share the same metabolic 
pathway, using metabolic precursors common to both amino acids, such as α-
ketoisovalerate, labeling techniques often result in the incorporation of isotopes into 
both amino acids. Isoleucine, can also be labeled using α-ketobutyrate, one of its 
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metabolic precursor.23 For alanine and methionine, residue specific labeling can be 
obtain by via of supplementation of  minimal expression medium with the 
appropriate isotopically labeled amino acid.24  
 
1.1.4.3.2 19F labeled molecules 
Although classical spectroscopic methods, 1H, 15N, and 13C, have been used 
to study the behavior of biomolecules in solution, 19F-NMR is also becoming very 
popular although its implementation requires manipulation of the system. The 19F 
nucleus displays different properties that render it ideal for NMR studies. In fact, 
19F is an NMR active isotope with spin ½, and it is 100% naturally abundant. It also 
possesses a high gyromagnetic ratio that results in excellent sensitivity (83% of 1H).  
In addition, the fluorine chemical shifts are extremely sensitive to changes in local 
environment (the chemical shift is +/- 100-fold larger than that of 1H).25 
The 19F atom has been used in biological NMR, like a molecular probe into 
proteins, peptides, and carbohydrates26–29 to provide information on structure and 
dynamics,30–32 protein-ligand interactions,25,33 and protein (un)folding,34,35 
demonstrating unequivocally its versatility as probe for NMR. 
In the protein field, several methods to prepare 19F-modified proteins have 
been described.25,30–35 These methods fall into three main categories:  
i. Post-translational covalent attachment of 19F-containing moieties to 
the protein by conjugation of the 19F-containing moiety to a reactive 
group with an -SH group on a solvent accessible cysteine.25,30,31,33 
The great advantage of this method is the ability to incorporate the 
label into proteins for which biosynthetic labeling is expensive, like 
a mammalian cells expression.  
ii. Specific incorporation of the type of biosynthetic amino acids 
modified with 19F.25,33–35 This approach is carried out by expression 
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in a defined growth media, supplemented with the 19F-modified 
amino acid 
iii. Site-specific incorporation of the 19F-modified amino acid using 
recombinant expressed orthogonal tRNA / tRNA-tRNA pairs.25,33 
This system is based on an extension of the genetic code to beyond 
the natural 20 amino acids. 
 
1.1.5 Carbohydrates and Carbohydrate-Protein Interactions 
Carbohydrates (glycans, sugars, saccharides) are the most abundant 
biomolecules in nature and they are estimated to account for 70% of the total 
biomass on earth.36 As a product of the photosynthesis process, carbohydrates 
function as energy storage in organisms and their ability to form polymers make 
them important for the structure of the cell. Cell membranes themselves contain 
sugars (as well as proteins and lipids.) These glycans play a fundamental role in a 
variety of biological processes, including cell adhesion and communication. 
Therefore, molecular recognition events between sugars and proteins constitute the 
first interaction process in many molecular mechanisms related to health and 
disease. 
In the initial part of this chapter, different NMR concepts have already been 
introduced. Although the particular systems of interest that have been studied in 
this Thesis will be explicitly described below, I will briefly point out now the 
different types of information that can be extracted from NMR experiments in this 
particular topic, along with the description of the basic features that are behind the 
recognition of glycans by protein receptors.  
In brief, key features of the structural, conformational, dynamic and 
interaction properties of carbohydrates will be explored in the following chapters:  
i. Molecular shape (structure and conformation), which can be 
deduced from NOEs and J-couplings.  
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ii. Molecular motion, which can be investigated by NMR relaxation 
and chemical exchange, depending on the timescale of motion.  
iii. Molecular interactions, which can be assessed by chemical shift, 
relaxation and NOE data. 
 
1.1.5.1 Structure and Conformation 
Carbohydrates are extremely diverse, as consequence of the large number of 
different monosaccharide units that can be combined by employing different types 
of glycosidic linkages to form oligo- or polysaccharides.37 These complex 
glycosylation patterns result in a large variation in shapes and geometries of 
carbohydrates.  
 Monosaccharides, the simplest forms of carbohydrates, are 
polyhydroxylated carbon chains carrying a aldehyde functionality (aldoses) or a 
keto functionality (ketoses). The carbon chains contain at least three carbons 
(trioses), although molecules with five (pentoses) and six (hexoses) carbon atoms 
are the most common ones.  
Monosaccharides exist in many different diastereomeric forms because of 
the high number of stereogenic centers. Each diastereomer has its own name (e.g., 
glucose, galactose). Enantiomers are named according to the D and L notation, 
which is determined by the stereochemistry at the highest numbered stereogenic 
carbon in the saccharide chain (Figure 1.8). The typical cyclization process results 
in the formation of a new stereogenic center at the hemiacetal carbon (anomeric 
carbon), which now displays either α or β configuration (Figure 1.8). 
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Figure 1.8 - Cyclic forms of D-galactose (Gal). The hashtag marks the highest numbered 
stereogenic carbon that defines the enantiomeric notation.  
 
1.1.5.1.1 The anomeric effect 
The anomeric effect was first described in the 1950s by J. T. Edward and R. 
U. Lemieux.38 The anomeric effect phenomenologically describes the stabilization 
of the axial (versus equatorial) alkoxy groups at Cl of a pyranose ring. Nowadays, 
it is accepted that the reason is due to orbital and electronic factors produced by the 
simultaenous presence of two oxygens attached to one single carbon atom. 
In principle, the tendency of the anomeric hydroxyl group or electronegative 
substituent to adopt axial orientation (α-anomer) rather than equatorial (β-anomer) 
is against to what would be expected based on steric factors. However, the favorable 
interaction between one lone electron pair located at a molecular orbital (n) on 
either glycoside oxygen atoms and the vicinal anti-bonding molecular orbital (σ*) 
of the contiguous C-O bond overcomes the possible steric hindrance provided by 
the axisal orientation. The anomeric effect (endo and exo) are now reasonably 
explained by computational approaches, including ab initio calculations (Figure 
1.9).39  
 
β-D-Galactofuranose
α-D-Galactofuranose α-D-Galactopyranose
β -D-Galactopyranose
#
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Figure 1.9 - Schematic representation of the lone pair-σ* interactions responsible 
for the endo- or exo-anomeric effects in α- and β- glycosides. The endo-anomeric effect 
exists only in α-glycosides due to the geometrical requirements that allow the molecular 
orbital overlapping. For the exo-anomeric effect, different conformers are represented, 
both for α- and β-glycosides. However, the overlapping between the σ* and the lone electron 
pairs is possible only for two of the three conformations. The fill color of the orbitals does 
not refer to the orbital phase, but it is a schematic representation for full or empty orbitals. 
 
1.1.5.1.2 Conformation  
The sugar ring conformation introduces another source of structural 
variability.40 Once cyclized, the sugar ring may experience conformational 
flexibility, depending on the type of cycle (furanose, pyranose, septanose,…), the 
configuration of the stereogenic centers, and the size and chemical nature of the 
substituents. For pyranoses, the ring conformations may include envelope, boat and 
skew ring puckers, as well as alternative chairs, usually in fast equilibrium (Figure 
1.10).40,41  
 
α
β
endo-anomeric effect exo-anomeric effect
exo-syn exo-anti non-exo
σ*C1-O1
σ*C1-O1
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Figure 1.10 - Ring conformations adopted by monosaccharide rings. The energetically 
favored chair conformations are labeled as 4C1 or 1C4, depending on the position of carbons 
1 and 4 (above or below the sugar ring plane, as noted by the position of the numeral). The 
other conformations are as Skew boat (labeled as S) or boat (labeled as B). 
 
This 3D shape has special relevance for the molecular recognition of sugars 
by receptors, since it determines the orientation of functional groups in the three-
dimensional space.42 For the common D-pyranose rings, the 4C1 geometry is the 
typical chair conformation, since it minimizes steric clashes. However, 
monosaccharide rings may populate a number of additional, distinct 3D shapes, at 
relative ratios that depend on the free energy of the different conformers.43 
 
1.1.5.2 Carbohydrate-protein interactions 
Glycans play different roles inside the cell, as well as on the cell surface. 
Glycoproteins, glycolipids, and/or peptidoglycans are present at the cell surface and 
modulate the concomitant molecular recognition events. In this context, the 
knowledge of the 3D structure of these molecules at the maximum possible 
resolution, as well as the characterization of their recognition features by different 
entities, such as lectins, enzymes, antibodies, viruses, and bacteria (Figure 1.11) are 
essential for a thorough understanding of many vital processes and to open the 
possibility of their modulation. 
As mentioned above, glycans play a key role in cellular transport and 
adhesion, cell signaling processes, cell-cell communication, immune response, 
hyperacute rejection of tissue transplants of nonhuman sources, fertilization, tissue 
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maturation, apoptosis, blood clotting, infection by bacterial and viral pathogens, 
tumor growth, and metastasis.44 Thus, understanding the structure and function of 
carbohydrates is crucial to realize their function in health and disease, as well as, to 
develop new glycan-based therapeutics. 
 
 
Figure 1.11 - Examples of carbohydrate-protein interactions. GalNAc represents N-
acetylgalactosamine; GlcNAc: N-acetylglucosamine; Neu5NAc: N-Acetylneuraminic Acid; 
Gal: Galactose; Fuc: Fucose; Man: Mannose and Glc: Glucose.44 
 
In general, glycans bind at domains defined by shallow pockets on the 
hydrophilic surface of proteins. The interaction with the receptors requires the 
payment of an entropy penalty due to desolvation, which is usually compensated 
by the enthalpically favored interactions established with the receptor. Overall, 
sugar binding to proteins is made possible via several attractive forces including 
polar and hydrophobic interactions, especially CH–π interactions, solvation effects, 
hydrogen bonds, van der Waals interactions, and electrostatics.45 
The establishment of hydrogen bonds between sugars and their receptors 
constitutes perhaps the most evident protein-carbohydrate bonding potential due to 
the existence of numerous –OH groups in all saccharides. Furthermore, hydrogen 
bonding is made possible not only thanks to the hydroxyl groups, but also to the 
Extracellular 
Intracellular 
GlcNAcGalNAc Neu5Ac Gal Fuc Man Glu
Antibody
Lectin
Enzyme
Virus
Bacterium
Dendritic Cell
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presence of amine and carboxyl groups in many sugars. Hydroxyl groups may 
participate in hydrogen bonds both as donors and as acceptors, by means of their 
oxygen lone electron pairs. In some instances, the same –OH group simultaneously 
acts as donor and acceptor, a characteristic phenomenon in sugar-protein 
interactions, known as cooperative hydrogen bonding. Sugar hydroxyl groups 
establish hydrogen bond contacts with the side chains of polar residues, most often 
aspartic and glutamic acid, asparagine, glutamine, arginine and serine, as well as 
backbone amide and carbonyl groups.46,47 
Apart from hydrogen bonding, non-polar interactions also contribute to the 
molecular recognition between biochemical species. They are of special interest 
when aromatic protein residues are involved in the recognition event. For instance, 
the non-polar CH groups of a ligand tend to pack with adjacent aromatic rings 
establishing CH-π interactions. The geometry condition for CH-π interactions 
requires the presence of CH groups perpendicular to the aromatic ring where the 
CH-π system stabilize the complex formation by entropic and enthalpic 
contributions. Since the stabilizing energy of one CH-π interaction is rather low, 
(CH-π interaction ca.= 1 kcal/mol), the simultaneous CH-π interaction of various 
CH groups could finally drive the molecular recognition. Indeed, CH-π interactions 
have been deeply described in carbohydrate recognition.29,45,48–51  
Due to the biochemical complexity of these systems, other polar and non-
polar intermolecular interactions may take place in the molecular recognition event. 
Some of them involve third partners, such as ions or water molecules. Water 
mediated interactions take place when a water molecule establishes hydrogen bond 
simultaneously with both partners, ligand and receptor. The nature of this 
interaction resides in the presence of solvating water molecules in the binding 
pocket that enhances the ligand binding mediating as a “bridge” between the ligand 
and receptor.52,53 Another type of interaction involves the coordination of a divalent 
cation bridging certain sugar hydroxyls and negatively charged aspartates or 
glutamates. Such interaction is displayed by proteins belonging to the C-type family 
of lectins, which require the presence of Ca2+ ions to bind their sugar ligands.14,52 
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Further forces involved in the recognition of glycans by their protein 
receptors include electrostatic interactions between charged saccharides, such as 
sialic acid residues or sulfated glycosaminoglycans, and protein residues of 
opposite charge.54  
Carbohydrate-protein interactions can be studied by several methods. High-
throughput microarrays55–57 can be employed to monitor the binding of a glycan to 
a protein. This qualitative approach is usually complemented by surface plasmon 
resonance (SPR) data.55 Indeed, besides NMR, binding affinities can be quantified 
by SPR or by isothermal titration calorimetry (ITC);58 These two techniques 
provide specific advantages. ITC is able to determine the thermodynamic 
parameters (enthalpy and entropy) of the interaction, whereas SPR may provide the 
kinetics (koff) of binding. However, neither method yields detailed structural 
information on the conformation of the bound partners.  
From the structural point-of-view, advances in cryo-electron microscopy are 
providing details on different biological mechanisms involving sugars, especially 
during the last years. Additionally, better protocols for the structural refinement of 
the electron density acquired by X-ray methods for analyzing protein–sugar 
complexes and glycoproteins are also available, with important consequences in the 
glycoscience field.59,60 Alternatively, NMR spectroscopy remains as one of the 
most rewarding techniques to explore protein–glycan interactions. Without 
forgetting the power of the other techniques, this Thesis is particular focused in the 
use of NMR approaches.61  
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1.2 Goals 
From the training perspective, the key objective of this Thesis has been to 
acquire knowledge on the application of NMR methods to study distinct molecular 
recognition events.  
Therefore, ligand- and receptor-based NMR methods were used to study the 
interaction of a variety of ligands with diverse chemical nature with receptors of 
biological and/or biomedical interest. Within the explored ligands, glycans have 
been specially employed. Thus, the scientific objective of this thesis has been to 
advance in the understanding of the structural features that govern glycan 
interactions, including the derivation of the binding epitopes.  
Within glycoscience field, the specific objectives have aimed to:  
- understand of the mechanism of action of GalNAc-Ts.  
- evaluate the interactions of different natural and synthetic molecules with 
antimicrobial peptides and MD-2 protein, in the context of understanding TLR4-
related innate immunity. 
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From structure to function in human health & disease 
 
 Deciphering GalNAc O-glycosylation 
Introduction 
 
 
 37 
2.1 Introduction 
 Glycosylation is the most complex and common modification of proteins 
and lipids, with a supreme capacity to generate a wide array of different structures.1 
Protein glycosylation is a complex and multifaceted post-translational 
modification, where several variables can be modified. They include the type of 
sugar-protein linkage, the sugars that are transferred and the resulting glycan 
structure and length. Recognition of glycans by specific receptors translates the 
glycome into unprecedented biological signals in diverse physiological and 
pathological events.2 For example, human cell surface mucin-type glycoproteins 
play many crucial roles in biological processes and significantly influence specific 
cellular adhesion during differentiation, proliferation, or malignant alteration in 
embryogenesis, organogenesis, carcinogenesis, and cancer metastasis.3  
The specific and strictly controlled glycosylation of proteins depends on the 
action of highly “specialized” enzymes known as glycosyltransferases (GTs) and 
glycosidases, which are precisely located in different organelles in cells, thus 
showing cell and tissue specificities.  
Two of the most abundant forms of glycosylation occurring on proteins 
destined to be secreted or membrane-bound are dubbed N-linked (to asparagine) 
and mucin-type O-linked (to serine or threonine). Glycan chains of mucin 
glycoproteins are commonly constructed by a variety of  GTs at the endoplasmic 
reticulum (ER) and/or the Golgi apparatus membranes through highly complicated 
biosynthetic pathways.4 In the ER, where N-glycosylation is initiated, folded 
proteins exit using the COPII-coated protein carriers and are exported to the Golgi 
complex. Herein, N-glycans are modified and O-glycosylation is initiated.5 
The Golgi complex is a collection of cisternae connected by tubules, which 
can be divided into cis, medial, and trans compartments.5 This compartmentation 
permits that those proteins penetrating through the Golgi encounter the various 
enzymes for just a limited time. In particular, GTs are usually distributed by their 
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order of action: early-acting enzymes are localized in the cis-Golgi, while late-
acting enzymes are concentrated in the trans-Golgi (Figure 2.1.1). It is well 
established that the main factors that contribute to the regulation of O-glycosylation 
in the Golgi is the competing activities of the glycosyltransferases and their 
localization. 
 
 
Figure 2.1.1- Schematic representation of the biosynthesis of mucin-type O-glycans. 
 
2.1.1 GalNAc-Transferases 
The large GalNAc-transferase (GalNAc-Ts) family is responsible to initiate 
the post-translational modification of O-GalNAc glycosylation of many cell-
surface proteins.6 O-GalNAc glycosylation is the most complex and differentially 
regulated type of protein glycosylation. The initial step of protein O-GalNAc 
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glycosylation pathway is mediated by a large family of GalNAc-Ts, up to 20, 
localized in the Golgi complex (Figure 2.1.1), which catalyze the transfer of N-
acetylgalactosamine (GalNAc) from a sugar donor (UDP-GalNAc) to the Ser/Thr 
side chains on proteins/peptides (Figure 2.1.2).6  
 
 
Figure 2.1.2- Schematic representation of the enzymatic reaction mediated by GalNAc-Ts. 
 
Mucin type-O-glycosylation elongation was first thought to mainly occur in 
the luminal regions of the cis-Golgi. However, recent studies have indicated that it 
occurs throughout the cis-, medial-, and trans- Golgi regions. In fact, the 
localization and compartmentalization of GalNAc-Ts and other 
glycosyltransferases varies among these regions of the Golgi.7,8 These are key 
factors that contribute to the regulation of O-glycosylation in the Golgi together 
with the competing activities of the GTs. Other factors include the concentrations 
of the metal ion Mn2+, the donor (UDP-GalNAc) and the acceptor substrates, the 
substrate transport rate through the Golgi, and the luminal environment of the Golgi 
(including pH). 7–9 
Mammalian GalNAc-Ts are distributed among all organs with isoforms 
having different expression levels in each tissue. Previous studies have shown that 
GalNAc-T1 and T2 mRNAs are ubiquitously (>70%) expressed among all organs.10 
The expression of other transferase isoforms, such as GalNAc-T5, T8, T9, T10, 
T13, T15, T17, T19 and T20 are less ubiquitous and more regulated to specific 
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organs.6  Lastly, the remaining transferases, GalNAc-T3, T4, T6, T11, T12, T16 
and T18 have more broad expression levels (< 30%) spread across tissues.6  
A number of distinct GalNAc-Ts have been associated with human diseases. 
The loss of GalNAc-T3 causes familial tumoral calcinosis due to an unregulated 
cleavage of FGF23.11 Others include GalNAc-T2, T5 and T19, which have been 
linked to levels of HDL cholesterol and coronary artery disease,12,13 hereditary 
multiple exostoses14 and the Williams-Beuren Syndrome,15 respectively. 
GalNAc-Ts also display marked changes in their expression during 
malignant transformation.6,16 It has been reported, using cancer cell lines, that the 
GalNAc-Ts can relocate to the ER, through the regulation of Src (a proto-
oncogene).17 This fact, in turn, increases the levels of the Tn-antigen (α-GalNAc-
O-Ser/Thr) and enhances tumor cell migration and invasiveness.17–19 These findings 
indicate that the localization of the GalNAc-Ts heavily relies on the physiological 
state of the cell.  
 
2.1.1.1 Structure 
GalNAc-Ts are type-II Golgi membrane proteins, with a extracellular 
domain structure that includes a short N-terminal cytoplasmic tail and a 
hydrophobic transmembrane domain. Structurally, the extracellular domain of 
GalNAc-Ts displays a unique two-domain architecture consisting of a N-terminal 
catalytic domain tethered by a short flexible linker to a C-terminal lectin domain 
(Figure 2.1.3). The catalytic domain is much larger than the lectin domain, and 
consists of ~230 amino acids, while the lectin domain has only ~120 amino acid 
residues. Both domains are linked via a short flexible linker that varies from ~10 to 
25 amino acids in length among isoforms, thus creating flexibility between domains 
(Figure 2.1.3).  
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Figure 2.1.3-Left: Scheme of the structure of GalNAc-Ts. To yellow the catalytic domain 
and to green the lectin domain bound by a flexible strand, in yellow. Right: Crystal structure 
of GalNAc-T2 in complex with UDP and MUC5AC-13 (pdb ID: 5AJP), adapted from 20 . 
 
The catalytic domain is responsible for all catalytic activity: 1) the binding 
of the acceptor substrate and the UDP-GalNAc, and 2) the subsequent transfer of 
GalNAc onto the acceptor substrate. The catalytic domain is responsible to initiate 
glycosylation in naked acceptor substrates and to proceed short-range glycosylation 
in partially glycosylated substrates.21 
The C-terminal lectin domain of GalNAc-Ts, which belongs to the Ricin-
type lectin family, specifically recognizes GalNAc residue and is responsible to 
ensure long-range-glycosylation on a prior GalNAc glycosylated substrates. It 
consists of a folded β-trefoil structure built from three homologous repeat units, the 
α, β and γ repeats.6 The β-trefoil repeats all share a common binding motif, known 
as the carbohydrate lectin domain (CLD) and QxW motifs (where x can be any 
amino acid) that are ~40 amino acids apart. One Asp residue of the CLD motif is 
critical for the lectin binding properties. Mutagenesis studies on GalNAc-Ts 
showed that only one or two specific subdomains (α, β or γ) actively bind GalNAc. 
For example, in GalNAc-T1, the α and β subdomains are important for GalNAc 
binding. For GalNAc-T2, T3 and T4 only the α-subdomain recognizes the sugar, 
catalytic 
domain
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domain
A
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while for GalNAc-T10, the β-subdomain was determined to be important for 
GalNAc-binding.9,22–27  
One more important feature is the Mn2+ coordinating DxH motif at the 
catalytic domain (Figure 2.1.4). This is responsible for binding the phosphate 
moiety of the UDP-GalNAc through coordination of the Mn2+ ion. Previous studies 
showed that metal ions are required for catalysis, being Mn2+ the preferred divalent 
metal ion,28 which allows the required octahedral geometry. 
Another unique structural feature of the catalytic domain of GalNAc-Ts is 
the flexible loop that extends out of the UDP-GalNAc and substrate binding sites. 
This loop undergoes drastic conformational changes between the so called open 
(inactive) and closed (active) conformations (Figure 2.1.4). The active form appears 
upon binding of the UDP-GalNAc and the substrate.20,22,29 Recent structural 
studies20 have shown that, during the catalytic cycle, the flexible loop of GalNAc-
T2 exists in multiple conformations; either semi-open, open and closed (Figure 
2.1.4). This conformational equilibrium is coupled to the interactions of a key 
catalytic residue, identified as Trp331. In the active form (closed), the Trp331 adopts 
the in conformation, and it is located fairly close to the UDP-GalNAc and the 
acceptor substrate. In contrast, when the enzyme is in its inactive (open) 
conformation, the Trp331 displays the out conformation, being away from the UDP-
GalNAc and the acceptor substrate (Figure 2.1.4).20  
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Figure 2.1.4 - A. Structural features of GalNAc-T2-UDP-MUC5AC-13 complex. DxH motif 
in red highlight and the Trp331 and Mn2+ identified with blue arrow. B. The two 
conformations called open (inactive) and closed (active) and the W331 “in” and “out” was 
showed with GalNAc-T2-MUC5AC-13, GalNAc-T2-MUC5AC-13-UDP complexes.20 
 
2.1.1.2 Preferences and Specificity 
Currently there is no consensus on the specific peptide motif that undergoes 
O-glycosylation. To initiate the O-linked glycosylation process there are up to 
twenty GalNAc-Ts isoforms that can attach GalNAc, as opposed to the only one 
transferase enzyme that exists for N-linked glycosylation. GalNAc-Ts show 
distinct, although partly overlapping, kinetic properties and acceptor substrate 
specificities. 9 Thus, it is the available repertoire of GalNAc-Ts the factor that 
determines which proteins are O-glycosylated and where. In this context, in one 
hand there are individual GalNAc-Ts exclusively responsible to glycosylate a 
single site in proteins30–33 (non-redundant glycosylation). In other hand, 
Mn2+
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B
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glycosylation of mucins, proteins that have multiple sites of glycosylation, is 
covered by multiple GalNAc-Ts (redundant glycosylation).   
The recognition of O-glycosylation sites by GalNAc-Ts depends whether 
these enzymes interact with naked or previous glycosylated regions of the substrate. 
While naked peptides appear to be exclusively recognized by the catalytic domain, 
glycopeptides recognition rely on the existence of a cooperative mechanism 
between the catalytic and lectin domains (Figure 2.1.3).34  Additionally, Thr is a 
much better acceptor than Ser, while the preferred glycosylation sites are associated 
with high contents of Pro, Gly, and, obviously, Ser and Thr. Other predictive trend 
among most GalNAc-Ts is a common motif where a Pro residue is essential at +3 
position and positive effect in positions −1, +1, +2 and +4 from the site of 
glycosylation (PxP motif, where x can be any amino acid).20,35,36  
The lectin domain mediates the GalNAc-peptide substrate specificity thus 
increasing the efficiency of the enzymatic activity and modulating glycosylation 
site specificity in partially glycosylated acceptor substrates.23 Lectin binding to the 
GalNAc attached at the glycopeptide directs the peptide acceptor onto the catalytic 
domain in a particular direction (N- and/or C-terminal) (Figure 2.1.5).21 For 
example, GalNAc-T3/T4/T6/T12 preferentially glycosylate those C-terminal sites 
that are remote from the prior N-terminal GalNAc site,21,37 whereas GalNAc-
T1/T2/T14 exhibit the opposite preference.20,29,38 Other GalNAc-Ts, such as 
GalNAc-T5/T13/T16 do not exhibit orientation preferences for long-range 
glycosylation.21  
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Figure 2.1.5 – Schematic representation of preferences of two GalNAc-Ts groups. 
 
The present chapter focuses on the application of a multidisciplinary 
approach combining different experimental and theoretical techniques and methods 
to provide new structural insights with atomic resolution to understand the 
mechanism of action of GalNAc-Ts. 
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2.2  GalNAc-Ts glycosylation follow an 
induced-fit catalytic mechanism.  
 
 
The work presented in this subchapter has been performed in collaboration 
with different research groups 
-Matilde de las Rivas (PhD student) and Dr. Erandi Lira-Navarrete, at the 
laboratory of Dr. Ramon Hurtado-Guerrero (BIFI, University of Zaragoza) 
performed the expression and purification of GalNAc-Ts and the X-Ray 
crystallography experiments. 
- Dr. Francisco Corzana at the Universidad de La Rioja was responsible for 
the Molecular Dynamics simulations, while Ismael Compañón (PhD student) was 
in charge of the synthesis of the peptide. 
- Dr. Henrik Clausen and Dr. Sergey Y. Vakhrushev Labs at the Copenhagen 
Center for Glycomics, University of Copenhagen, Denmark performed the MS/MS 
assays. 
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Navarrete, Ismael Compañón, Jesús Jiménez-Barbero,  Katrine T. Schjoldager, Eric 
P. Bennett, Sergey Y. Vakhrushev, Henrik Clausen, Francisco Corzana, Filipa 
Marcelo, Ramon Hurtado-Guerrero (2018) Chemistry - A European Journal, 24, 
8382 –8392. (co-first author). 
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2.2.1 Introduction 
Deficiencies and dysregulation of individual GalNAc-Ts have been found to 
cause diseases and predispositions. Recently, it was demonstrated that a GALNT2 
mutant (F104S) leading to the inactivation of the enzyme, induces low levels of high-
density lipoprotein cholesterol (HDL-C) in humans. It was also discovered that the 
low levels of HDL-C were likely due to the disruption of the O-glycosylation of 
phospholipid transfer protein (PLTP), which leaded to a decrease in its activity.32 
Structurally, GalNAc-Ts display a unique characteristic among glycosyl-
transferases: apart of the N-terminal catalytic domain, they also possess a unique 
C-terminal lectin domain, being both domains connected by a short flexible linker 
(Figure 2.2.1). Another interesting structural feature of these enzymes is that there 
is a flexible loop in the catalytic domain, comprising residues Val360 to Gly372 in 
GalNAc-T2.20,29 The flexible loop present in the catalytic domain may adopt 
different conformations during the catalytic cycle, thus dictating the catalytic 
activity of the enzyme, either active or inactive.20,29,39,40 This unique conformational 
behavior of the flexible loop has been reported exclusively by using X-ray 
crystallography.20,29,39,40 Thus, the significance of this structural element required 
additional experiments in solution to address the dynamic and association of this 
loop to GalNAc-T2 enzyme kinetics.  
Structural studies on GalNAc-Ts may also serve as a platform to infer how 
mutations on these enzymes might lead to a loss-of-function.20,22,25,29,39,40 The F104S 
mutant in GalNAc-T2 precisely illustrates this idea, since Phe104 is not located at 
the active site, but placed at a distance of ~5 Å from the flexible loop or the 
D224xH226 motif, which in turn coordinates a manganese ion together with His359 
(Figure 2.2.1)20,22,25,29,39,40 Thus, it is not obvious how the mutation of Phe to Ser 
may impair GalNAc-T2 activity. The objective this work was to understand how 
the mutation F104S in GalNAc-T2 leads to a loss-of-function. 
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Figure 2.2.1 - States of the flexible loop and location of Phe104. (I) Superimposition of the 
crystal structures of the complexes of GalNAc-T2 with UDP and the MUC5AC-1320 
glycopeptide (white color; PDB: 5AJP, with that of GalNAc-T2 with UDP (white color; 
PDB: 2FFV). The GalNAc residue in MUC5AC-13 is colored in orange. UDP and 
MUC5AC-13 are depicted as orange and green carbon atoms, respectively. The D224xH226 
motif/His359 site is shown as black carbon atoms. The flexible loop is depicted in blue (open 
conformation) and yellow (closed conformation) for the PDB entries 2FFV and 5AJP, 
respectively. Mn+2 is shown as a pink sphere. (II) Close-up view of the active site (PDB 
entry 5AJP) showing the distance of Phe104 from the flexible loop and His226. The structure 
is shown in grey. The other structural features/amino acids are shown with the same colors 
above except Phe104 is depicted as blue carbon atoms. 
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2.2.2 Results and Discussion  
2.2.2.1 Stability and Binding assays 
A thermal shift-assay experiment was performed to evaluate the stability of 
WT GalNAc-T2 and its F104S mutant. The results clearly evidenced that the WT 
enzyme was 5°C more than the mutant F104S (with denaturation temperature of 47 
± 0.09°C for the WT enzyme 42 ± 0.05°C for the mutant), implying that the 
mutation leads to a significant decrease on the stability of the mutant (Figure 2.2.2). 
In addition, the tryptophan fluorescence spectroscopy analysis of UDP-GalNAc 
binding revealed that both enzymes bind UDP-GalNAc in a similar manner, being 
the Kd of to the mutant 1.7-fold higher than that determined for the WT enzyme 
(Figure 2.2.2).  
 
 
Figure 2.2.2 - Stability and binding properties of the WT GalNAc-T2 and the F104S mutant. 
(I) Thermal denaturation curves of the WT GalNAc-T2 and the F104S mutant as monitored 
by fluorescence using 1-anilino-8-naphthalene sulfonate (ANS) as probe. (II) Kd values for 
UDP-GalNAc binding determined from the tryptophan fluorescence intensity as a function 
of the nucleotide concentration. 
 
Fittingly, STD-NMR experiments of the peptide substrate MUC5AC only 
showed STD response in the presence of the WT enzyme, but not with the F104S 
mutant (Figure 2.2.3 and Figure 2.2.4). This result points out that the mutant is not 
able to properly recognize the peptide substrate, thus explaining the observed 
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inactivity of the mutant towards the protein substrate, PLTP.32 In addition, the WT 
enzyme evidenced the strongest STD-NMR signals for the “PSPVPT” fragment 
within the peptide sequence. It is noteworthy mentioning that this Thr residue 
constitutes the main acceptor site on this peptide for GalNAc-T2.  
 
 
Figure 2.2.3 - STD-NMR experiments were recorded at 298K and 600MHz. (Up) STD 
experiments (Off resonance spectrum at the top, in black) for MUC5AC (740 µM) in the 
presence of the F104S mutant (18.5 µM), UDP (75 µM) and MnCl2 (75 µM). (Down) STD 
experiments (Off resonance spectrum in black) for MUC5AC (560 µM) in the presence of 
WT GalNAc-T2 (14 µM), UDP (75 µM) and MnCl2 (75 µM).  
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Figure 2.2.4- STD-NMR-derived epitope mapping of MUC5AC. The different colored 
spheres indicate the normalized STD signal (in percent) observed for each proton.  
 
The STD-NMR derived epitope is in agreement with the importance of the 
PxP motif previously described to be essential for GalNAc-Ts recognition in a 
variety of protein substrates. For the interaction with the WT enzyme, Thr9 of 
MUC5AC was the best-recognized acceptor site, which also agrees with previous 
results that demonstrated that this residue is the most glycosylated one.38 Hence, 
while there are not major differences in recognition to UDP-GalNAc between the 
WT enzyme and the mutant, the differences in activity are accounted for the 
inability of the mutant F104S to bind peptide substrates. 
 
2.2.2.2 X-Ray Crystallography & MD Simulations 
To clarify the molecular basis of why the F104S mutant does not bind to the 
MUC peptides, tetragonal crystals of this mutant in complex with UDP were 
obtained, which were subsequently soaked with UDP-GalNAc. The resulting 
crystal allowed us to solve the corresponding structure at 2.70 Å resolution. The 
crystal structure shows a compact structure with the typical GT-A fold for the 
catalytic domain at the N-terminus, while the lectin domain is located at the C-
terminal region (Figure 2.2.5).  
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Figure 2.2.5 - Crystal structure of the F104S mutant. Cartoon representation of the overall 
mutant F104S in complex with UDP-GalNAc (left) and the WT (right panels) either in 
complex with UDP29 (PDB entry 2FFV) or UDP/MUC5AC-1320 (PDB entry 5AJP). The 
proteins and the GalNAc moiety of MUC5AC-13 are colored in grey and orange, 
respectively. UDP/UDP-GalNAc (orange), MUC5AC-13 (green), the flexible loop (yellow), 
and the loop α1-α2 (blue) are also highlighted. The Phe104, Val360/Arg362 and the D224xH226 
motif/His359 are shown as sticks in blue, yellow and black carbon atoms, respectively. Other 
residues interacting with Phe104 are shown as brown carbon atoms. The Mn+2 ion is showed 
as a pink sphere.  
 
The crystal structure shows that the flexible loop in the F104S mutant is 
disordered (Figure 2.2.5), exposing the UDP-GalNAc to the solvent. The UDP 
moiety in the PDB entry 2FFV is also exposed to the solvent. In this structure, the 
flexible loop displays an open conformation rendering the enzyme in an inactive 
state (Figure 2.2.5). Thus, the structure of the mutant F104S with UDP-GalNAc 
resembles the structure of the WT enzyme in its inactive state. This conformation 
is completely different to that observed in the active state. In this case, the flexible 
loop displays a closed conformation that functions covering either UDP-GalNAc 
or UDP from the solvent (e.g. see PDB entries 5AJP, 4D0T and 4D0Z; Figure 
2.2.5). This particular geometry is required to bind the peptide/protein 
substrates.20,29 The closed conformation of the flexible loop is stabilized by 
interactions of His365 and Phe369 with Trp331 (in-conformation) and by additional 
interactions with the donor substrate UDP-GalNAc (Figure 2.2.6).29  Thus, it is 
important mentioning that the active state can only be achieved when the flexible 
loop adopts the close conformation and the Trp331 displays the “in-conformation”. 
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Figure 2.2.6 - Close-up view of the sugar nucleotide and peptide binding site of the F104S-
UDP-GalNAc and WT-UDP-5S-GalNAc-mEA2 complexes. Hydrogen bond interactions 
are shown as dotted green lines. 
 
The detailed analysis of the structure of the mutant permitted to observe that 
there was not enough electron density to properly define the orientation of Ser104 
along with most of the residues of the loop between the secondary structures α1 and 
α2 (named hereafter loop α1-α2) (Figure 2.2.5). Thus, it is tempting to suggest that 
these disordered states of both the flexible loop and the loop α1-α2 in the inactive 
mutant might also explain why this mutant is 5°C less than the WT enzyme. On the 
other hand, for WT GalNAc-T2, the Phe104 residue establishes hydrophobic 
stacking interactions with Ala151, Ile256, Val360 and Phe261, probably stabilizing the 
loop α1-α2 in the WT enzyme and the flexible loop in the inactive state (Figure 
2.2.7). In the active state of the enzyme, Phe104 also establishes a cation-π 
interaction with Arg362 (Figure 2.2.7), which is located at the flexible loop. This 
interaction appears to be key to render the closed conformation. The mutation to 
Ser104, which is a polar residue, probably disrupts the interactions with the 
hydrophobic/aromatic residues, leading to the destabilization of the loop α1-α2 and 
the inability of reaching the required closed conformation for the flexible loop. 
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Figure 2.2.7 - Close-up view of the complete sugar nucleotide and partial peptide-binding 
site of the different complexes. The residues interacting with Phe104 are magnified. Trp331 is 
shown in the “out” and “in conformations”. 
 
To understand how the F104S mutation disturbs the dynamics of the flexible 
loop, molecular dynamics (MD) simulations (during 200 ns) were performed in 
explicit water for both the WT GalNAc-T2 and the F104S mutant in presence of 
UDP-GalNAc. The analysis of the data permitted to conclude that the flexible loop 
of the F104S mutant exhibited significantly larger conformational changes, with 
root-mean-square-deviation (RMSD) ranging between 1-5.3 Å, as compared to 1-
3 Å deviations for the WT analogue (Figure 2.2.8). The variations of the Cα 
distances between the Phe104 or Ser104 residues and Val360 were also rather different 
highlighting the different flexibilities between the two structures. A shorter distance 
of 5.74 Å was found between Phe104 and Val360, while highly variable and larger 
distances (between 4.5-16 Å) were found between Ser104 and Val360 (Figure 2.2.8).  
Furthermore, the distance distributions between the Arg362/Phe104 and 
Arg362/Ser104 Cα pairs were also determined (Figure 2.2.8). For the WT GalNAc-
T2, the average distance of 4.71.4 Å suggests that there are hydrophobic 
interactions between the aromatic ring of Phe104 and the side-chain of Val360. In 
contrast, two populations were found for the F104S mutant. A minor population, 
with distances ranging between 3.5-7 Å and a major population, with rather 
oscillating distances, between 7.5-17 Å (Figure 2.2.8). These results also point out 
that the flexible loop and the loop α1-α2 are much more structured in the WT 
enzyme than in the F104S mutant. 
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Figure 2.2.8 - Molecular dynamics simulations on the WT GalNAc-T2 and the F104S mutant. 
The RMSD values calculated by 200 ns molecular dynamics simulations for the flexible 
loop. Distances between Ser104 (Cα) and Val360 (Cα)/Arg362 (Cα) compared to the 
corresponding distances (Phe104-Val360 and Phe104-Arg362) found in the WT GalNAc-T2. The 
center of mass of the π-electron system of Phe104 was used to calculate the distances. 
 
2.2.2.3 19F labelling of the WT GalNAc-T2 and F104S mutant for NMR 
experiments. 
19F-NMR spectroscopy experiments were also performed on both enzymes 
to experimentally monitor the dynamics of the flexible loop. 19F-NMR chemical 
shifts are highly sensitive to changes in the local conformational environment and 
therefore, the measurement of these parameters constitutes a well-established 
approach for studying protein structure and dynamics.41 The inclusion of a 19F label 
required the mutation of Thr375 by a more nucleophilic Cys residue, in both WT 
GalNAc-T2 and the mutant F104S variants. In particular, Thr375 was selected for 
different reasons: 
i) This residue is rather exposed and therefore amenable to modifications;  
ii) It is very close to the flexible loop (Val360 to Gly372);  
iii) The X-ray crystallographic analyses indicate that Thr375 is sensitive to the 
flexible loop dynamics and may adopt different conformations depending on the 
geometry of the flexible loop (open or closed) (Figure 2.2.9).  
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Figure 2.2.9 – The conformation of Thr375. Close-up view of the active site of PDB entries 
2FFV and 5AJP (inactive and active states, respectively). The flexible loop adopts an open 
(2FFV) or closed conformation (5AJP) and is colored in yellow. MUC5AC-13 is depicted 
with sticks using the green carbon atoms, whereas the GalNAc-moiety is in orange carbon 
atoms. UDP is colored in orange. The secondary structures are brown and grey for the 
PDB entries 2FFV and 5AJP, respectively. Thr375 is depicted as sticks in brown (2FFV) and 
blue (5AJP) carbon atoms. 
 
Consequently, both the WT GalNAc-T2 and the F104S mutant variants, 
containing the T375C mutation were produced.42 The 19F label could be efficiently 
introduced using 3-bromo-1,1,1-trifluoroacetone (BFA),41 under mild conditions (5 
min, phosphate buffer pH 7.0, room temperature) to give a single SCH2(CO)CF3 
adduct (GalNAc-T2* and F104S*). However, while the GalNAc-T2* was 100% 
labelled, the F104S* was not fully modified resulting in 93%, as shown by the 
analysis of the MS/MS data (Figure 2.2.10).  
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Figure 2.2.10 - Relative quantification based on the extracted ion chromatogram between 
peptides with and without the 19F label at the position Cys375.  
 
The activities of the WT GalNAc-T2 and GalNAc-T2* analogues were 
compared under the same conditions. Upon introduction of the SCH2(CO)CF3 tag, 
the GalNAc-T2* variant displayed a reduction of nearly 50% in activity in 
comparison to the WT GalNAc-T2 analogue. Nevertheless, the new enzyme stills 
remained active was able to glycosylate the peptide substrates (Figure 2.2.11). 
 
 
Figure 2.2.11 - Specific activity of the WT GalNAc-T2 and GalNAc-T2* using the MUC1 
peptide as acceptor substrate. The data represent means ±SD. for 3 independent 
experiments. 
GalNAc-T2* F104S*
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2.2.2.4 19F-NMR experiments 
2.2.2.4.1  The modified native GalNAc-T2* enzyme 
First, 1H-NMR experiments were performed to monitor the ability of both 
enzymes, GalNAc-T2* and F104S* to glycosylate the MUC5AC peptide (Figure 
2.2.12). In the presence of UDP-GalNAc and MUC5AC, only GalNAc-T2*, and 
not the F104S* mutant, was able to glycosylate MUC5AC. This fact is in agreement 
with previous kinetic experiments that that the F104S mutant was inactive on certain 
peptide/protein substrates.32 The appearance of new NMR signals at 2.05 ppm 
corresponding to the NHAc methyl group of the GalNAc-Thr motif and a dramatic 
alteration of the chemical shifts of the methyl protons of the Thr amino acids of the 
peptide (δ = 1.20-1.35ppm) clearly indicated the presence of glycosylation (Figure 
2.2.12). 
 
 
Figure 2.2.12 - Glycosylation experiment of MUC5AC at 298K and 600MHz. (I) 1H-NMR 
of MUC5AC (1760 μM). (II) 1H-NMR of MUC5AC (1760 μM) in presence of GalNAc-T2* 
(22 μM), MnCl2 (150 μM) and 5280 μM UDP-GalNAc after 12 h (III) 1H-NMR of MUC5AC 
(1760 μM) in presence of F104S* (22 μM), MnCl2 (150 μM) and 5280 μM UDP-GalNAc 
after 12 h.  
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Then, in order to evaluate whether the 19F-NMR label was sensitive to the 
dynamics of the flexible loop upon glycosylation, different 19F-NMR experiments 
on GalNAc-T2* were performed using a variety of conditions (Figure 2.2.13). 
 
 
Figure 2.2.13 - 19F-NMR Spectra of GalNAc-T2* at 298K and 600MHz. Blue color 
corresponds to GalNAc-T2* (135 µM). Green color corresponds to GalNAc-T2* 
(135 µM) and MnCl2 (225 µM). Red color corresponds to GalNAc-T2* (135 µM), 
MnCl2 (225 µM) and UDP-GalNAc (225 µM). Grey color corresponds to the 
GalNAc-T2* (135 µM), MnCl2 (225 µM), UDP-GalNAc (225 µM) and MUC5AC 
(150 µM).  
 
The 19F-NMR spectra (Figure 2.2.13) also showed signals corresponding to 
the external reference 1,1,1,3,3,3-hexafluoro-2-propanol (δ = -75.7 ppm), added for 
calibration purposes. Additional signals were observed for the 3-bromo-1,1,1-
trifluoroacetone reactive used for the protein labelling (δ = -83.3 ppm) as well as 
for the trifluoracetic acid used in the peptide synthesis procedure (δ = -75.4 ppm). 
Two specific 19F-NMR signals at δ = -84.0 ppm and δ = -84.3 ppm were also present 
for GalNAc-T2*. The 19F signal at δ = -84.3 ppm remained unperturbed during all 
the set of conditions and combinations in terms of addition of substrates. The 
linewidth of this 19F-NMR peak (161 Hz) is significantly larger than that at δ = -
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84.0 ppm (111 Hz). Thus, this 19F-NMR resonance can potentially be attributed to 
the oligomeric state of GalNAc-T2*. Which is consistent with a reduced transverse 
relaxation time of the oligomeric enzyme.43 In fact, it has been previously 
demonstrated, by using SAXS experiments, that GalNAc-T2 forms oligomers that 
are not involved in the catalysis process.20 This premise may satisfactorily explain 
the lack of perturbation of this NMR signal to the distinct sample conditions.  
In contrast, after addition of UDP-GalNAc, the 19F-NMR signal at -84.0 ppm 
vanished, and a new signal appeared at δ = -83.7ppm (Figure 2.2.13 and Figure 
2.2.14). It is remarkable that the interconversion between these two 19F-NMR 
resonances (-84.0 ppm and -83.7 ppm) only occurs in the presence of UDP-
GalNAc. Indeed, in the absence of UDP-GalNAc, the addition of Mn+2 or the 
MUC5AC peptide (Figure 2.2.14 panel II (in grey: peptide without UDP-GalNAc)) 
did not induce any appreciable perturbation in the 19F-NMR spectrum of GalNAc-
T2*. This result strongly suggests that the 19F-NMR resonances at δ = -84.0 ppm 
and δ = -83.7 ppm correspond to the open and closed conformations of the flexible 
loop, respectively. These two populations are in equilibrium and in slow exchange 
in the NMR chemical shift timescale and therefore, are detected as two signals.  
 
 
Figure 2.2.14 - 19F-NMR Spectra of GalNAc-T2* showing the open and closed loop 
conformations as a function of donor and acceptor substrate additions. (I) Blue color 
corresponds to unliganded GalNAc-T2*. The green color corresponds to GalNAc-
T2* in the presence of MnCl2 (225 µM). Red color corresponds to GalNAc-T2*, 
MnCl2 (225 µM) and UDP-GalNAc (225 µM). Grey color corresponds to GalNAc-
T2*, MnCl2 (225 µM), UDP-GalNAc (225 µM) and MUC5Ac (150 µM). (II) Blue 
open
Monomer
closed
Monomer
Oligomer
19F ppm
open
Monomer
closed
Monomer
Oligomer
19F ppm
Blue: Protein Green: MnCl2 Red: UDP-GalNAc Grey: MUC5AC       Magenta:UDP
open
Monomer
closed
Monomer 
Oligomer
19F ppm
IIIIII
 Deciphering GalNAc O-glycosylation 
GalNAc-Ts glycosylation follow an induced-fit catalytic mechanism  
 
 
 63 
color corresponds to unliganded GalNAc-T2*. Grey color corresponds to GalNAc-
T2* and MUC5AC (150 µM). Green color corresponds to GalNAc-T2*, MUC5AC 
(150 µM) and MnCl2 (225 µM). Red color corresponds to GalNAc-T2* (135 µM), 
MUC5Ac (150 µM), MnCl2 (225 µM) and UDP-GalNAc (225 µM). (III) Blue 
corresponds to GalNAc-T2* (135 µM). Green corresponds to GalNAc-T2* (135 
µM), MnCl2 (225 µM). Magenta corresponds to GalNAc-T2* (135 µM), MnCl2 (225 
µM) and UDP (225 µM). Gray corresponds to GalNAc-T2* (135 µM), MnCl2 (225 
µM), UDP (225 µM) and MUC5AC (150 µM). The Full spectra are present in Figure 
2.2.13 and Supporting Information (Figure S1-S2). 
 
An additional set of experiments in the presence of UDP (Figure 2.2.14 panel 
III) were also recorded. The addition of UDP yielded a similar result than that 
described for UDP-GalNAc. However, the effect in the interconversion between 
the open and closed conformations of the flexible loop was not as pronounced as in 
the presence of UDP-GalNAc. All together, these evidences show that UDP-
GalNAc is absolutely required for the interconversion between the open and closed 
conformations of the flexible loop and that provides a better stabilization of the 
closed conformation than UDP (Figure 2.2.14).  
In this proposed mechanism, the unliganded GalNAc-T2 enzyme rests 
always in an inactive state (open flexible loop) that only moves to the active state 
(closed flexible loop) in the presence of UDP-GalNAc/MnCl2. In contrast to the 
earlier hypothesis,29 these evidences precludes the potential existence of an 
equilibrium between the inactive and active states in the absence of UDP-
GalNAc/MnCl2. Once the enzyme is in the active state, the peptide can bind and 
then catalysis will take place.  
 
2.2.2.4.2  The modified F104S* mutant enzyme 
The same set of experiments was performed for F104S* (Figure 2.2.15). In 
this case, and independently of the conditions used in the experiments, no alteration 
in the 19F-NMR spectrum was observed. In particular, the addition of UDP-GalNAc 
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did not induce any perturbation of the 19F- NMR resonance signal at δ = -84.0 ppm. 
This result also confirms the assignment of the peak at δ = -84.0 ppm to the open 
conformation of the flexible loop. Furthermore, the analysis of the 19F-NMR 
experiments demonstrated that the flexible loop in F104S* is fixed in open 
conformation that precludes further binding to the peptides. This geometry 
corresponds to an inactive enzyme, which is not able to glycosylate peptides.  
Overall, the 19F-NMR experiment provides the molecular basis to explain 
why the mutant F104S does not recognize peptides and, therefore, it is inactive.  
 
 
Figure 2.2.15 - 19F-NMR Spectra of F104S* showing the open conformation even in 
presence of donor and acceptor substrate. (I) Blue color corresponds to unliganded F104S*. 
The green color corresponds to F104S* in the presence of MnCl2 (130 µM). Red color 
corresponds to F104S*, MnCl2 (130 µM) and UDP-GalNAc (130 µM). Grey color 
corresponds to F104S*, MnCl2 (130 µM), UDP-GalNAc (130 µM) and MUC5Ac (100 µM). 
(II) Blue color corresponds to unliganded F104S*. The green color corresponds to F104S* in 
the presence of MnCl2 (130 µM). Magenta color corresponds to F104S*, MnCl2 (130 µM) 
and UDP (130 µM). Grey color corresponds to F104S*, MnCl2 (130 µM), UDP (130 µM) 
and MUC5Ac (100 µM). Full spectra are present in Supporting Information (Figure S3 and 
S4). 
 
2.2.3 Conclusions  
The study presented herein provides another excellent example of the effect 
of remote mutations in the structure and function of enzymes. Within this work, we 
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have provided compelling evidences that indicate that the inactive-to-active state 
transition of the flexible loop in the GalNAc-T2 F104S mutant is hindered. The 
presence of the polar residue Ser104 precludes the establishment of stabilizing 
interactions with a variety of residues. This causes the instability of both the flexible 
and the α1-α2 loops, which hampers the flexible loop to adopt the closed 
conformation required for binding and catalysis.42 The recognition process follows 
an induced-fit-mechanism for which UDP-GalNAc is absolutely required.  
Finally, these results have exploited the knowledge obtained from a mutant 
associated to a pathology to get more insights into the molecular mechanism of the 
GalNAc-Ts. This fact also exemplifies the importance of the understanding the 
molecular basis of mutations associated to disease for the design and 
implementation of plausible therapeutic approaches. 
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2.2.4 Supporting Information  
2.2.4.1 19F-NMR spectra 
 
Figure S1 - 19F-NMR Spectra of GalNAc-T2* at 298K and 600MHz. Blue color 
corresponds to GalNAc-T2* (135 µM). Grey color corresponds to GalNAc-T2* (135 
µM), MUC5AC (150 µM). Green color corresponds to GalNAc-T2* (135 µM), 
MUC5AC (150 µM) and MnCl2 (225 µM). Red color corresponds to GalNAc-T2* 
(135 µM), MUC5AC (150 µM), MnCl2 (225 µM) and UDP-GalNAc (225 µM). 
 
 
Figure S2 - 19F-NMR Spectra of GalNAc-T2* at 298K and 600MHz. Blue 
corresponds to GalNAc-T2* (135 µM). Green corresponds to GalNAc-T2* (135 
µM),  MnCl2 (225 µM). Magenta corresponds to GalNAc-T2* (135 µM), MnCl2 (225 
µM) and UDP (225 µM). Gray corresponds to GalNAc-T2* (135 µM), MnCl2 (225 
µM), UDP (225 µM) and MUC5AC (150 µM). 
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Figure S3 - 19F-NMR Spectra of F104S* at 298K and 600MHz. Blue corresponds to F104S* 
(86 µM). Green corresponds to F104S* (86 µM) and MnCl2 (130 µM). Red corresponds to 
F104S* (86 µM), MnCl2 (130 µM) and UDP-GalNAc (130 µM). Grey corresponds to F104S* 
(86 µM), MnCl2 (130 µM), UDP-GalNAc (130 µM) and MUC5AC (100 µM). 
 
Figure S4 - 19F-NMR Spectra of F104S* at 298K and 600MHz. Blue corresponds to F104S* 
(86 µM). Green corresponds to F104S* (86 µM) and MnCl2 (130 µM) Magenta corresponds 
to F104S* (86 µM), MnCl2 (130 µM) and UDP (130 µM). Grey corresponds to F104S* (86 
µM), MnCl2 (130 µM), UDP (130 µM) and MUC5AC (100 µM). 
TFA open
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2.3 Deciphering the Mechanism of Long 
and Short Distance-Glycosylation of 
GalNAc-Ts 
 
 
The work presented in this subchapter has been performed in collaboration 
with: 
-Matilde de las Rivas (PhD student) and Dr. Erandi Lira-Navarrete, at the 
laboratory of Dr. Ramon Hurtado-Guerrero (BIFI, University of Zaragoza) 
performed the expression and purification of GalNAc-Ts (mutants and chimeras) 
and the X-Ray crystallography experiments.  
- Dr. Francisco Corzana, Dr. Gonzalo Jiménez-Osés (Universidad de La 
Rioja, Logroño, Spain), Dr. Carmen Rovira and Lluis Raich (PhD student) 
(IQTCUB, Universitat de Barcelona, Barcelona, Spain) were responsible for the 
Molecular Dynamics simulations, while Ismael Compañón (PhD student) at the 
laboratory of Dr. Francisco Corzana was responsible for the synthesis of the 
peptides.  
- Dr. Thomas A. Gerken and Dr. Earnest James Paul Daniel performed the 
kinetic studies and the Edman-based amino acid sequencing process. 
 
Publications: (1) - Matilde de las Rivas, Erandi Lira-Navarrete, Earnest James Paul 
Daniel, Ismael Compañón, Helena Coelho, Ana Diniz, Jesús Jiménez-Barbero, Jesús M. 
Peregrina, Henrik Clausen, Francisco Corzana, Filipa Marcelo, Gonzalo Jiménez-Osés, 
Thomas A. Gerken & Ramon Hurtado-Guerrero (2017) Nature Communications 8: 1959 
(DOI: 10.1038/s41467-017-02006-0).       
(2) - Matilde de las Rivas, Earnest James Paul Daniel, Helena Coelho, Erandi Lira-
Navarrete, Lluis Raich, Ismael Compañón, Ana Diniz, Laura Lagartera, Jesús Jiménez-
Barbero, Henrik Clausen, Carme Rovira, Filipa Marcelo, Francisco Corzana, Thomas A. 
Gerken, and Ramon Hurtado-Guerrero (2018) ACS Central Science, 4, 1274−1290 
(DOI: 10.1021/acscentsci.8b00488). 
 Deciphering GalNAc O-glycosylation 
Deciphering the Mechanism of Long and Short Distance-Glycosylation of GalNAc-Ts  
 
 
 71 
2.3.1 Introduction 
GalNAc-Ts display distinct kinetic properties as well as different 
glycosylation capacities on their peptide and glycopeptides substrates. On this 
basis, GalNAc-Ts can be classified following three distinct glycosylation modes: 
i) Only catalytic domain-dependent glycosylation on unglycosylated 
peptides and glycopeptides (Figure 2.3.1a) 
ii) short distance-glycosylation21,37 (Figure 2.3.2b) 
iii) lectin domain-assisted, long distance-glycosylation on 
glycopeptides21,37 (Figure 2.3.1c). 
 
 
Figure 2.3.1 - Modes of O-glycosylation found for GalNAc-Ts. a–c. The panels describe 
the three distinct modes of O-glycosylation performed by GalNAc-Ts: the neighboring 
glycosylation activity by the catalytic domain in a and b, and the long-range lectin 
domain-mediated glycosylation activity in c. Peptides are indicated in blue. The black 
hexagon-shaped Figure denotes the position of prior GalNAc moieties at the 
glycopeptides. Arrows indicate the positions of the acceptor sites.  
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Short distance-glycosylation refers to the glycosylation on GalNAc-
containing glycopeptides. In this case, the sites of glycosylation are only 1 to 3 
residues away from the prior glycosite.21,37 Sites adjacent and neighboring to an 
existing GalNAc glycosite are glycosylated in a catalytic domain-dependent 
manner. In particular, GalNAc-T4, together GalNAc-T7, T10 and T12 are the only 
GalNAc-Ts that have been shown to glycosylate contiguous or nearby sites.21 
Long-range glycosylation activity refers to the glycosylation of GalNAc 
glycopeptides where the sites of glycosylation are 5-15 residues away from the 
prior glycosite. In this case, the lectin domain binds a particular GalNAc residue 
already present at the glycopeptide, and directs the peptide acceptor onto the 
catalytic domain towards the N- and/or C-terminal directions.21 For example, 
GalNAc-T3, T4, T6, and T12 preferentially glycosylate C-terminal glycopeptides 
sites remote from the prior N-terminal GalNAc glycosites,21,37 whereas GalNAc-
T1, T2, and T14 exhibit the opposite preference.20,29,38 Other GalNAc-Ts, T5, T13, 
or T16 do not exhibit preferences for long-range glycosylation.21  
Structural studies on GalNAc-T2 bound to unglycosylated and glycopeptides 
have provided insights into the catalytic domain reaction, and have also 
demonstrated how the GalNAc-T2 lectin domain guides catalysis to N-terminal 
acceptor sites very distant from the prior C-terminal GalNAc glycosite.20,29 On the 
other hand, the molecular basis of how other GalNAc-Ts such as GalNAc-T3, T4, 
T6, and T12 realize the opposite long range-glycosylation preferences remains 
unclear.21,37  
Thus, the understanding of the molecular basis of how long and short range-
glycosylation proceed is of paramount importance to decipher the GalNAc-Ts 
preferences and how these enzymes perform their so-called “filling in” activities, 
this is how they complete the glycosylation process on heavily glycosylated mucin 
domains.    
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2.3.1 Results and Discussion  
2.3.1.1 Long distance-glycosylation  
Two possible models have been proposed to explain the different preferences 
for long distance-glycosylation37 (Figure 2.3.2). In model 1, rotation of the 
GalNAc-binding lectin domain is required. It is noteworthy to mention that 
GalNAc-Ts lectin domains contain three potential carbohydrate-binding sites 
dubbed α, β and γ. However, in most GalNAc-Ts, only one of them is 
functional.21,23,27,31 In model 2, GalNAc-binding lectin domain adopts the same 
orientation as that found in GalNAc-T2. In contrast, the glycopeptide must adopt 
an inverse orientation on the catalytic domain (Figure 2.3.2).  
Herein, we have adopted a multidisciplinary approach using different 
constructs of GalNAc-T4 and GalNAc-T2 to reveal the molecular basis of the long-
distance glycosylation preferences of GalNAc-Ts.  
 
 
Figure 2.3.2 - Two possible models have been proposed to explain the different long-
distance glycosylation preferences of GTs. Peptides are indicated in blue, while the black 
hexagon-shaped Figure denotes the position of the prior GalNAc moieties in the 
glycopeptides. Arrows indicate the positions of the acceptor sites. 
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2.3.1.1.1 The interaction and kinetics of GalNAc-T4 
Three peptides were designed and synthetized to test the long-distance 
glycosylation preference of GalNAc-T4 (Table 2.3.1). One of these peptides was 
the naked peptide, 1 (--TT--), whereas the other two were monoglyco-peptides, 2 
(TT--T*; the * denotes the glycosylated Thr) and 3 (T*--TT), which contained a 
GalNAc moiety (T*), located either at the C- and N-terminus, respectively. All 
peptides show two potential Thr acceptor sites and also contain the PxP motif, 
which is selectively recognized by most GalNAc-Ts.20 
 
Table 2.3.1 - Peptide sequences used in this study. * denotes the location of the existing 
GalNAc moiety.  
Peptides Sequence 
1 (--TT--) GAGAGAGTTPGPG 
2 (TT--T*) AGAGTTPGPGAGAT*GA 
3 (T*--TT) GAT*GAGAGAGTTPGPG 
 
Based on the kinetics results (Figure 2.3.3a), GalNAc-T4 selectively 
glycosylates peptide 3 with high affinity, Km ~40 µM, and catalytic efficiency ~75 
nmole min−1. The enzyme did not show any evidence of glycosylation on peptides 
1 and 2 (Figure 2.3.3a). These observations are in agreement with previous results 
that described that GalNAc-T4 only glycosylates C-terminal sites of monoglyco-
peptides when the prior glycosite is at the N-terminus, using the lectin domain as 
template for the process. Thus, binding studies using saturation-transfer difference 
(STD) NMR experiments were performed (Figure 2.3.3b and Figure SI1). 
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Figure 2.3.3 - Biophysical characterization of GalNAc-T4 against peptides 1-3. a, Peptide 
glycosylation kinetics of GalNAc-T4 on peptides 1-3 (black, red, and blue symbols, 
respectively). The plot represents the average of triplicate experiments. b, STD-NMR- 
derived epitope mapping.  STD spectra are present in Supporting Information (Figure S11). 
 
The results revealed that the unglycosylated peptide was very poorly 
recognized by GalNAc-T4, in agreement with the kinetic assays. The recognition 
of glycosylated peptides by GalNAc-T4 showed weak but observable STD signals, 
indicating that the peptide backbone is poorly recognized by GalNAc-T4, using the 
methoxy group of α-methyl-GalNAc as control (Figure 2.3.3b). It is noteworthy to 
mention that the GalNAc moiety of the mono-glycopeptides 2 and 3 showed 
unambiguous STD signals (Figure 2.3.3b and Figure SI1). Fittingly, 2 and α-
methyl-GalNAc showed identical STD-derived epitope mapping. The highest STD 
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response corresponded to GalNAc H2, followed by H4, H3 and the N-acetyl group. 
In contrast, peptide 3 presents a rather different GalNAc STD pattern. In this case, 
H2, H4, and the N-acetyl group of the GalNAc-moiety display the highest STD 
response, closely followed by H3. These observations indicate that 3 has a distinct 
binding mode of interaction with the enzyme, different to that found for 2 and the 
control.  
Therefore, from the kinetic and STD results, it is possible to infer that only 
glycopeptide 3 is display the proper orientation of GalNAc for lectin recognition. 
The interaction enables the efficient glycosylation at the C-terminal site. Hence, the 
location of a prior glycosite in the mono-glycopeptide with respect to the potential 
acceptor sites is essential for the optimal interaction that provides the correct 
orientation of the peptide within the enzyme, critical for getting an efficient 
turnover rate. 
 
2.3.1.1.2 The crystal structure of GalNAc-T4 with glycopeptide 3 
The molecular basis of GalNAc-T4 glycosylation was further explored by 
using X-Ray crystallography. Crystals of GalNAc-T4 were first obtained that 
subsequently were soaked with peptide 3. The new crystal structure was solved at 
high resolution (1.90 Å), showing a compact structure with the typical GT-A fold 
at the N-terminus and the lectin domain at the C-terminal region.  
 GalNAc-T2 and T4 display a sequence identity of 40 % (Figure SI2). There 
are large resemblances between the two enzymes at the secondary structural level. 
In fact, the global superimposition renders a root-mean-square deviation (RMSD) 
of 2.12 Å, while the RMSD for the catalytic domains is 1.23 Å and 1.82 Å for the 
lectin domains (aligned Cα atoms). Thus, a major shift takes place between the 
lectin domains (Figure 2.3.4a).  
The GalNAc-binding site is located at the right side of the lectin domain, as 
in model 1. This orientation requires a rotation of ~28º with respect to the 
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homologous one in GalNAc-T2 (Figure 2.3.4a). This finding explain why GalNAc-
T4 achieves a distinct long distance-glycosylation on C-terminal acceptor sites. 
Moreover, these findings suggest that the location of the GalNAc-binding site is 
coupled with the long distance-glycosylation preferences of these enzymes.  
 
 
Figure 2.3.4 – a) (left) Superimposition of the GalNAc-T4-glycopeptide 3 (gray) and 
GalNAc-T2-MUC5AC-3-UDP-Mn+2 (yellow) structures. The glycopeptide and the GalNAc 
moieties are shown in green and orange carbon atoms, respectively. The lectin α-
subdomain GalNAc-binding residues, Asp458 and Asp459, of GalNAc-T2 and GalNAc-T4 are 
shown as sticks in black and gray carbon atoms, respectively. (right) Close-up view of the 
superimposition between GalNAc-T2 and GalNAc-T4. b) Close-up view of the lectin α-
subdomain GalNAc-binding site for both GalNAc-T4 (left) and T2 (right). The residues of 
both enzymes are depicted as gray carbon atoms. Hydrogen bond interactions are shown 
as dotted green lines. Electron density maps are FO–FC (blue) contoured at 2.2 σ for Thr3-
GalNAc. Note that both GalNAc-binding sites are depicted in the same orientation. c) 
Surface representation of GalNAc-T4 (model built with mono-glycopeptide 3 and 
UDP/Mn+2), and GalNAc-T2 (with UDP/Mn+2/MUC5AC-13). Both enzymes are viewed 
from the same orientation as in b. Colors for the glycopeptide and the flexible loop are the 
same as above.  
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Then, crystals of GalNAc-T4 were soaked with a high concentration of 
peptide 3, UDP, and MnCl2. A well-defined density was only observed for the Thr3-
GalNAc fragment of peptide 3 bound to the lectin domain (Figure 2.3.4b). There is 
absence of density for the rest of the peptide backbone of 3, in agreement with its 
very weak affinity (Kd was estimated in the high mM range by SPR, data not shown) 
and with the extremely weak STD signals observed for the peptide backbone 
(Figure 2.3.3b).  
A more exhaustive analysis of the GalNAc-binding site showed that the 
GalNAc-moiety is close to four conserved residues: Asp459, Asn483, Phe475 and 
His478 (equivalent residues for the α- site in GalNAc-T2 are Asp458, Asn479, Tyr471 
and His474; see Figure 2.3.3b). Most of the interactions are due to hydrogen bonds, 
while CH-π interactions also take place, involving the GalNAc moiety and 
Phe475/Tyr471 for GalNAc-T4/T2, respectively.  
 
2.3.1.1.3 Molecular dynamics simulations  
To understand how the lectin domain guides the approach of the potential 
acceptor sites to the catalytic domain, molecular dynamics (MD) simulations were 
performed on GalNAcT4 in the presence of UDP/Mn+2 and 3. The calculations 
showed that, although the peptide bound at the catalytic domain was highly 
dynamic, showing the existence of two potential acceptor Thr residues in close 
contact to the UDP during the simulation time (200 ns).  
Previous studies have suggested that the flexible linker allows the existence 
of interdomain translational-like motion in these enzymes.20 Thus, MD 
simulations of native GalNAc-T2/T4 in water solution were performed. These 
enzymes show rather different interdomain linkers. However, the MD simulations 
clearly showed that the lectin domains of GalNAc-T2 and GalNAc-T4 apo enzymes 
do not show significant rotation during the long 500 ns simulation time, strongly 
suggesting that the orientation of the GalNAc-binding sites with respect to the 
catalytic domain is well preserved after the GalNAc-Ts folding.  
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Therefore, new MD simulations were performed on chimeras 1-2 were now 
carried out. These constructs corresponded to GalNAc-T2 modified with different 
lengths of the flexible linker of GalNAc-T3 (Table 2.3.2). For chimera 2, the correct 
rotation of the lectin domain towards a position similar to that found for GalNAc-
T4 was observed (Figure 2.3.5). In fact, the required stepwise motion was 
completed in only ~30 ns and involved sequential extension of the flexible linker, 
rotation of the lectin domain around the Z and mainly the Y axes, followed by a 
final compression of the linker (Figure 2.3.5). Indeed, although the GalNAc-T3 
linker was initially forced to adopt the compact conformation of the GalNAc-T2 
native linker, it quickly (~10 ns) recovered its native extended conformation. As a 
consequence, the lectin domain springs and rotates to re-assemble in a structure 
similar to that of the homologous GalNAc-T4 described above. Likely, this motion 
is smoothed by the absence of strong inter-domain interactions in the chimera, 
which do take in place in GalNAc-T4. In this case, a highly persistent salt bridge 
between Arg397 and Glu487 is difficult to overcome. Strikingly, the intrinsic 
conformational preferences of a rather small, unfolded fragment (only 14 - 16 
residues) determine the relative orientation of rather large protein domains.  
 
Table 2.3.2- Sequences of the chimeras and mutant GalNAc-Ts 
Transferase Sequence of Flexible 
linker* 
GalNAc-T2 P435ELRVPDHQDIAF447 
GalNAc-T2-t3Flexible linker (Chimera 1) P494EVYVPDLNPVIS506 
GalNAc-T2-t3Flexible linker –AF (Chimera 2) P494EVYVPDLNPVIS506AF 
GalNAc-T2-t4Flexible linker (Chimera 3) P433NLHVPEDRPGWH445 
GalNAc-T2-t3Flexible linker -AF-P503A 
(Chimera 2_P503A) 
P494EVYVPDLNAVIS506AF 
GalNAc-T2 (double mutant, R438A-D444A) P435ELAVPDHQAIAF447 
GalNAc-T2 (triple mutant, R438A-D444A-F447A) P435ELAVPDHQAIAA447 
GalNAc-T3 P494EVYVPDLNPVIS506 
GalNAc-T4 P433NLHVPEDRPGWH445 
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Figure 2.3.5 - 0.5µs MD simulations of chimera 2. The 28 ns time-lapse snapshots show 
the dynamic events occurring during the lectin domain re-orientation process. The GalNAc-
T2 (far left) and GalNAc-T4 (far right) crystal structures are shown as references for the 
initial and final states. All structures are illustrated in a surface view with two different 
orientations. The lectin and catalytic domain, and the flexible linker of GalNAc-T2 and 
GalNAc-T4 are depicted as yellow/purple blue, orange/light gray, and red/deep teal, 
respectively. The colors used for the chimera 2 and GalNAc-T2 are the same, except for the 
flexible linker of the former, which is pale green. Flexible linkers are also shown at the 
bottom in a cartoon- and sticks-like view. 
 
2.3.1.1.4 Kinetic characterization of the chimeras  
Chimeras 1-3 were expressed and purified to validate the conclusions of the 
MD simulations. Chimeras 1-2 have the flexible linker of GalNAc-T3, while 
chimera 3 has that of GalNAc-T4 (Table 2.3.2). Although all contain most of 
GalNAc-T2 architecture, chimeras 1-3 rendered glycosylation preferences similar 
to GalNAc-T4 (Figure 2.3.6). These results support that glycosylation preferences 
are determined by the orientation of the functional GalNAc-binding site of the 
lectin domain with respect to the catalytic domain. In particular, and as suggested 
by MD simulations, the lectin domain of these chimeras must adopt an equivalent 
position to that found for GalNAc-T4 to account for their glycosylation preferences.  
Notably, GalNAc-T2 is less specific than GalNAc-T4 and is able of 
glycosylating all peptides. However, GalNAc-T2 preferentially glycosylates mono-
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glycopeptide 2, ~2-fold and ~4-fold better than mono-glycopeptide 3 and the naked 
peptide 1, respectively. On the contrary, chimeras 1-3 prefer glycosylating 3, ~4-
fold better than 2 and 1, resembling GalNAc-T4 (Figure 2.3.6). Furthermore, the 
specific activity of chimeras 1-3 and GalNAc-T2, T4 towards their preferred naked 
peptide substrates is fairly similar, indicating that the new linkers do not affect the 
overall architecture of the active site. The specific Thr residues that were 
glycosylated were assessed by Edman amino acid sequencing. The Thr residue 
adjacent to the PxP motif was glycosylated by all chimeras, as expected.21 Little or 
no glycosylation was observed at the proximal Thr, except for chimera 2_P503A 
(Figure 2.3.6). Together, these results indicate that the glycosylation preferences 
for these chimeras can be reasonably explained by the rotation of the lectin domain 
of chimera 2, as predicted by the MD simulations. Hence, the flexible linker causes 
the rotation of the lectin domain and drives the distinct glycosylation preferences 
of the GalNAc-Ts. 
 
 
Figure 2.3.6 – a) Time course plots of glycosylation by GalNAc-T2 and the GalNAc-T2 
chimeras and mutants of (glyco)peptides 1–3 using a substrate concentration of 1.4 mM. b) 
Complete glycosylation kinetics (initial specific activity versus substrate concentration) for 
GalNAc-T2, the GalNAc-T2-triple mutant, and the GalNAc-T2 chimera 3 against 1–3. 
Kinetic values are summarized in Table SI1. 
a
b
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2.3.1.1.5 Site-directed mutagenesis of the flexible linker 
Finally, the possible existence of particular residues within the flexible 
linkers that could be responsible for the lectin domain orientation was explored. A 
multiple alignment of the flexible linkers (Figure SI3) showed that GalNAc-T3, T4, 
T6, and T12, which also share the same long-distance glycosylation preferences,21 
contain one additional Pro residue that is not present in GalNAc-T1, T2, and T14, 
which display the opposite glycosylation preferences. These Pro residues (P503 and 
P442, respectively) are located at the end of the loop in GalNAc-T3 
(P494EVYVPDLNP503VIS506) and GalNAc-T4 (P433NLHVPEDRP442GWH445). 
There is an Asp residue at the corresponding position in GalNAc-T2 
(P435ELRVPDHQDIAF447). Since prolines are very abundant in protein turns, this 
additional Pro might be responsible of the different orientation found in the crystal 
structure of the GalNAc-T4 lectin domain and in the computational model of 
chimera 2. Thus, Pro503 in chimera 2 was mutated to Ala to provide chimera 2_P503A 
(Table 2.3.2). This chimera showed a very similar glycosylation preference as the 
starting chimera 2 (Figure 2.3.6), rather than the wild type GalNA-T2. This fact 
suggests that very complex events within the flexible linker take place that account 
for the suggested interplay between flexible linker motion and its coupling to the 
lectin domain rotation.  
The interactions between different residues of the flexible linker in the 
compact and extended crystal structures of GalNAc-T2 were then evaluated. Two 
main interactions, a salt bridge between Arg438 and Asp444, and a CH-π bond 
between Pro440 and Phe447, were observed. Their importance to maintain the 
compact and folded structure of the flexible linker (Figure SI4) and to fix the lectin 
domain orientation with respect to the catalytic domain was explored by generating 
the corresponding R438A-D444A double mutant and R438A-D444A-F447A triple 
mutant.  
MD simulations on these structures showed that only in the triple mutant 
lectin domain rotated (160-450 ns) towards the orientation observed in chimera 
2 and GalNAc-T4. These predictions were experimentally by confirmed the 
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corresponding kinetic analysis. Whereas the double mutant gave nearly equal 
mono-glycopeptide preferences as that observed for GalNAc-T2, the triple 
mutant provided an almost 2-fold preference for 3 over 2, resembling the 
preference found for GalNAc-T4 (Figure 2.3.6, and Table SI1).  
Overall, these results suggest that the entire flexible linker plays a 
significant role in directing the long-range glycopeptide specificity of this family 
of GTs, altering the relative orientations of the catalytic and lectin domains.   
 
2.3.1.1 Short distance-glycosylation  
On the other hand, sites adjacent to an existing GalNAc glycosite are 
glycosylated just in a catalytic domain-dependent manner, with GalNAc-T4 being 
part of a small number of GalNAc-Ts (including GalNAc-T7, T10 and T12).21 
While GalNAc-T4 glycosylates acceptor sites that are located at the C-terminal 
direction with respect to a prior GalNAc glycosite, GalNAc-T7 and T10 do it at the 
N-terminal position. GalNAc-T12 places the new GalNAc unit exactly three 
residues away from the prior glycosite towards the N-terminal direction.21. 
 
2.3.1.1.1 Kinetics of GalNAc-T4 with glycopeptide  
The glycopeptide library was expanded to characterize the short-distance 
glycosylation. Thus, mono-glycopeptide 4 (-T*T-) and di-glycopeptides 5 and 6 
(denoted -T*T--T*- and -T*--T*T-, respectively) were generated (Table 2.3.3). 
The di-glycopeptides contain a prior C- or N-terminal glycosylation site that is 
designed to evaluate the effects of prior glycosylation within the same substrate. In 
this case, the new substrates display one potential Thr acceptor site (i.e. -T*T-) with 
an adjacent C-terminal PxP motif (as -PGP-).20,21 According to the crystal structure 
of GalNAc-T4 bound to 3 (-T*--TT-) (Figure 2.3.4a and Table 2.3.1), the remote 
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N-terminal GalNAc motif of 3 and 6 (-T*--T*T-) should bind to the GalNAc 
binding site at the lectin domain.   
Table 2.3.3 – Peptide sequences used in this study. * denotes the location of the GalNAc 
moiety.  
Peptides Sequence 
4 (-T*T-) GAGAGAGT*TPGPG 
5 (-T*T--T*-) AGAGT*TPGPGAGAT*GA 
6 (-T*--T*T-) GAT*GAGAGAGT*TPGPG 
 
The enzyme kinetics data of GalNAc-T4 are gathered in Figure 2.3.7 and 
Table SI2. The data for 3, 4 and 5 could be fit to a standard Michaelis-Menten 
model, while those for 6 were fit to a model that included apparent substrate 
inhibition. As shown in Figure 2.3.7, glycopeptides 3 (-T*--TT-) and 6 (-T*--T*T-
) show the greatest activity, ~10-13 fold higher than those for 4 (-T*T-) and 5 (-
T*T--T*-). This fact is not unexpected since 1 (-TT-) and 2 (-TT--T*-) were 
basically unaffected by GalNAc-T4 (Figure 2.3.4a and Table 2.3.1).  
 
 
Figure 2.3.7 – Peptide glycosylation kinetics of GalNAc-T4 against (glyco)peptides 1-6.  
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For peptide 4 (-T*T-), glycosylation takes place (Figure 2.3.7). Therefore, 
the neighboring glycosylated Thr must directly bind to the catalytic domain, rather 
than to the lectin domain, since the acceptor Thr is contiguous to the glycosylated 
residue. The existence of similar kinetic constants for di-glycopeptide 5 (-T*T--
T*-) and glycopeptide 4 (-T*T-), (Figure 2.3.7 and Table SI2) strongly suggests 
that the glycosylation of 5 is also promoted by binding at the catalytic domain.  
A comparison of the two mono-glycopeptides 3 (-T*--TT-) and 4 (-T*T-) 
reveals the influence of the existence of prior glycosylation at the remote N-
terminal site on the enzymatic activity. Peptide 3 displays a ~10-fold higher Vmax, 
~5-fold lower Km, and, thus, a ~50-fold higher catalytic efficiency (Vmax/Km) 
compared to peptide 4. This fact is also observed for di-glycopeptide 6 (-T*--T*T-
), which shows both remote and neighboring glycosites at the acceptor site (Figure 
2.3.7). In this case, the kinetic profile measured for 6 fits to a Michaelis Menten 
model with substrate inhibition (Figure 2.3.7 and Table SI2).  The Km of 6 (-T*--
T*T-) is ~3 fold lower than that for peptide 3 (-T*--TT-) also suggesting a 
synergistic effect of the two glycosites with possible separate binding events to the 
lectin and catalytic domains. This synergistic effect is also observed when 
analyzing the Kd values obtained by SPR (Figure SI5), in the presence of excess of 
UDP and MnCl2. While Kd for mono-glycopeptides 4 (-T*T-) and 3 (-T*--TT-) are 
relatively weak (in the mM range), the Kd of the di-glycopeptide 6 (-T*--T*T-) is 
70 ± 15 µM. Although there are certain discrepancies the Km values from the kinetic 
studies (Table SI2) and the SPR-based Kd values, particularly for 3 and 4, it should 
be mentioned that the kinetic studies were performed only with UDP-GalNAc. As 
described above, UDP-GalNAc stabilizes the flexible loop of the catalytic domain 
active site in the closed conformation, promoting the enzyme activity. For peptide 
6, the Kd is only ~4.5-fold higher than the Km. We can speculate that interaction of 
the two GalNAc moieties of 6 with the two domains of GalNAc-T4, might further 
stabilize the essential closed conformation of the flexible loop. 
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2.3.1.1.2 GalNAc-T4 interactions with glycopeptide by STD-NMR 
The binding of the glycopeptides to GalNAc-T4 were also assessed using 
saturation-transfer difference (STD) NMR experiments. No significant STD 
enhancements (Figure 2.3.3b) were detected for naked peptide 1. Differences in the 
relative STD intensity pattern of the GalNAc protons were deduced for 
glycopeptides 2 and 3, probably reflecting their different binding mode at the lectin 
domain. Indeed, this fact might explain the differences in their glycosylation 
activities.  
In contrast, glycopeptides 4 (-T*T-), 5 (-T*T–T*-) and 6 (–T*--T*T-) 
(Table 2.3.3), displayed significant STD-NMR enhancements for the Thr and Pro 
residues at the –TTPGP– peptide sequence (Figure 2.3.8 – 2.3.10).  
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Figure 2.3.8 – Up: STD-NMR experiments for glycopeptides 4 (-T*T-) at 877.5 μM in the 
presence of GalNAc-T4 (13.5 μM), UDP (75 μM), MnCl2 (75 μM) at 298 K. The key proton 
resonances are marked in each STD spectrum. Down: STD-NMR-derived epitope mapping. 
. STD-NMR-derived epitope mapping obtained for 4 (-T*T-) with GalNAc-T4. The protons 
that could not be analyzed in the STD spectrum with accuracy were not mapped. The proton 
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signals that appeared at the same region of the spectrum are identified in the Figure and 
display *. 
 
The GalNAc moieties in 4, 5 and 6 also showed clear STD-NMR signals. 
For 4, 5 and 6, and independently of the relative GalNAc position in the peptide 
sequence, the methyl protons of NHAc group provided high STD response (> 85%). 
Some differences in the relative STDs of the other GalNAc protons could be clearly 
deduced for 3 (Figure 2.3.3b), 4 (Figure 2.3.8), 5 (Figure 2.3.9) and 6 (Figure 
2.3.10). In the case of the mono-glycopeptides 3 (-T*--TT-) (Figure 2.3.3b) and 4 
(-T*T-) (Figure 2.3.8), the different STD patterns are consistent with the distinct 
binding contribution of the GalNAc residue at the lectin or catalytic domain for 3 
and 4, respectively. For glycopeptide 3 the highest STD-NMR response (>75%) is 
observed for the H2, H4 and NHAc while in glycopeptide 4 the H2 and H4 shows 
low STD effect than H3 and NHAc. These differences in STD-NMR intensities of 
H2, H3 and H4 protons between both glycopeptides 3 and 4 suggest that the 
GalNAc moiety is recognized differently which may indicate that they bind at 
different sites on the enzyme. 
For the di-glycopeptides 5 (Figure 2.3.9) and 6 (Figure 2.3.10), it is only 
possible to distinguish the protons of the NHAc group for both 5 and 6 and H2 in 
the case of 6. Thus, the reported STDs for the other GalNAc ring protons represent 
their combined enhancements. The NHAc group is strongly recognized for both 
glycopeptides. However, the STD response of H2 in the two GalNAc units in 6 is 
rather different. The H2 of GalNAc at Thr 3 (N-terminal domain) shows stronger 
STD intensity than that at Thr 11 (C-terminal domain), which is similar to that 
observed for mono-glycopeptide 4. This fact suggests that the GalNAc moiety 
preferentially binds to the catalytic domain. This is further supported by the 
observation of STD (74%-35%) for the peptide residues of the -T*TPGP- sequence 
in 4 (Figure 2.3.8), 5 (Figure 2.3.9) and 6 (Figure 2.3.10). Fittingly, such STD in 
the peptide backbone are absent for 2 and 3, which lack the prior N-terminal 
neighboring glycosite (Figure 2.3.3b). All these observations suggest that the both 
the vicinal GalNAc in -T*T-, and the -PGP- motif are required for proper peptide 
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binding in the absence of a remote N-terminal prior glycosite. Moreover, this 
binding event specifically occurs at the catalytic domain.  
 
 
Figure 2.3.9 – Up: STD-NMR experiments for glycopeptides 5 (-T*T—T*-) at 877.5 μM in 
the presence of GalNAc-T4 (13.5 μM), UDP (75 μM), MnCl2 (75 μM) at 298 K. The key 
proton resonances are marked in each STD spectrum. Down: STD-NMR-derived epitope 
mapping. STD-NMR-derived epitope mapping obtained for 5 (-T*T—T*-) with GalNAc-
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T4. The protons that could not be analyzed in the STD spectrum with accuracy were not 
mapped. The proton signals that appeared at the same region of the spectrum are identified 
in the Figure and display *. 
 
 
Figure 2.3.10 – Up: STD-NMR experiments for glycopeptides 6 (-T*--T*T-) at 877.5 μM 
in the presence of GalNAc-T4 (13.5 μM), UDP (75 μM), MnCl2 (75 μM) at 298 K. The key 
proton resonances are marked in each STD spectrum. Down: STD-NMR-derived epitope 
mapping. . STD-NMR-derived epitope mapping obtained for 6 (-T*--T*T-) with GalNAc-
T4. The protons that could not be analyzed in the STD spectrum with accuracy were not 
mapped. The proton signals that appeared at the same region of the spectrum are identified 
in the Figure and display *. 
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Strikingly, glycopeptides 3 (-T*--TT-) and 6 (-T*--T*T-), showing the 
remote N-terminal glycosite and displaying very large catalytic efficiencies (Table 
SI2), display rather different STDs in their –T*TPGP- sequences. In particular, 6 
shows very high relative STD at the peptide moiety, while 3 essentially does not 
show any STD. We may hypothesize that this fact is consistent with a mechanism 
in which the remote N-terminal prior glycosite binds at the lectin domain and 
productively directs the peptide acceptor site onto the catalytic domain. In the 
presence of a N-terminal neighboring prior glycosite (-T*T-) and a PxP motif, the 
substrate binding becomes further stabilized. This is also in agreement with the 
observed substrate (or product) inhibition deduced for 6 (-T*--T*T-) and with the 
X-ray structure of 3 (-T*--TT-) bound to GalNAc-T4 (pdb: 5NQA). Indeed, very 
little electron density was found for bound the peptide that the catalytic domain of 
GalNAc-T4 contains an alternative GalNAc-binding site that accounts for the N-
terminal short-range glycosylation preference.  
 
2.3.1.1.3 The crystal structure of GalNAc-T4 with di-glycopeptide 6 
Triclinic crystals of GalNAc-T4 were obtained that were subsequently 
soaked with diglycopeptide 6, UDP, and MnCl2. The resulting crystal was solved 
by X-ray diffraction, providing a 3D structure of the transferase-diglycopeptide 
complex at 1.80 Å resolution. The structure shows a compact GT-A fold and a 
lectin domain located at the N- and C-terminal regions, respectively (Figure 2.3.11).  
In contrast with the structure of GalNAc-T4 with peptide 3 (-T*--TT-), 
where the flexible loop at the catalytic domain and the ligand were disordered, the 
di-glycopeptide 6 (-T*--T*T-) was now clearly bound to both lectin and catalytic 
domains. The flexible linker connecting both domains and the flexible loop of the 
catalytic domain (Figure 2.3.11) were also well defined.  An additional loop at the 
lectin domain pointing towards the GalNAc binding site at the catalytic domain 
(residues 460-472; hereafter dubbed LFL) was also observed (Figure 2.3.11). 
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Figure 2.3.11 - Crystal structure of GalNAc-T4 in complex with UDP-Mn+2 and the 
peptide 6 (-T*--T*T-). Two different views of GalNAc-T4 in complex with 6. The catalytic 
and lectin domains are colored in grey and the flexible linker and loop are depicted in red 
and yellow, respectively. The lectin flexible loop is indicated by a black arrow. The GalNAc 
moiety is shown as orange carbon atoms while the rest of the peptide is shown as green 
carbon atoms. The nucleotide is depicted as brown carbon atoms whereas the manganese 
atom is shown as a pink sphere. Surface representation of GalNAc-T4 is depicted with the 
same orientation as the cartoon representation of the GalNAc-T4 structure shown on the 
left. 
 
The comparison of the GalNAc-T2 structure bound to MUC5AC-13 
(GTTPSPVPTTSTT*SAP) and UDP/Mn+2 (pdb: 5AJP)20 with GalNAc-T4 bound 
to 6 (-T*--T*T-) and UDP/Mn+2 was then performed. For GalNAc-T2, the closed 
conformation of the flexible loop is stabilized by interactions of His365 and Phe369 
with Trp331 (in-conformation) and by additional interactions with the donor 
substrate UDP-GalNAc29, as described in subchapter 2.2. The GalNAc-T4-
glycopeptide 6 complex also shows the “in-conformation” (close) of the catalytic 
Trp334, accounting for the presence of an active form.20   
Several direct and water-mediated interactions were observed, 
predominantly through hydrogen bonds, with a few hydrophobic interactions. 
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Direct hydrogen bonds are observed between Gly8/Ala9 and Pro13 of the peptide 
and the side chain NH’s of Arg372 and Trp286, respectively (Figure 2.3.12). A CH-π 
interaction is established between Pro15 and Trp286. The Thr12 side chain hydroxyl 
group is hydrogen bonded to the UDP β-phosphate, properly placing this residue to 
accept the GalNAc moiety of the UDP-GalNAc. In addition, the Thr12 methyl 
group is located within a hydrophobic environment formed by the side chains of 
Thr283, Phe284 and Ala310 (Figure 2.3.12). This non-polar box helps places the 
acceptor Thr hydroxyl group in the proper position to accept the anomeric carbon 
of UDP-GalNAc. This fact explains why Thr residues are better acceptors than Ser 
moieties. Water mediated hydrogen bonds are observed through the Ala9/Gly10 
and Gly16 backbones with Ala368/Arg372 backbones and Thr258 side chain, 
respectively, besides those between the Thr12 backbone with Arg372 and the Thr12 
side chain with the Asn338 and Ala310 (Figure 2.3.12). 
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Figure 2.3.12 - Structural features of peptide, UDP and lectin domain-binding sites. View 
(central panel) of complete sugar nucleotide, peptide and lectin domain-binding sites of the 
GalNAc-T4-UDP-peptide 6 complex. Close-up view of peptide (upper panel) and the 
manganese (lower panel) binding sites. The residues forming sugar-nucleotide, peptide and 
lectin domain-binding sites are depicted as black, yellow and grey carbon atoms, 
respectively. UDP and the glycopeptide are shown as brown and green carbon atoms, 
respectively. Mn+2 and GalNAc moiety are depicted as a pink sphere and orange carbon 
atoms, respectively. Hydrogen bond interactions are shown as dotted green lines. Water 
molecules are depicted as red spheres. 
 
This structure also supports the STDs (Figure 2.3.10) observed for the 
T*TPGP sequence as well as the absence of relative STDs for the Ala methyl 
protons. Furthermore, the methyl group of NHAc of the GalNAc unit at Thr11 is 
pointing towards Thr283 and Gln285 of the enzyme, matching the large STD 
response. The structure also explains the low STD observed for the H2 proton of 
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the GalNAc unit at Thr11, in comparison to that measured when the GalNAc 
moiety binds to the lectin domain. Thus, this result also corroborates that the 
GalNAc residue of 4 binds to the catalytic domain.   
In summary, the kinetics and STD-NMR experiments confirm the existence 
of a GalNAc binding site at the GalNAc-T4 catalytic domain, supporting the initial 
random glycopeptide studies.21 Moreover, the analysis of the X-Ray structure of 
GalNAc-T4 bound to the di-glycopeptide 6 (-T*--T*T-) has revealed that the 
GalNAc moiety at Thr11 is recognized by the catalytic domain (Figure 2.3.12). In 
particular, there is a hydrogen bond between GalNAc-O6 and Lys366 and another 
one between the GalNAc-NHAc group and Gln285. In addition, water-mediated 
(between GalNAc-O6 and Pro365) and hydrophobic (between GalNAc-NHAc group 
and Thr283) interactions also take place (Figure 2.3.12). All together, these specific 
interactions at the catalytic domain provide the impetus to direct the adjacent C-
terminal Thr (or Ser) acceptor into the correct orientation for subsequent GalNAc 
transfer from the UDP-GalNAc donor: both substrate GalNAc moieties make 
specific and essential contacts with the enzyme, facilitating the presentation 
required for achieving optimal activity.  
 
2.3.2 Conclusion  
In this work, we identified the molecular basis for GalNAc-T4 long and short 
range prior GalNAc glycosylation preferences.  
Long-range glycosylation: The distinctive long-range glycosylation 
preferences of GalNAc-Ts, which is based on a very small flexible linker that 
provides rotational capacity to the lectin domain.  
Short-range glycosylation: The catalytic domain binding site residues are 
responsible for the binding of the neighboring GalNAc residue have been 
identified. Interestingly, the binding of GalNAc to the catalytic domain is mediated 
by few direct interactions to the enzyme suggesting weak interactions.    
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2.3.3 Supporting Information  
 
Figure SI1 - STD-NMR Experiments. For all compounds the reference spectrum (Off res) 
is displayed in blue color while the STD spectrum is displayed in red. The key proton 
resonances are marked in each STD spectrum. 
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Figure SI2 - Sequence alignment of human GalNAc-T2 and GalNAc-T4. Secondary 
structure elements from the GalNAc-T2 and T4 structures are shown, with α-helices, 310-
helices and β-strands in red and green, respectively. The regions encompassing the flexible 
loop and linker are indicated with double sided arrows.  
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Table SI1 - Michaelis-Menten Kinetic Parameters for GalNAc-T2, GalNAc-T2-Triple 
Mutant, GalNAc-T2 Chimera 3, and GalNAc-T4 against (glyco)peptide substrates 1, 2 and 
3. Parameters were obtained from the nonlinear fit of the data plotted in Fig. 2a and 4c 
using GraphPad Prism 7.03. 
 
Note that the GalNAc-T2 kinetic data was analyzed by GraphPad Prism's 1/y 
weighting feature that improved the concordance of the fit for peptide 3 at high 
substrate concentrations, i.e its Vmax value. Parameters for peptides 1 and 2 were 
unchanged using this weighting compared to the unweighted fit. 2) Vmax units: 
mM/(nmole*min), with standard deviation. 3) Km units: mM, with standard 
deviation. 4) Catalytic efficiency (Vmax/Km): (nmole*min)-1 . Note that the given 
errors were estimated from the largest percent error of the Vmax or Km value. 5) For 
GalNAc-T4 the activities of peptides 1 and 2 were too low to determine their 
kinetic constants.  
Transferase Kinetic parameters  (glyco)peptide substrate 
  1(--TT--) 2(-TT—T*-) 3(-T*--TT-) 
GalNAc-T2 Vmax1 0.7 ± 0.09 3.2 ± 0.06 4.4 ± 0.5 
 Km2 1.2 ± 0.31 0.2 ± 0.01 1 ± 0.2 
 Cat eff3 0.57 ± 0.08 15.4 ± 0.81 4.2 ± 0.4 
 Vmax 1.1 ± 0.35 1.8 ± 0.06 2.8 ± 0.1 
Triple Mutant Km 3.3 ± 1.55 0.4 ± 0.04 0.6 ± 0.05 
 Cat eff 0.33 ± 0.05 4.5 ± 0.3 4.9 ± 0.3 
 Vmax 0.8 ± 0.1 1.35 ± 0.1 3.7 ± 0.3 
Chimera 3 Km 1 ± 0.2 0.7 ± 0.15 1 ± 0.15 
 Cat eff 0.79 ± 0.09 1.9 ± 0.25 3.9 ± 0.3 
GalNAc-T4 Vmax - - 3.1 ± 0.25 
 Km - - 0.041 ± 0.018 
 Cat eff - - 75.2 ± 40 
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Figure SI3 - Multiple sequence alignment for GalNAc-Ts spanning the regions around the 
flexible linker. The sequence highlighted in red denotes the flexible linker of GalNAc-T4. 
The additional Pro in GalNAc-T4/T3/T6/T12 is highlighted in green. The alignment shows 
the most conserved region between the flexible linkers is towards the N-termini whereas 
more dissimilarities are around the C-termini.  
 
Figure SI4 - a-b, Structure and dynamics of GalNAc-T2 flexible linker (in purple) 
connecting the catalytic (in pale green) and lectin (in grey) domains. The X-ray structures 
of both the closed (PDB entry 5AJP) and open (PDB entry 2FFU) forms of the protein are 
used as references. c, Key polar and van der Waals interactions responsible for the folded 
conformation of the flexible peptide monitored throughout MD simulations in explicit water. 
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CH–π interactions (in green) are tightly maintained along the whole simulation; salt-bridge 
(in orange) fluctuates more but stays in the attractive range most of the simulation time. 
 
Table SI2 - Kinetic parameters for the wild-type and the mutants.  
  
  
  
  
3 
(-T*--T-) 
Michaelis 
Menten fit 
4 
(-T*T-) 
Michaelis 
Menten fit 
5 
(-T*T--T*) 
Michaelis 
Menten fit 
6 
(-T*--T*T-) 
Substrate 
Inhibition fit 
GalNAc-T4 
Vmax (mM/nmol*min) 3.5  ± 0.1 0.35 ± 0.02 0.29 ± 0.02 3.6 ± 0.38 
Km (μM) 49 271 201 15 
Ki  (μM) - - - 890 
Catalytic efficiency 
(nmol*min) -1 
71.4 1.3 1.4 240 
R2 curve fit 0.82 0.89 0.90 0.80 
Note that the catalytic efficiency is the Vmax/Km ratio 
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Figure SI5 - SPR sensogram. (Sensogram (left) and fitting (right) of SPR data for binding 
of the peptide 4 to GalNAc-T4. Used ligand concentrations are reported in the inset legend 
of the sensogram. The end-points of the various injections were plotted against protein 
concentration. Note that the Kd could not be determined for peptide 4 because binding 
saturation could not be achieved. However, the Kd was accurately determined for peptide 
6.  
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2.4 O-glycosylation of mucin 
MUC1 by GalNAc-Ts 
 
 
 
 
 
The work presented in this subchapter has been performed in collaboration 
with: 
-Dr. Ramon Hurtado-Guerrero Lab, BIFI, University of Zaragoza, 
Zaragoza, Spain and Matilde de las Rivas (PhD student), who were responsible for 
the expression and purification of GalNAc-Ts.  
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2.4.1 Introduction 
Mucin glycoproteins contain multiple sites of glycosylation decorated with 
complex O-GalNAc glycans with distinct core structures and are involved in 
fundamental biological processes in health and disease.44–46 Therefore, mucin 
glycoproteins are one of the main protein substrates of GalNAc-Ts. In particular, 
MUC1 is a heavily O-glycosylated transmembrane glycoprotein of 500-1000 kDa, 
expressed in the apical surfaces of ductal and glandular epithelial cells.47 The full-
length MUC1 is composed of the VNTR and the SEA domains, both located at the 
N-terminal region, and the transmembrane domain, the cytoplasmatic tail and some 
residues of the extracellular domain, which are in the C-terminal region (Figure 
2.4.1).  
 
 
Figure 2.4.1 - Schematic representation of the structure of MUC1. The N-terminal is 
constituted by the VNTR domain and by the SEA domain (sea urchin sperm protein 
Enterokinase domain), while the C-terminal is composed by the transmembrane domain, 
cytoplasmic domain and some residues of the extracellular domain.  
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The C-terminal domain (N-glycosylated (23-25 kDa)) is composed by an 
extracellular domain constituted by 58 residues, a single hydrophobic spanning 
transmembrane domain (28 amino acids) and a cytoplasmatic tail of 72 amino acids 
with various tyrosine, serine and threonine phosphorylation sites that can bind to 
various signaling motifs (kinases and growth factor receptors).48 The later 
interactions affect and regulate several cancer processes, like the proliferation, the 
apoptosis and the transcription of various genes.49–51 MUC1 has been shown to be 
a docking protein for signaling molecules such as β-canetin (a regulator of 
transcription), FGFR3 (Fibroblast growth factor receptor 3) and other proteins 
involved in cancer regulation via the phosphorylation of its cytoplasmic tail.49,52  
The N-terminal domain of MUC1 contains a variable number of 20-120 
tandem repeats (VNTR). Each tandem repeat (TR) encodes a polymorphic 
sequence of 20 amino acids, with five potential sites for O-glycosylation in Ser and 
Thr residues (Figure 2.4.2). 
 
Figure 2.4.2 – Sequence of one tandem repeat of MUC1. The larger letters in bold 
are the five sites for O-glycosylation. 
 
It has been proposed that the aberrant glycosylation of the N-terminal domain 
of MUC1 glycoproteins is a universal feature of cancer (Figure 2.4.3).17,45,53–56   
Figure 2.4.3 – MUC1 expressed at the cell surface. Left: MUC1 in normal cells, Right: 
(GVTSAPDTRPAPGSTAPPAH)n
1 3 4 8 1415 20
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MUC1 in cancer cells. Complex glycans are expressed in normal cells. Short glycan 
epitopes are exclusively overexpressed in cancer cells.  
 
In this context, the VNTR domains of MUC1 protein core are one of the 
major sites for GalNAc-Ts O-glycosylation and alterations in expression, location 
and function of GalNAc-Ts also occur during malignant transformation.57 
Therefore, it is vitally needed to understand GalNAc-Ts binding specificities and 
their mechanism of action in mucin templates, like MUC1, to further develop 
potential glycan-based therapeutic approaches for cancer.  
Specific transfer of the GalNAc unit to the five potential positions of the 
MUC1 sequence (Figure 2.4.2) was studied in vitro by Edman degradation and 
mass spectrometric analysis.27,34,58 GalNAc-T1 and GalNAc-T3 prefer to 
glycosylate Thr3 in the VTSA region but they are also capable to glycosylate the 
Ser14 and Thr15 residues of the GSTA region, (Figure 2.4.2).34,59 On the other 
hand, GalNAc-T2 transfers sugar faster to Thr15 at the GSTA region, while Thr3 
in the VTSA region and Ser14 in the GSTA region are glycosylated with lower 
efficiency.34 The remaining sites, Ser4 at the VTSA region and Thr8 at the PDTR 
region are exclusively catalyzed by other enzyme, GalNAc-T4.27,33,60,61  
Furthermore, GalNAc-T4 appears to exhibit a strict dependence on the prior 
glycosylation of the MUC1 substrate.27,33,62  Hence, the concerted action of 
GalNAc-T1, T2, T3 and T4 enzymes yields the fully glycosylation of MUC1 TR 
domains. Nevertheless, the complete glycosylation state may or may not be 
achieved in a disease context and can be dependent of various parameters, such as 
the repertoire and cellular activity of the GalNAc-Ts, the location of these enzymes 
in the cell compartments (Golgi and/or endoplasmic reticulum) and the accessibility 
of the donor substrate.19  
Our current knowledge about GalNAc-Ts family and their glycosylation 
mechanism arise in great extension from kinetic studies in tandem with mass 
spectrometry analysis.21,23,26,38,63 In addition, from a structural perspective new 
molecular details to explain the mechanism of action of GalNAc-T2/T4 by 
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employing X-Ray and NMR techniques have recently been reported42,64,65 
(described in the subchapters 2.2 and 2.3). However, most of these studies have 
been performed on short peptide acceptor substrates ignoring the real complexity 
of the multiple domains of mucins. In fact, three main aspects of this complex 
process are poorly understood:  
1) how distinct GalNAc-Ts cooperate in an orchestrated manner the catalysis 
of a substrate with multiple sites of glycosylation such as the ones present in 
mucins;  
2) how the interplay between the lectin and the catalytic domain dictates the 
efficiency and the preference order of glycosylation of GalNAc-Ts during the 
glycosylation process of mucins;  
3) whether the TR repeats are independently O-glycosylated of each other or 
whether the order of the O-glycosylation of the acceptor sites takes place in a step-
wise manner in the context of multiple domains of mucins.  
To address these questions, NMR methods have been herein employed to 
follow the O-glycosylation process of the MUC1 acceptor substrate. Thus, a MUC1 
construct encoding multiple TR domains was designed (MUC1-4TR) and 
heteronuclear NMR experiments were carried out.  By simply monitoring the 
chemical shift perturbations of the amide signals in 1H/15N-HSQC spectra, the 
mechanism of action of different GalNAc-Ts (GalNAc-T2/T3/T4) have been 
dissected within the context of a mucin multivalent analogue. In addition, special 
emphasis has been focused on the understanding of the role of the lectin domain to 
guide GalNAc-Ts catalysis. For that purpose, the lectin binding ability of GalNAc- 
T2/T3/T4 has been disrupted, mutating a critical residue at the lectin domain 
binding site. 
Furthermore, we study how conformation of MUC1 changes during 
glycosylation and how these modifications influence the glycosylation process by 
GalNAc-Ts, namely GalNAc-T4.  
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2.4.1 Results and Discussion  
2.4.1.1 Design, Expression, Purification and NMR characterization of isotopic 
labeled MUC1 with four TR domains 
A DNA construct encoding a KSI protein, a histidine tag, a Tobacco Etch 
Virus (TEV) cleavage site and four TR domains of MUC1 (MUC1-4TR) was 
synthetized and sub-cloned into the bacterial expression vector pHTP-KSI by 
NZYTech (pHTP-KSI-MUC1-4TR). The sequence of the KSI-MUC1-4TR 
construct is presented in Figure 2.4.4.  
 
MGHTPEHITAVVQRFVAALNAGDLDGIVALFADDATVEDPVGSEPRSGTAAI
REFYANSLKLPLAVELTQEVRAVANEAAFAFTVSFEYQGRKTVVAPIDHFRF
NGAGKVVSIRALFGEKNIHACQAMGSSHHHHHHSSGPQQGLRENLYFQGVT
SAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTA
PPAHGVTSAPDTRPAPGSTAPPAH 
Figure 2.4.4 - KSI-MUC1-4TR sequence. This sequence consists of KSI-tag (blue), a His-
tag (green), a TEV (Tobacco Etch Virus) site (red) and the amino acid sequence of MUC1-
4TR (underlined). 
 
The expression vector encodes for a hexahistidine tag and a TEV recognition 
site to facilitate the MUC1-4TR purification. The expression and purification of 
MUC1-4TR is described in detail on Material and Methods. The success of the 
expression and purification was confirmed by mass spectrometry (MALDI-TOF) 
with the presence of the peaks with 7592.62 m/z for 15N-MUC1-4TR (Figure 2.4.5). 
The yield of purified MUC1-4TR was approximately 9 mg L-1 of culture. The yield 
of expression/purification was estimated by 1H-NMR analysis and using 2,2,3,3-
tetradeutero-3-trimethylsilylpropionic acid (TSP) as a chemical shift reference (δ 
TSP = 0 ppm). The 1H/15N-HSQC-NMR resonances of MUC1-4TR at pH 6.3 and 
283K were completely assigned through standard 2D-TOCSY, 3D-TOCSY 15N-
edited, 2D-NOESY and 3D-NOESY 15N-edited (Figure 2.4.5 and Table S4). 
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Figure 2.4.5 – MUC1-4TR template. Left: 1H/15N-HSQC of the MUC1-4TR with 
corresponding NMR assignment. Right: MALDI-TOF spectrum of the MUC1-4TR. 
 
The assignment of MUC1-4TR is in agreement with previously reported data 
for a similar MUC1-5TR construct59 and confirms that MUC1-4TR construct was 
successfully expressed and isotopically labeled with high degree of purity.  
 
2.4.1.2 Monitoring MUC1-4TR glycosylation by GalNAc-Ts using NMR 
spectroscopy. The role of the lectin domain. 
The glycosylation of the multivalent MUC1 with multiple TR domains was 
investigated by employing GalNAc-T2, T3 and T4 isoforms. These enzymes were 
selected based on their well-established preferences towards MUC1 peptide 
substrates.27,33,34  
Before monitoring the O-glycosylation process of MUC1-4TR by GalNAc-
Ts, several control experiments were initially carried out a) 1H/15N-HSQC of 
MUC1-4TR in presence of UDP-GalNAc and MnCl2 and in absence of GalNAc-
Ts; b) 1H/15N-HSQC of MUC1-4TR in presence of GalNAc-Ts and MnCl2 and in 
absence of UDP-GalNAc. For both combinations, the spectra remained 
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unperturbed. Indeed, the presence of distinct components on the sample does not 
induce any chemical shift or line width perturbation on the 1H/15N-HSQC of 
MUC1-4TR.   
The GalNAc transfer to mucins induces a perturbation on the structure of the 
amino acid directly glycosylated, in this case the Ser and Thr amino acids, as well 
as in the neighboring amino acids of the glycosylation site. Therefore, 1H/15N-
HSQC experiments on isotopically labeled MUC1-4TR can simultaneously 
monitor the catalysis of GalNAc-Ts within the context of a MUC1 multivalent 
analogue with five O-glycosylation sites and multiple tandem repeat domains. 
To investigate the role of the lectin domain during MUC1-4TR glycosylation 
process, critical mutations in the α-repeat of the lectin domain of GalNAc-T2, T3 
and T4 were used.3,23,26 For all the isoforms, the mutated residue was the conserved 
Asp in GalNAc-T2/T3 and T4 (D458 in GalNAc-T2, D517 in GalNAc-T3 and D459 in 
GalNAc-T4). This residue is critical for GalNAc binding, since it establishes H-
bonds with OH-3 and OH-4 of GalNAc (Figure 2.4.6). Figure 2.4.6 has been 
adapted from the X-Ray structure of the complex between GalNAc-T2 and 
MUC5AC-13 and displays the key interactions between the Asp residue and 
GalNAc. 20  
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Figure 2.4.6 - View of lectin domain-binding site of the GalNAc-T2 bound to the 
glycopeptide MUC5AC-13. The residues of the lectin domain-binding sites are depicted as 
grey carbon atoms, the peptide is displayed in green and the GalNAc moiety is depicted 
with orange carbon atoms. Hydrogen bond interactions are shown as dotted green lines. 
Adapted from  20. 
 
The substitution of Asp (negative charge) to Arg or His amino acids (positive 
charge) in the lectin domain of GalNAc-T2/T3 and T4 strongly affects the 
recognition of GalNAc by the lectin. Indeed, previous studies have demonstrated 
that the GalNAc-T2 D458R, GalNAc-T3 D517H and GalNAc-T4 D459H mutants lost 
the capacity for GalNAc binding.3,23,26 Hence, by using these mutants, the role of 
the lectin domain in the glycosylation process of a multivalent MUC1 substrate was 
investigated.  
 
2.4.1.2.1 GalNAc-T2 WT vs GalNAc-T2 D458R 
GalNAc-T2 WT catalyzes the glycosylation of three out of the five 
glycosylation sites in the MUC1 sequence, namely Thr3, Ser14 and Thr15 (Figure 
2.4.7 panel I).63 To ascertain the role of the lectin domain during glycosylation of 
MUC1-4TR, distinct 1H/15N-HSQC of MUC1-4TR were recorded in the presence 
D458 – R458
- +
Lectin domain/GalNAc interactions
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of GalNAc-T2 WT and the GalNAc-T2 D458R mutant. The 1H/15N-HSQC spectra 
were recorded over time and after adding an excess or restricted amount of UDP-
GalNAc.  
Figure 2.4.7 - Panel II shows the 1H/15N-HSQC of 15N-labeled MUC1-4TR 
in the presence of GalNAc-T2 WT and MnCl2 after addition of UDP-GalNAc 
(excess) at 0, 10 min, 20 min and 24 h. The shifts observed in the spectra are due 
to GalNAc transfer to the Ser and Thr residues of MUC1-4TR by GalNAc-T2. At 
10 min, the observed shifts correspond to complete glycosylation of Thr15 (blue 
arrows) along with partial glycosylation of Thr3 (green arrows). Glycosylation of 
Thr15 induces strong chemical shift perturbation (CSP)i of Thr15 (0.42 ppm). 
However, also the vicinal amino acids suffer CSPii. Ala16 experiences significant 
CSP (0.60 ppm), while Ser14 and Gly13 experience small ones (0.05 ppm and 0.11 
ppm, respectively). Glycosylation of Thr3 prompts its corresponding CSP (0.44 
ppm) along with that of Ser4 (0.37 ppm), Ala5 (0.29 ppm) and Val2 (0.06 ppm). 
The significant CSP of the neighboring residues to the glycosylation site indicates 
an alteration of the chemical and structural environment of MUC1 TR domain due 
to the presence of GalNAc units.  
                                                     
i The values of chemical shift presented are the combined chemical shift calculated to each 
backbone NH groups of MUC1-4TR.79 
ii See on conformational studies, section 2.4.2.1. 
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Figure 2.4.7 – I: Scheme of the MUC1-4TR glycosylation event by GalNAc-T2 under 
the NMR experimental conditions. The amino acid sequence of MUC1-4TR displays in red 
the glycosylation sites; II - Glycosylation of MUC1-4TR by GalNAc-T2 (WT) in the 
presence of an excess of UDP-GalNAc, over time. HSQC of MUC1-4TR in the presence of 
GalNAc-T2 and MnCl2 before (black) and after addition of UDP-GalNAc (in excess) at 10 
min (green), 20 min (red) and 24 h (blue). The arrows indicate the observed CSP that occur 
as result of GalNAc additions to the MUC1 at Thr15 (blue arrows), Thr3 (green arrows) 
and Ser14 (orange arrows). The * labeling in the amino acid on the spectra indicates the 
glycosylation site. 
 
After 20 min, the glycosylation at Thr3 is completed and a new peak arise 
for Ser14 which corresponds to the third glycosylation event catalyzed by GalNAc-
T2 (orange arrows). After 20 min, only 75 % of Ser14 was glycosylated, which 
matches with the glycosylation of three tandems out of the four present in MUC1-
4TR. The complete glycosylation of Ser14 (the rest 25 %) was only reached at the 
end of 24 h. Glycosylation of Ser14 induces its corresponding CSP (0.16 ppm) and 
that at the neighbor glycosylated Thr15* (* indicates GalNAc, 0.19 ppm). 
Furthermore, CSP were also detected for Ala16 (0.19 ppm) and Gly13 (0.12 ppm). 
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After 24h, MUC1-4TR contains 12 GalNAc residues as confirmed by mass 
spectrometry (Figure 2.4.8). The full NMR assignment of the product allowed to 
confirm that Thr15, Thr3 and Ser14 are glycosylated, while Ser4 and Thr8 remain 
non-glycosylated (Figure 2.4.8, Table S6 on the supporting information). Indeed, 
even longer reaction times and further additions of GalNAc-T2 did not yield 
glycosylation at Ser4 or Thr8.  
  
 
Figure 2.4.8 – The purified MUC1-4TR-T3S14T15 product. Left: 1H/15N-HSQC 
with the corresponding NMR assignment. The * labeling in the amino acid on the spectra 
indicates glycosylation. Right: MALDI-TOF spectrum.  
 
The O-glycosylation process of MUC1-4TR by GalNAc-T2 WT was also 
exhaustively monitored. For that purpose, restricted amount of the donor substrate 
(UDP-GalNAc) were sequentially added to a 15N-labeled MUC1-4TR sample in the 
presence of MnCl2 and GalNAc-T2 and 1H/15N-HSQC experiments were carried 
out after each addition (Figure 2.4.9).  
The first 1H/15N-HSQC was acquired with the minimum UDP-GalNAc 
concentration required to glycosylate 4 glycosylation sites out of the 20 available 
B MUC1-4TR-T3S14T15
A16
A5A11
A19
R9
V2
H20
C-Term
D7
H20
T8
G1
G13
T3*
T15*
S4
S14*
15N
10035.451
9831.607
7532.085
0.0
0.2
0.4
0.6
0.8
1.0
4x10
In
te
n
s.
 [a
.u
.]
8000 9000 10000 11000 12000
m/z
1003 .451
9831.607
10000
Deciphering GalNAc O-glycosylation 
O-glycosylation of mucin MUC1 by GalNAc-Ts 
 
 
 116 
in MUC1-4TR. The analysis (Figure 2.4.9, Panel I-a), 4 sites) evidenced that 
GalNAc-T2 prefers to glycosylate Thr15 (blue arrows). However, before finishing 
glycosylation of all the Thr15 residues, GalNAc-T2 starts the addition of GalNAc 
at Thr3 (green arrows). Figure 2.4.9 – Panel I -b noticeably shows that, at this point 
(4 sites), 54 % of the Thr15 residues are glycosylated (two TR domains) and only 
7 % of Thr3 contains GalNAc. Thus, it is expected that glycosylation of Thr3 takes 
place in a TR domain with a GalNAc-containing Thr15 moiety (Figure 2.4.9- Panel 
I-a 4 sites). As previously mentioned, GalNAc-T2 uses the lectin domain to assist 
the long-range glycosylation of glycopeptides and thus it is capable to glycosylate 
the N-terminal site (Thr3), which is 12 amino acids far from the prior glycosylated 
site at the C-terminus (Thr15).23 After adding the proper amount of UDP-GalNAc 
that may allow the glycosylation of the 20 glycosylation sites (Figure 2.4.9 Panel 
I-b), Thr15 and Thr3 sites are fully glycosylated (100 %, 4 TR domains), while 
Ser14 presents a glycosylation around 45 %. From Figure 2.4.9-Panel I-a/b (UDP-
GalNAc for 14 sites), it is also possible to deduce that glycosylation in Ser14 occurs 
after full glycosylation of Thr15 (100 %, 4 TR domains) and when glycosylation of 
Thr3 is almost finished (83 %, 3 TR domains). Hence, it is very likely that 
glycosylation in Ser14 is initiated in a TR where both Thr3 and Thr15 are already 
glycosylated (Figure 2.4.9 – Panel II 14 sites). 
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Figure 2.4.9 - I - Glycosylation of MUC1-4TR by GalNAc-T2 (WT) following addition of 
small amounts of UDP-GalNAc (step-by-step). a) 1H/15N-HSQC of MUC1-4TR in the 
presence of GalNAc-T2 and MnCl2 before (black) and in the presence of UDP-GalNAc for 
4 glycosylation sites (red) and 14 glycosylation sites (purple). The arrows indicate CSP that 
occur as result of GalNAc additions to the MUC1 at Thr15 (blue arrows), Thr3 (green 
arrows) and Ser14 (orange arrows). The * labeling in the amino acid on the spectra 
indicates glycosylation. b) Relative glycosylation of MUC1-4TR by GalNAc-T2 (WT) with 
control addition of UDP-GalNAc (step-by-step). II – Schematic representation of the 
products obtained in presence of GalNAc-T2 (WT) after the step-by-step experiment. The 
glycosylation sites are displayed in red. 
 
As mentioned above, glycosylation of MUC1-4TR was also investigated by 
using the D458R mutant. For that purpose, distinct 1H/15N-HSQC of MUC1-4TR in 
the presence of GalNAc-T2 D458R and MnCl2 and after addition of UDP-GalNAc 
(excess) were recorded. In particular, Figure 2.4.10 – Panel I-a shows the 1H/15N-
HSQC spectra at 0, 20 min, 1 h 30 min and 24 h. 
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Figure2.4.10 – I- Glycosylation of MUC1-4TR by the mutant GalNAc-T2 (D458R) in 
presence of an excess of UDP-GalNAc, over time. a) 1H/15N-HSQC spectrum of the MUC1-
4TR in presence of the mutant GalNAc-T2 (D458R) before addition of UDP-GalNAc (black) 
and after addition of an excess of UDP-GalNAc at 20 min (red), 1 h 30 min (purple) and 
24 h (blue). Arrows indicate peak shifts that occur as result of GalNAc additions to the 
MUC1 at Thr15 (blue arrows), at Thr3 (green arrows) and at Ser14 (orange arrows). The 
* labeling in the amino acid on the spectra indicates glycosylation. b) Relative glycosylation 
of MUC1-4TR by GalNAc-T2 (D458R) over time. II - Schematic representation of the 
products obtained in presence of the mutant GalNAc-T2 (D458R). The amino acid sequence 
of the MUC1-4TR displays in red the glycosylation sites. 
 
After 20 min, new HSQC peaks arise only for Thr15, Ala16, Ser14 and 
Gly13 residues, supporting that Thr15 is glycosylated (Figure 2.4.10 Panel I-a, 20 
min). In contrast to GalNAc-T2 WT, full glycosylation at Thr15 occurs after 20 
min (100 %, 4 TR domains) with no glycosylation at Thr3 (Figure 2.4.10 Panel I-
b, 20 min). No CSP of Thr3 residues and neighboring amino acids are perceived 
after 20min. After 1 h 30 min, glycosylation of Thr3 around 20 % takes place 
(Figure 2.4.10 Panel I-a/b, 1h 30 min). Thus, after finishing glycosylation of all 
Thr15 sites the mutant initiates the glycosylation at Thr3 (Figure 2.4.10 Panel II). 
GalNAc-T2 (D458R)
A16
A5
A11
A19
R9
V2
H20
C-Term
D7 S4
T3
H20 T15
S14
T8
G1
G13
A16
A5
A19
R9
V2
H20
C-Term
D7
S4
T3
H20
S14
T8
G1
G13
T15*
A16
A5
A11
A19
R9
V2
H20
C-Term
D7 S4
T3
H20
S14
T8
G1
G13
T3*
T15*
S4
A16
A5
A11
A19 R9
V2
H20
C-Term
D7
H20
T8
G1
G13
T3*
T15*
S4
S14*
20min 1h30min 24h
A11
a)
b)
0
20
40
60
80
100
0 0,5 1 1,5
%
 G
ly
co
sy
la
te
d
Time (h)
T3
S14
T15
1 3 4 8 1415 20
GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH
8 1415 20 1 3 4 8 1415 20 8 1415 201 3 4 1 3 4
1 3 4 8 1415 20
GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH
8 1415 20 1 3 4 8 1415 20 8 1415 201 3 4 1 3 4
1 3 4 8 1415 20
GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH
8 1415 20 1 3 4 8 1415 20 8 1415 201 3 4 1 3 4
1 3 4 8 1415 20
GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH|GVTSAPDTRPAPGSTAPPAH
8 1415 20 1 3 4 8 1415 20 8 1415 201 3 4 1 3 4
GalNAc-T2 (D458R)
20min
1h30min
24h
I
II
GalNAc
15N
1H
 Deciphering GalNAc O-glycosylation 
O-glycosylation of mucin MUC1 by GalNAc-Ts 
 
 
 119 
After 24 h, (Figure 2.4.10 Panel I-a) glycosylation at Thr3 was 80 % (Figure 2.4.10 
Panel II) with a very small fraction at Ser14 (5 %). These results show that the 
D458R mutant is able to glycosylate Thr3 and Ser14 sites, although the catalytic 
efficiency of the enzyme is severely affected (for the WT enzyme and after 20 min 
of incubation with the substrates, both Thr15 and Th3 are fully O-glycosylated 
while Ser14 is 75% O-glycosylated (Table 2.4.1).  
 
Table 2.4.1 – Percentage of glycosylation / min at Thr3, Ser14 and Thr15 by GalNAc-T2 
WT and GalNAc-T2 D458R.  
  GalNAc-T2 (WT)  
(%/min) 
GalNAc-T2 (D458R) 
(%/min) 
T3 4,6 0,2 
S14 3,5 0 
T15 5 5 
 
As expected, glycosylation at Thr15 is not affected by the mutation, while 
the kinetics of glycosylation of Thr3 and Ser14 are strongly modulated by the lectin 
binding function. However, the D458R mutant is still capable to finish the 
glycosylation at Thr3. In contrast, glycosylation at Ser14 is severely compromised. 
GalNAc-T2 WT glycosylates Thr15 depending exclusively of the catalytic domain 
and glycosylates Thr3 and Ser14 with assistance of the lectin domain. For 
glycosylation of Thr3, the lectin binds the GalNAc moiety located at Thr15 of the 
same TR domain (distant 12 amino acids of the glycosylation site, TR independent), 
while for Ser14 glycosylation, the lectin binds Thr3 of the downstream TR domain 
(distant 9 amino acids of the glycosylation, TR dependent) (Figure 2.4.11).  
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Figure 2.4.11 – Schematic representation of the glycosylation processes at Thr3 and Ser14 
in MUC1 by GalNAc-T2. 
 
Therefore, glycosylation at Ser14 depends on the glycosylation at Thr3 of 
the following TR domain.  Indeed, for GalNAc-T2 WT, a Ser14 site corresponding 
to one TR domain of MUC1-4TR is difficult to glycosylate (after 20 min, 75 % of 
Ser14 are glycosylated, 3 TR domains). An HSQC recorded after 16 h shows that 
glycosylation at Ser14 only progresses up to 85 %. Fully glycosylation of all Ser14 
(100 %, 4 TR domains) is only achieved after 24 h. This result points out that the 
last Ser14 to be glycosylated is located at the C-terminal TR domain of MUC1-
4TR, and without assistance of the lectin domain. Indeed, a mass around 9831 m/z 
was detected corresponding to a product of MUC1-4TR with 11 GalNAc units 
attached (Figure 2.4.8).  
The difficulty to glycosylate Ser14 by GalNAc-T2 has previously been 
reported.34 The presence of a GalNAc moiety at the adjacent Thr15 residue strongly 
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influences the catalytic efficiency of the enzyme. Molecular interactions between 
GalNAc at Thr15 and the catalytic domain cannot be ruled out, prompting the 
inhibition of the catalytic center by the glycosylated product.    
 
2.4.1.2.1.1 Summary:  
⎯ Thr15 is the first glycosylation site catalyzed by GalNAc-T2. This 
glycosylation of Thr15 is not affected with the D458R mutation. The GSTA region 
is the natural preference for the catalytic domain at MUC1. The GalNAc-T2 
displays preference to glycosylate at the GSTA region in MUC1-4TR. 
⎯ Glycosylation of Thr3 is the second glycosylation site catalyzed by 
GalNAc-T2. The glycosylation of this site is assisted by the lectin domain and is 
TR independent. The lectin binds to a GalNAc moiety located at the Thr15 of the 
same TR domain.  
⎯ Finally, the glycosylation of Ser14 is assisted by the lectin domain and is 
TR dependent. Herein, the lectin binds to a GalNAc moiety located at Thr3 of the 
downstream TR domain.  
 
2.4.1.2.2 GalNAc-T3 WT vs GalNAc-T3 D517H 
The employed methodology to monitor the O-glycosylation process of 
MUC1-4TR by GalNAc-T2 and their mutant was also followed to investigate the 
glycosylation process of MUC1-4TR by GalNAc-T3 WT and its corresponding 
D517H mutant. GalNAc-T3 is able to initiate glycosylation of MUC1, modifying the 
same three sites as GalNAc-T2 (Figure 2.4.12 - Panel I).34 Nevertheless, the order 
of glycosylation preference is different than that for GalNAc-T2. GalNAc-T3 
glycosylates Thr3 first and then, Thr15.34 GalNAc-T3 preferentially glycosylates 
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peptides with a Val residue at -1.66 As GalNAc-T2, GalNAc-T3 ends with the 
transfer of GalNAc to Ser14.  
Figure 2.4.12 - Panel II-a and II-b shows the HSQC of 15N-labeled MUC1-
4TR in the presence of MnCl2 and GalNAc-T3 WT and GalNAc-T3 D517H, 
respectively, after addition of UDP-GalNAc (excess) at 0, 20 min, 1 h 30 min, and 
24 h. After 20 min of the addition of UDP-GalNAc, the CSPs correspond to the 
partial glycosylation at Thr3 (blue arrows) and Thr15 (green arrows) with 
glycosylation percentages around 76 % and 70 %, respectively (Figure 2.4.12 Panel 
II-a). In addition, a very small fraction of Ser14 is glycosylated (less than 5 %) 
(Figure 2.4.13 panel I). For the D517H mutant, the HSQC after 20 min only shows 
CSP for Thr3, Val2, Ser4 and Ala5 compatible with glycosylation at Thr3 (Figure 
2.4.12 Panel II-b). At this point, 65 % of Thr3 of MUC1-4TR, which corresponds 
to 2-3 TR domains, are glycosylated. No glycosylation at Thr15 was detected. 
Indeed, for the mutant, just after 1 h 30 min, after the conclusion of glycosylation 
at Thr3, the transfer of GalNAc at Thr15 is initiated (around 25 %, one TR domain). 
After the same period, in the presence of GalNAc-T3 WT, glycosylation at Thr3 
and Thr15 are ca. 100 %. These observations are rather similar to those perceived 
for the analogue mutant GalNAc-T2 D458R. 
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Figure 2.4.12 – I: Scheme of MUC1-4TR glycosylation by GalNAc-T3 under the NMR 
experimental conditions. the glycosylation sites are displayed in red; II: Glycosylation of 
MUC1-4TR construct by GalNAc-T3 (WT) and mutant D517H, in presence of excess of UDP-
GalNAc. II-a): HSQC of MUC1-4TR in the presence of GalNAc-T3 (WT) before (black) 
and after addition of UDP-GalNAc (in excess) at 20 min (red), 1 h 30 min (pink) and 24 h 
(blue). Arrows indicate CSPs that occur as result of GalNAc additions at Thr3 (green 
arrows), Thr15 (blue arrows) and Ser14 (orange arrows). The * labeling in the amino acid 
on the spectra indicates glycosylation. II-b) HSQC of the MUC1-4TR in presence of the 
GalNAc-T3 D517H mutant before (black) and after addition of an excess of UDP-GalNAc at 
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20 min (red), 1 h 30 min (pink) and 24 h (blue). Arrows indicate CSP that occur as result 
of GalNAc additions to the MUC1 at Thr3 (green arrows), Thr15 (blue arrows) and Ser14 
(orange arrows).  
 
 Figure 2.4.13 Panel I and II show the plots of the percentage of glycosylation 
in function of time for GalNAc-T3 and the D517H mutant, respectively. 
Glycosylation at Thr15 and Ser14 by GalNAc-T3 is strongly affected by the 
mutation in the lectin domain. 
 
 
Figure 2.4.13- Relative glycosylation of MUC1-4TR over time. Panel I.- In the presence of 
GalNAc-T3 WT. Panel II.- In the presence of the GalNAc-T3 D517H mutant.  
 
After 24 h, for GalNAc-T3 WT, the fraction of glycosylation at Ser14 is ca. 
70 % (Figure 2.4.13 Panel II-a), contrasting with that observed for the D517H 
mutant, where no glycosylation at Ser14 is detected (Figure 2.4.13 Panel II-b). For 
GalNAc-T3 WT, long time reaction (72 h) yielded glycosylation at Ser14 close to 
88 %, in contrast with the mutant, which is unable to transfer GalNAc at Ser14.   
Table 2.4.2 shows the percentage of glycosylation between the GalNAc-T3 
WT and the D517H mutant. Thus, while glycosylation at Thr3 by GalNAc-T3 is only 
dependent on the natural affinity of the catalytic domain to the GVTS region of 
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MUC1, remote glycosylation at Thr15 and Ser14 is assisted by the lectin domain. 
In contrast to Thr3 residue, the percentage of glycosylation/min of Thr15 and Ser14 
amino acids is severally decreased by the mutation in the lectin domain (Table 
2.4.2). 
 
Table 2.4.2 – Percentage of glycosylation / min at Thr3, Ser14 and Thr15 by GalNAc-T3 
WT and GalNAc-T3 D517H.  
  GalNAc-T3 (WT)  
(%/min) 
GalNAc-T3 (D517H) 
(%/min) 
T3 3.8 3.2 
S14 0.2 0 
T15 3.5 0.2 
 
Therefore, to accomplish long-range glycosylation, GalNAc-T3 uses the 
lectin domain to bind the GalNAc moiety located at Thr3 and directs the transfer of 
GalNAc to Thr15 and Ser14 at the same TR domain. This result is in agreement 
with the preference of GalNAc-T3 to glycosylate C-terminal sites remote from the 
prior N-terminal GalNAc glycosites in glycopeptides.21,37 This behavior is opposite 
to that observed for GalNAc-T2 and -T1 isoforms.37,38 The directionality of the 
lectin-mediated long-range glycosylation is modulated by the linker that connects 
the lectin and catalytic domain in GalNAc-Ts, as reported on subchapter 2.3 of this 
thesis.64  
As for GalNAc-T2, interactions of the GalNAc moiety at the adjacent Thr15 
with the catalytic center of GalNAc-T3 are expected. Comparing GalNAc-T2 with 
GalNAc-T3, it is evident that GalNAc-T3 presents lower efficiency to glycosylate 
Ser14 than GalNAc-T2. The percentage of glycosylation / min for this residue is 
3.5 for GalNAc-T2 and 0.2 for GalNAc-T3. These differences in the ability to 
incorporate GalNAc at Ser14 have already been described by Wandall and co-
workers34. Kinetics studies assisted by mass spectrometry have demonstrated that 
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GalNAc-T2 glycosylates Ser14 faster than GalNAc-T1 and -T3 isoforms.   The 
differences in the directionality of the lectin-mediated long-range glycosylation 
cannot explain the difference in the kinetics of glycosylation of Ser14 by the 
different GalNAc-Ts, since GalNAc-T1 and -T2 display the same behavior.20,29,38  
 
2.4.1.2.2.1 Summary: 
⎯ Glycosylation at Thr3 is the first event processed by GalNAc-T3.  This 
glycosylation is not affected with the D459H mutation. The GVTS region is the 
natural preference for the GalNAc-T3 catalytic domain at MUC1. The GalNAc-T3 
displays preference to glycosylate the GVTS region in MUC1-4TR 
⎯ Thr15 is the second site glycosylated by GalNAc-T3. It is assisted by the 
lectin domain and is TR independent. The lectin binds the GalNAc moiety located 
at Thr3 of the same TR domain.  
⎯ The last site glycosylated by GalNAc-T3 is Ser14. It is assisted by the 
lectin domain and is TR independent.  The lectin binds the GalNAc moiety located 
at Thr3 of the same TR domain, opposite to GalNAc-T2.  
⎯ GalNAc-T3 has lower efficiency to glycosylate Ser14 than GalNAc-T2. 
 
2.4.1.2.3 GalNAc-T4 WT vs GalNAc-T4 D459H  
GalNAc-T4 is the unique GalNAc-T isoform able to glycosylate the latest 
two sites of MUC1 sequence, the Ser residue at GVT*SA (* indicates that the 
residue is O-glycosylated) and the Thr moiety at the immunogenic PDTRP 
region.27,33,60,61 Therefore, O-glycosylation of these two latest sites was also 
investigated by NMR.  The purified glycosylated product MUC1-4TR-T3S14T15, 
obtained after enzymatic glycosylation by GalNAc-T2/T3 (see description in 
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material and methods), was used as starting material (Figure 2.4.14 – Panel I). From 
analysis of the HSQC spectra (Figure 2.4.14 Panel II) the detected CSP arise from 
glycosylation at Ser4 and at Thr8. Glycosylation at Thr8 induces its strong CSPiii 
(0.39 ppm),iv together with CSP at Arg9 (0.62 ppm) and Asp7 (0.23 ppm). 
Interestingly, glycosylation at Ser4 only provides a moderate CSP at the 
corresponding Ser4 (0.13 ppm) and at Ala5 (0.09 ppm). Additionally, Figure 2.4.14 
Panel II-a shows that GalNAc-T4 slightly prefers to glycosylate Ser4 than Thr8. 
After 5 h, glycosylation at Ser4 and Thr8 reaches 40 % and 24 %, respectively 
(Figure 2.4.14 Panel II-b). The mass spectrometry analysis shows that the product 
after GalNAc-T4 catalysis only contains nineteen GalNAc moieties instead of the 
expected twenty GalNAc residues (Figure 2.4.15). Assignment of the HSQC of the 
purified product after glycosylation confirms that Ser4 at the N-terminus is in fact 
non-glycosylated suggesting that the glycosylation of this acceptor site is lectin 
assisted (Figure 2.4.15). In fact, glycosylation at Ser4 by GalNAc-T4 would likely 
require the binding of the lectin domain to a GalNAc moiety present at the 
preceding MUC1 TR domain. In this context, the lectin could bind the GalNAc 
moiety at either Ser14 or Thr15, distant 10 or 9 amino acids, respectively, to the 
Ser4 glycosylation site of the subsequent TR domain.  
 
                                                     
iii The values of chemical shift presented are the combined chemical shift calculated to each 
backbone NH groups of MUC1-4TR.79 
iv See on conformational studies, section 2.4.2.1. 
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Figure 2.4.14 – I: The glycosylation pattern of the initially glycosylated MUC1-
4TR-T3S14T15 provided by GalNAc-T4 under the NMR experimental conditions. the 
glycosylation sites are displayed in red; II – a) Glycosylation of MUC1-4TR-T3S14T15 by 
GalNAc-T4 WT in the presence of an excess of UDP-GalNAc. HSQC of the MUC1-4TR-
T3S14T15 product in the presence of GalNAc-T4 and MnCl2 before (black) and after 
addition of UDP-GalNAc (in excess) at 2 h (magenta) and 24 h (blue). The arrows indicate 
CSP that occur as result of GalNAc additions at Ser4 (gray arrows) and at Thr8 (yellow 
arrows). The * labeling in the amino acid on the spectra indicates glycosylation. b) Relative 
glycosylation of MUC1-4TR-T3S14T15 by GalNAc-T4 (WT) along the reaction time.  
 
 
Figure 2.4.15 - Data of purified MUC1-4TR-T3S4T8S14T15 product. Left: HSQC with the 
corresponding NMR assignment. The * labeling in the amino acid on the spectra indicates 
glycosylation. Right: MALDI-TOF spectrum. 
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It has been previously demonstrated that GalNAc-T4 displays a strict 
dependence on the prior glycosylation of MUC1 substrate.33,61 Therefore, to address 
whether Ser4 and Thr8 are likely to be glycosylated in a lectin domain dependent 
manner, the D459H mutant was utilized. From HSQC analysis (Figure 2.4.16 Panel 
I), it is clear that mutation at the lectin domain affects glycosylation at Ser4 and 
Thr8 in different manners. Hence, our results indicate that the abolishment of the 
lectin domain function entirely precludes glycosylation at Ser4, supporting the 
hypothesis that the lectin domain of GalNAc-T4 binds the previous TR domain to 
direct the catalysis at Ser4 at the succeeding TR domain. Besides to be severely 
affected, glycosylation at Thr8 is carried out by the D459H mutant and after 24 h, a 
20 % of the Thr8 residues are glycosylated, reaching a maximum of 35 % after 72 
h. Table 2.4.3 compares the percentage of glycosylation / min of Ser4 and Thr8 for 
GalNAc-T4 and its respective D459H mutant. The results show that not only 
GalNAc-T4 prefers to glycosylate Ser4 over Thr8 but also this process relies on the 
lectin domain for an efficient glycosylation. In addition, the mutant is not capable 
of glycosylating Ser4 and partly glycosylates Thr8. Our data agrees well with 
previous cellular studies using CHO-K1 cells overexpressing GalNAc-T4 and the 
D459H mutant, respectively.60 These results showed an increase in the glycan 
occupancy of Ser4 and Thr8 in the former cell line while Ser4 glycosylation was 
decreased ~50 % and Thr8 glycosylation was not affected in the latter cell line.60 
Note also that the glycosylation rate of Ser4 is lower than the observed for Thr3 
and Thr15 achieved by GalNAc-T2 and T3, respectively. However, Ser4 
glycosylation rate is similar to the one observed for Ser14 by both GalNAc-T2 or 
T3. Both acceptor sites are glycosylated in a lectin domain dependent manner and 
are contiguous to a prior glycosite that likely impedes an optimal glycosylation (see 
subchapter 2.3).65 
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Figure2.4.16 – I a) Glycosylation of MUC1-4TR-T3S14T15 product by GalNAc-T4 
(D459H) in the presence of an excess of UDP-GalNAc. HSQC of the MUC1-4TR-T3S14T15 
product in the presence of GalNAc-T4 (D459H) before (black) and after addition of UDP-
GalNAc (in excess) at 24 h (blue) and 72 h (green). The arrows indicate CSP that occur as 
result of GalNAc additions to the MUC1 at Thr8 (yellow arrows). The * labeling in the 
amino acid on the spectra indicates glycosylation. b) Relative glycosylation of MUC1-4TR 
by GalNAc-T4 D459H over time.  
 
Table 2.4.3 – Percentage of glycosylation / min at Ser4 and Thr8 by GalNAc-T4 WT and 
GalNAc-T4 D459H.  
  
GalNAc-T4 (WT)  
(%/min) 
GalNAc-T4 (D459H)  
(%/min) 
S4 0.13 0 
T8 0.08 0.03 
 
The effect of the mutation on glycosylation at Thr8 can be explained by two 
different scenarios (Figure 2.4.17):  
a) lectin assisted, where the lectin domain would likely bind to either the 
GalNAc moiety bound to Ser14 or Thr15 of the previous TR domain (14 or 13 
amino acids away from Thr8), since the binding of the lectin domain at Thr3 or 
Ser4 within the same TR domain is highly unlikely because of their short distance 
to Thr8 (5 and 4 amino acids away from Thr8). However, the catalytic domain of 
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GalNAc-T4 is still capable to partially glycosylate the Thr8 located at the PDTRP 
region.  
b) not lectin assisted, where the lectin domain would not bind to the GalNAc 
located at the preceding MUC1 TR domain and glycosylation at Thr8 would be 
entirely dependent on the catalytic domain. Thus, it is likely that glycosylation at 
Thr8 indirectly depends on the previously glycosylation at Ser4. In other words, in 
this scenario the simultaneously presence of GalNAc at Thr3, Ser4, Ser14, and 
Thr15 of MUC1 TR is essential to induce the conformation change of MUC1 
required to favor glycosylation at Thr8 within the PDTRP region. 
 
 
Figure 2.4.17 – Schematic representation of the two possible scenarios to explain 
glycosylation at Thr8 by GalNAc-T4 Panel a1) Lectin assisted via GalNAc binding located 
Ser14/Thr15. Panel a2) Lectin assisted via GalNAc binding located at Thr3/Ser4 Panel b) 
Not lectin assisted. 
 
The potential of GalNAc-T4 to glycosylate the Ser residue at GST*A has 
also been described (Ser14 in our MUC1 template).60 To investigate the 
glycosylation preference of GalNAc-T4 and its D459H mutant at Ser14, a MUC1-
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4TR peptide already glycosylated at Thr3 and Thr15 sites (MUC1-4TR-T3T15) 
was used as acceptor substrate. In particular, MUC1-4TR-T3T15 was obtained by 
glycosylation of MUC1-4TR by the GalNAc-T2 D458R mutant (see materials and 
methods). Figure 2.4.18 shows the HSQC and the corresponding mass of the 
purified MUC1-4TR-T3T15.  
 
 
Figure 2.4.18 - Data of the purified MUC1-4TR-T3T15 product. Left: HSQC with 
corresponding NMR assignment. The * labeling in the amino acid indicates glycosylation. 
Right: MALDI-TOF spectrum. 
 
Glycosylation of MUC1-4TR-T3T15 by GalNAc-T4 WT and its D459H 
mutant (Figure 2.4.19 Panel I) was monitored by HSQC-NMR experiments. The 
CSP are compatible with glycosylation at Ser4, along with reactions at Ser14 and 
Thr8 (Figure 2.4.19 Panel II-A). Furthermore, the results clearly pinpoint that Ser4 
at the GVT*SA region is preferentially glycosylated by GalNAc-T4 rather than 
Ser14 at GST*AP and then Thr8 at PDTRP (Figure 2.4.19 Panel II-B). Noteworthy, 
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Ser14 is also detected (1 %) (Figure 2.4.19 Panel II 2h). Thus, GalNAc-T4 initiates 
glycosylation of Ser14 after glycosylating Ser4 and before glycosylation of Thr8 
A16
A5
A11
A19
R9
V2
H20
C-Term
D7
H20
T8
G1
G13
T3*
T15*
S4
S14
MUC1-4TR-T3T15
9221.769
4881.558
5561.992
4677.551
4415.891
4611.639
9018.5477182.645
4779.166
4905.304
4862.589
7862.000 9424.663
39 .523
6458.317
5358.28452 7.654
6979.944
5095.737
8281.944
0
1000
2000
3000
4000In
te
n
s.
 [a
.u
.]
5000 6000 7000 8000 9000
m/z
9221.769
15N
1H
9000
9424.663
9018.547
 Deciphering GalNAc O-glycosylation 
O-glycosylation of mucin MUC1 by GalNAc-Ts 
 
 
 133 
starts. In fact, the 1H/15N-HSQC spectrum after 12 h shows a small percentage of 
glycosylation at Thr8 (6.4 %). After 48h, glycosylation at Ser4 reaches 70%, while 
at Ser14 and Thr8 are only 18 % and 13%, respectively, fairly similar. On the other 
hand, after 48 h, when MUC1-4TR-T3S14T15 is used as acceptor substrate, 
glycosylation at Ser4 and Thr8 reaches 79 % and 81 %, respectively. Thus, these 
results clearly show the relevance of the complementarity and hierarchy of 
GalNAc-Ts during the O-glycosylation process of MUC1. 
 
 
Figure 2.4.19 – I: Scheme of the MUC1-4TR-T3T15 glycosylation product 
synthesized by GalNAc-T4 (WT) under the NMR experimental conditions. The glycosylation 
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sites are displayed in red; II – a) The glycosylation process of MUC1-4TR-T3T15 by 
GalNAc-T4 (WT) in the presence of excess of UDP-GalNAc. 1H/15N-HSQC spectrum of the 
MUC1-4TR-T3T15 glycosylation product in the presence of GalNAc-T4 (WT) (black) and 
after addition of UDP-GalNAc 2 h (red), 12 h (pink) and 48 h (green). The arrows indicate 
the CSP that occur at Ser4 (gray arrows), Ser14 (orange arrows) and Thr8 (yellow arrows). 
The * labeling indicates the glycosylation site. b) The time course of relative glycosylation 
at the different residues. 
 
Long-range glycosylation at Ser4 is guided by the lectin domain of GalNAc-
T4. The results previously described for MUC1-4TR-T3S14T15 showed that the 
lectin domain could bind the GalNAc moiety either located at Ser14 or Thr15 of 
the upstream TR to drive the glycosylation of Ser4 residue of the downstream and 
contiguous TR domain. However, the percentage of glycosylation/min at Ser4 
using either MUC1-4TR-T3S14T15 or MUC1-4TR-T3T15 as acceptor substrates 
are similar (around 0.1 %/min) (Table 2.4.4), which strongly suggests that the lectin 
domain of GalNAc-T4 should bind the GalNAc moiety at Thr15 of the prior TR 
domain (Ser4 is 9 amino acids away from the GalNAc moiety at Thr15 of the 
precedent TR domain, Figure 2.4.20 a). Glycosylation event at Ser14 is also 
probably assisted by the lectin domain (Ser14 is 11 or 10 amino acids away from 
the GalNAc moieties at Thr3 or Ser4 in the same TR domain, Figure 2.4.20 b). 
However, GalNAc-T4 prefers to glycosylate Ser4 over Ser14. This is likely 
explained by the different peptide sequence around the acceptor site and the 
different location of the prior GalNAc moiety with respect to the acceptor site 
(GVT*SA vs GST*AP, where the Ser to be glycosylated is underlined (Figure 
2.4.20).  
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Figure 2.4.20 – Schematic representation to illustrate the different locations of the existing 
GalNAc respect to the glycosylation site. Panel a) Glycosylation of Ser4 within the GVT*SA 
sequence. Panel b) Glycosylation of Ser14 within the GST*AP sequence. 
 
The glycosylation process of MUC1-4TR-T3T15 was also investigated in 
the presence of the D459H mutant. In the case of the mutant Ser4, Ser14 and Thr8 
were not glycosylated (Table 2.4.4).  
 
Table 2.4.4 – Percentage of glycosylation / min at Ser4, Thr8 and Ser14 by GalNAc-T4 WT 
and GalNAc-T4 D459H.  
 
 
GalNAc-T4 (WT)  
(%/min) 
GalNAc-T4 (D459H)  
(%/min) 
S4 0.08 0 
T8 0.01 0 
S14 0.02 0 
 
The absence of glycosylation at S14 and S4 was expected. However, the 
absence of glycosylation at Thr8 was more surprising and implies two potential 
hypotheses (Figure 2.4.21): a) glycosylation of Thr8 is lectin assisted and lectin 
binds to the GalNAc located at S14 of the preceding TR domain (in this scenario 
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of Thr8 by GalNAc-T4) or b) the concomitant glycosylation of Ser4 and Ser14 
modulates MUC1 conformation allowing to increase the glycosylation at Thr8 by 
GalNAc-T4. 
 
 
Figure 2.4.21 – Schematic representation of the two possible scenarios to explain 
glycosylation at Thr8 by GalNAc-T4 Panel a) Lectin assisted. Lectin binds to the GalNAc 
located at Ser14. Panel b) Not lectin assisted and the conformation of glycosylated MUC1 
is important for glycosylation at Thr8.  
 
2.4.1.2.3.1 Summary:  
⎯ Ser4 is the first residue glycosylated by GalNAc-T4. Glycosylation of 
Ser4 is assisted by the lectin domain and is TR dependent. The lectin binds the 
GalNAc moiety located at Thr15 of the upstream TR domain. 
⎯ GalNAc-T4 is also capable to glycosylate Ser14 with assistance of the 
lectin domain. However, this glycosylation is TR independent. GalNAc-T4 
glycosylates Ser14 using the GalNAc moiety located either at Thr3 or at Ser4 of 
the same TR domain. 
⎯ The glycosylation of Thr8 may be either lectin-assisted or entirely 
dependent on the catalytic domain. We cannot exclude any of the two 
hypotheses. In the last case, the process would depend on the density of GalNAc 
moieties and thus, on the concomitant glycosylation at Thr3, Ser4, Ser14 and 
Thr15.  
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⎯ The lectin domain of GalNAc-T4 binds contiguous GalNAc moieties. 
 
2.4.1.3 Conformation of the glycosylated MUC1-4TR products modulates 
glycosylation preferences of GalNAc-Ts 
It is established that O-GalNAc glycosylation induces changes in the protein 
backbone conformations,67–70 with well-defined and distinct preferences for Ser and 
Thr residues.71,72  
The conformational analysis of the MUC1-4TR glycosylation products was 
carried out to evaluate the alterations on the native MUC1-4TR conformation upon 
O-GalNAc glycosylation.    
The glycosylation-induced chemical shifts were deducedv for each residue of 
the glycosylated MUC1-4TR-T3T15 (Figure 2.4.22), MUC1-4TR-T3S14T15 
(Figure 2.4.23) and MUC1-4TR-T3S4T8S14T15 (Figure 2.4.24), using the 
unglycosylated MUC1-4TR as reference. In some of the cases, for comparison 
reasons, the data acquired for the precedent glycosylated product were also used. 
Figures 2.4.22 – 2.4.24 clearly illustrate that the shifts occur both at the 
glycosylated- and neighboring peptide residues. Furthermore, the plots illustrate the 
downfield shift tendency observed upon O-glycosylation with respect to the 
reference (with exception of A5 orange bar in Figure 2.4.24).  
  
 
                                                     
v The chemical shift presented are the combined chemical shift (Δδcomb) calculated to each 
backbone NH groups of MUC1-4TR.79 
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Figure 2.4.22 - Plot of the Δδcomb values for backbone NH groups of MUC1-4TR-T3T15 
relative to naked MUC1-4TR. The * indicates the glycosylation site. 
 
 
Figure 2.4.23- Plot of the Δδcomb values for backbone NH groups of MUC1-4TR-
T3S14T15 relative to naked MUC1-4TR (Gray bars). The * indicates the glycosylation site. 
ΔΔδcomb is ΔδcombT3S14T15 - ΔδcombT3T15 (Orange bars). 
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Figure 2.4.24 - Plots of the Δδcomb values for backbone NH groups of MUC1-4TR-
T3S4T8S14T15 relative to naked MUC1-4TR (Gray bars). The * indicates the glycosylation 
site. ΔΔδcomb is ΔδcombT3S4T8S14T15 - ΔδcombT3S14T15 (Orange bars). 
 
The 1H and 15N NMR chemical shifts of the unglycosylated and glycosylated 
MUC1-4TR products are indicative of a random coil-like structure (Tables S4 - S7 
in supporting information).73 However, the downfield tendency upon O-GalNAc 
glycosylation is indicative of a deviation of the random coil to an extended 
conformation.  
The analysis also indicates that glycosylation at Thr3, Thr15 and Thr8 
induces larger chemical shift perturbations in the NH groups of the neighboring 
peptide residues than glycosylation at Ser4 and Ser14. Between the Thr units, 
glycosylation at Thr15 at GSTA region shows the larger variation in the chemical 
shift of the neighboring amino acids followed by glycosylation at Thr8 at the PDTR 
region. Another interestingly observation is that the highest chemical shift is 
usually experienced by the amino acid located at site +1 relative to the glycosylation 
site. For example, glycosylation at Thr15 (Figure 2.4.22) promotes a shift of 0.60 
ppm in Ala16 and of only 0.07 ppm in Ser14 (site -1 relative to the glycosylation 
site). The glycosylated Thr15 shifts 0.42 ppm. The same trend was observed for 
glycosylation at Thr3 and Thr8. The impact on the chemical shift of the NH of the 
amino acid located at the site +1 respective to the glycosylation site is more 
prominent when the glycosylated residue is a threonine than serine.  
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The differences in the chemical shift perturbation induced by O-GalNAc 
glycosylation in Thr or Ser can be correlated with the differences around the 
glycosidic linkages of GalNAc-Thr and GalNAc-Ser. Indeed, previous studies have 
already demonstrated that GalNAc-Thr glycopeptides are rather rigid in solution, 
with a O-glycosidic linkage in eclipsed conformation (Ф=80º and ψ=120º), while 
GalNAc-Ser analogues are more flexible and adopt the exo-anomeric/syn 
conformation (Ф=80º and ψ=180º).71,72,74 In the eclipsed geometry (GalNAc-Thr), 
the GalNAc moiety displays an almost perpendicular arrangement with respect to 
the amino acid. In contrast, in the GalNAc-Ser glycopeptides the GalNAc adopts a 
parallel disposition.71,72,74. The conformational analysis of GalNAc-Ser and 
GalNAc-Thr in MUC1-derived short glycopeptides75 clear pinpoint those 
conformers around the glycosidic sugar-peptide linkage (Figure 2.4.25). A 
characteristic NOE between the GalNAc moiety and the Thr residue is indicative 
of the perpendicular arrangement in the case of GalNAc-Thr glycopeptides. Thus, 
in the particular case of MUC1-4TR, the perpendicular disposition of the GalNAc 
moiety attached to all Thr residues (Thr3, Thr8 and Thr15) is supported by a NOE 
contact between the NH of the NHAc group of GalNAc and the backbone NH of 
the threonine (Table S1-S3). This NOE is not present in the GalNAc-Ser motifs 
(Ser4 and Ser14) indicating that a parallel arrangement between the GalNAc moiety 
and the peptide should take place.  
 
 
Figure 2.4.25 – Conformations of the GalNAc-Ser and GalNAc-Thr moieties in the GSTA 
region of MUC1. 
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An identical conformational behavior for GalNAc-Ser (parallel) and 
GalNAc-Thr (perpendicular) takes place for the contiguous GalNAc O-
glycosylation structures. Strong NOE contacts between the NH of the NHAc of 
GalNAc and the NH of threonine72,74 were detected in products MUC1-4TR-
T3S14T15 (Table S2) and MUC1-4TR-T3S4T8S14T15 (Table S3), corroborating 
this 3D disposition (Figure 2.4.26).  
 
 
 
Figure 2.4.26 – Conformation of the di-glycosylated GS*T*A motif of MUC1 (* indicates 
the site of glycosylation). 
 
Deviations from random-coil chemical shift values of Hα are also indicative 
of tendencies for a given secondary structure.76 The chemical shift index (CSI Hα) 
values (observed – random coil) for all residues of the unglycosylated MUC1-4TR 
and glycosylated MUC1-4TR products are indicative of the presence of extended-
like conformations (Figure 2.4.28 – 2.4.30  top panel).73,76 Indeed, the conformation 
of the unglycosylated MUC1 peptide thumbs in two major areas of the 
Ramachandran plot (Figure 2.4.27) both of them compatible with extended-like 
conformations: polyproline II-like and the β-strand conformations.  
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Figure 2.4.27 – Conformational clusters on the Ramachandran plot. ψ and Ф torsional 
angles are in degrees. Adapted from 77. 
 
Association of the catalytic affinities of different GalNAc-Ts with the major 
conformations displayed by the three distinct MUC1 regions (GVTS, DTRP, 
GSTA) was previously reported.77 By using MUC1 short peptides, Kinarsky and 
co-workers, demonstrated that the most populated area on the Ramachandran plot 
(Figure 2.4.27)  for the non-glycosylated GVTS motif was the B area (β-strand 
conformation), while the DTRP region matches in D area (inverse γ-turn 
conformation) and GSTA in the P area (polyprolines II-like conformation).77 
GalNAc-T2 initiates MUC1 glycosylation at Thr15 of the GSTA region, indicating 
that the catalytic domain of GalNAc-T2 has a preference to polyprolines II-like 
conformations. In contrast, GalNAc-T3 initiates MUC1 glycosylation at Thr3 of 
GVTS region, showing that the enzyme prefers to glycosylate peptides higher 
populated in β-strand conformations. GalNAc-T4 is the single GalNAc-T able to 
glycosylate the DTRP region therefore showing a marked preference to glycosylate 
peptide holding inverse γ-turn conformations. 
After glycosylation, the 1Hα chemical shift of the glycosylated residue and 
the residues around always experience a considerable downfield shift, pointing out 
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that the O-GalNAc glycosylation increases the population of extended-like 
conformations in peptides (polyprolines II-like and β-strand conformations).  
The Figure 2.4.28 – 2.4.30 analyze the effect of glycosylation on the CSI 1Hα 
of MUC1-4TR products. To distinguish the contribution of GalNAc glycosylation 
on the MUC1 conformation the difference between the CSI 1Hα of a MUC1-4TR 
product versus the CSI Hα of the previous MUC-4TR structure was carried out 
(Figure 2.4.28 – 2.4.30 bottom panel). 
 
 
 
Figure 2.4.28 – Effect of glycosylation at Thr3 and Thr15 on CSI 1Hα of MUC1-4TR. Top 
Panel. CSI 1Hα for the unglycosylated MUC1-4TR (green bars) and the MUC1-4TR-T3T15 
product (dark blue bars). Bottom Panel Difference between CSI 1Hα of MUC1-4TR-T3T15 
and MUC1-4TR.  
 
Glycosylation at Thr3 and Thr15 affect two other glycosylation sites, Ser4 
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residues clear modulates the succeeding glycosylation at Ser4 and Ser14, 
respectively. Noteworthy, the structural perturbation at Ser14 induced by 
glycosylation at Thr15 is larger than that observed in the case of Ser4 (induced by 
glycosylation at Thr3). The orientations of the side chains of the flanking amino 
acids to Thr and Ser residues are affected by glycosylation. In addition, the 
orientation of the side chains into opposite directions is typical for extended-like 
conformations. In this context, a virtual torsional θ (i, i+1) between vectors Cβ-
Cα(i) …Cα-Cβ (i+1), demonstrated that glycosylation at Thr15 modifies the 
torsional angle ca. 80º (from 85º in the unglycosylated to 165º in the glycosylated 
residue), while glycosylation at Thr3 only changes ca. 45º (from 120º to 165º). 77 
This observation explains why glycosylation at Thr15 strongly affects the 
conformation of the flanking Ser14.  
Furthermore, glycosylation at Thr15 (GSTA region) induces a reduction of 
the population at B region (β-strand conformation) in the Ramachandran plot and 
an increase of the population in the D area (inverse γ-turn conformation).77 Ser14 
is the last residue that is glycosylated by GalNAc-T2/T3. Additionally, in section 
2.4.2.2 we showed that the transfer of GalNAc to Ser14 by GalNAc-T2 and 
GalNAc-T3 is lectin assisted. However, the catalysis is less efficient in GalNAc-
T3 compared to GalNAc-T2. This observation suggests that GalNAc-T3 
glycosylates less favorably acceptor sites located in inverse γ-turn conformation.  
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Figure 2.4.29 – Effect of glycosylation at S14 on CSI 1Hα of MUC1-4TR. Top Panel. CSI 
1Hα for the MUC1-4TR-T3T15 (dark blue bars) and MUC1-4TR-T3S14T15 products 
(orange bars). Bottom Panel. Difference between CSI 1Hα of MUC1-4TR-T3S14T15 and 
MUC1-4TR-T3T15 products. 
 
Ser4 at the GVT*S region (* indicates glycosylation site) and Thr8 at PDTR 
region are both glycosylated by GalNAc-T4. GalNAc-T4 preferentially glycosylate 
peptides that adopt inverse γ-turn conformations,77 as that present in the PDTR 
motif. Also, glycosylation at Thr3 induces a change in the ψ and Ф angles of GVTS 
region from β-strand to inverse γ-turn conformations. The prevalence of inverse γ-
turn conformers in both of these regions can be associated with the catalytic 
preferences of GalNAc-T4 towards the MUC1 sequence.   
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Figure 2.4.30 - Effect of glycosylation at Ser4 and Thr8 on CSI 1Hα of MUC1-4TR. Top 
Panel. CSI 1Hα for the MUC1-4TR-T3S14T15 (orange bars) and MUC1-4TR-
T3S4T8S14T15 products (gray bars).  Bottom Panel. Difference between CSI 1Hα of 
MUC1-4TR-T3S4T8S14T15 product and MUC1-4TR-T3S14T15.  
 
The analysis of Figures 2.4.28 – 2.4.30 highlight that glycosylation at Thr 
residues has a major impact on the structural environment around the glycosylation 
site than at Ser. Specifically, our CSI data indicates that the glycosylation at Ser4 
has a negligible effect on the MUC1 conformation. Additionally, a reduced number 
of sugar-peptide NOEs was observed upon GalNAc addition at Ser residues in 
comparison to those detected after GalNAc introduction at Thr (Table S1-S3). This 
result is in agreement with the observation that glycans attached to serine residues 
are likely to hold more rotational flexibility.71,72,74 These observations together with 
the obtained NOE data (Table S1-S3) pinpoint that GalNAc-Ser barely modulates 
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the peptide conformation around the glycosylation site, when compared with 
GalNAc-Thr.  
This last conclusion rules out the hypothesis that concomitant glycosylation 
at Ser4 and Ser14 modulates MUC1 conformation allowing to increase the 
glycosylation event at Thr8 by GalNAc-T4.  Hence, glycosylation at Thr8 by 
GalNAc-T4 should be assisted by the lectin domain, with the lectin recognizing the 
GalNAc attached to Ser14 of the preceding TR domain. 
 
2.4.1.3.1.1 Summary  
⎯ The O-GalNAc glycosylation at Thr moieties induces higher chemical 
shift perturbations than at Ser units. Thus, glycosylation at Thr 
generate larger structural variations. 
⎯ The effect of the glycosylation at the two serines (Ser4 and Ser14) is 
minimal and does not affect the conformation of APDTR region. 
 
 
2.4.2 Conclusions 
The study presented herein provides the evidence that GalNAc-Ts 
glycosylate in a highly-ordered form the MUC1 substrate. Besides that, all the TR 
domains of MUC1 are fully O-glycosylated in a stepwise manner. Within this work, 
we have provided compelling evidences that the interplay between the lectin and 
catalytic domain of these enzymes, for the catalysis of all glycosylation sites of 
MUC1, is crucial. 
GalNAc-T2 and GalNAc-T3 are responsible to glycosylate the same three 
glycosylation sites at MUC1 (Thr3, Ser14 and Thr15). However, each enzyme has 
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own preferences and directionality. GalNAc-T2 prefers GSTA sequence (Thr15) at 
a naked MUC1 and, in contrast GalNAc-T3 has preference for GVTS region 
(Thr3). These preferences of the catalytic domain should be correlated with the 
conformation of each region at MUC1. The other two sites of glycosylation (Thr3 
in case of GalNAc-T2, Thr15 in case of GalNAc-T3 and Ser14 in both of cases) are 
glycosylated using the lectin domain to guide the glycosylation process. When the 
lectin domain is disrupted, considering the mutants GalNAc-T2 D458R and 
GalNAc-T3 D517H, the glycosylation of these sites was highly affected. 
Additionally, in the case of GalNAc-T3 D517H, the mutation disallows the 
glycosylation of Ser14.  
GalNAc-T4 is the only GalNAc-T isoform able to glycosylate the last two 
sites of MUC1 sequence, the Ser residue at GVT*SA (* indicates that the residue 
is O-glycosylated) (Ser4) and the Thr moiety at the immunogenic PDTRP region 
(Thr8). Within this work, we observed that Ser4 is assisted by lectin domain 
because the mutant GalNAc-T4 D459H is not able to glycosylate this glycosylation 
site. The lectin domain of GalNAc-T4 binds at GalNAc of the previous 
glycosylated Thr15 of upstream TR to guide the catalytic glycosylation at Ser4.  
It was more challenging to discriminate if the glycosylation of Thr8 is to be 
glycosylated in a lectin assisted manner or is entirely dependent of the catalytic 
domain. However, based on our results seems that the glycosylation of Thr8 is 
lectin assisted, using the O-GalNAc at Ser14 of the upstream TR. This suggestion 
is based considering that the glycosylation of Thr8 is affected in the case of the 
mutant GalNAc-T4 D459H, but still capable to glycosylate this position (Thr8) in 
the tri-glycosylated MUC1 (Thr3, Ser14, Thr15). Though, when the substrate is a 
di-glycosylated MUC1 (Thr3, Thr15), the mutant D459H loses completely the 
capacity to glycosylate Thr8. We also observed, that the effect of the glycosylation 
Ser4 and Ser14 in the conformation of MUC1 is minimal, and these glycosylations 
do not affect the APDTR region conformation at all. Leaving only the hypotheses 
that Thr8 is lectin assisted and is necessary a concomitant glycosylation at Thr3, 
Ser4, Ser14 and Thr15. 
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GalNAc-T4 is also capable to glycosylate Ser14 with assistance of the lectin 
domain. GalNAc-T4 glycosylates Ser14 likely using GalNAc moieties located at 
Thr3 or Ser4 of the same TR domain. Thus, the lectin domain of GalNAc-T4 binds 
contiguous GalNAc moieties. 
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2.4.3 Supporting information  
Table S1 – Carbohydrate-peptide NOEs of the MUC1-4TR-T3T15. The * labeling 
in the amino acid indicates glycosylation. 
H8 GalNAc-T3* Hα S4 Medium 
H8 GalNAc-T3* Hα T3* Medium 
H8 GalNAc-T3* Hα A5 Medium 
H8 GalNAc-T3* H2 GalNAc-T3* Weak 
H8 GalNAc-T3* Hβ A5 Strong 
NH GalNAc-T3* NH T3* Strong 
H5 GalNAc-T15* Hγ T15* Strong 
H8 GalNAc-T15* Hα T15* Medium 
H8 GalNAc-T15* Hα S14 Medium 
H3 GalNAc-T15* Hγ T15* Weak 
H6 GalNAc-T15* Hβ A16 Strong 
H8 GalNAc-T15* Hβ A16 Weak 
H2 GalNAc-T15* Hβ A16 Medium 
H6 GalNAc-T15* Hγ T15* Medium 
H2 GalNAc-T15* Hβ T15* Medium 
NH GalNAc-T15* NH T15 Strong 
 
Table S2 – Carbohydrate-peptide NOEs of the MUC1-4TR-T3S14T15. The * 
labeling in the amino acid indicates glycosylation. 
H8 GalNAc-T3* Hα T3* Medium 
NH GalNAc-T3* Hα S4 Weak 
NH GalNAc-T3* Hβ T3* Weak 
H2 GalNAc-T3* Hβ T3* Weak 
H8 GalNAc-T3* Hα S4 Medium 
H8 GalNAc-T3* Hβ A5 Medium 
NH GalNAc-T3* NH T3 Strong 
H5 GalNAc-S14* Hβ T15 Strong 
H8 GalNAc-S14* Hα S14* Weak 
H8 GalNAc-T15* Hβ A16 Medium 
H2 GalNAc-T15* Hβ T15* Medium 
H6 GalNAc-T15* Hβ A16 Strong 
H8 GalNAc-T15* Hα T15* Medium 
H5 GalNAc-T15* Hγ T15* Strong 
H3 GalNAc-T15* Hγ T15* Medium 
H6 GalNAc-T15* Hγ T15* Medium 
NH GalNAc-T15* NH T15 Strong 
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Table S3 – Carbohydrate-peptide NOEs of the MUC1-4TR-T3S14T15. The * 
labeling in the amino acid indicates glycosylation. 
 
H8 GalNAc-T3* Hα A5 Medium 
H3 GalNAc-T3* Hγ V2 Medium 
NH GalNAc-T3* Hβ T3* Medium 
NH GalNAc-T3* NH T3 Strong 
H8 GalNAc-T3* Hα A5 Medium 
H8 GalNAc-T3* Hα S4 Medium 
H8 GalNAc-S4* NH S4* Medium 
H2 GalNAc-T8* Hγ T8* Medium  
H4 GalNAc-T8* Hγ T8* Medium 
H5 GalNAc-T8* Hγ T8* Strong 
H8 GalNAc-T8* Hγ T8* Strong 
NH GalNAc-T8* NH T8* Medium 
NH GalNAc-S14* Hβ T15* Medium  
H8 GalNAc-S14* Hα T15* Weak 
NH GalNAc-T15* Hα A16 Weak  
H8 GalNAc-T15* Hβ A16 Medium 
NH GalNAc-T15* NH T15 Strong 
H8 GalNAc-T15* Hα T15* Medium 
H3 GalNAc-T15* Hβ A16 Strong 
H5 GalNAc-T15* Hγ T15* Strong 
H3 GalNAc-T15* Hγ T15* Medium 
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Table S4 -  1H-NMR assignments of the 15N-MUC1-4TR.  
 
Residue Atom  ppm 
G1 
N 110.42 
QA 3.97 
H 8.52 
V2 
QG2 0.95 
N 119.76 
HB 2.13 
HA 4.25 
H 8.26 
T3 
QG2 1.20 
N 118.71 
HA 4.44 
H 8.46 
S4 
N 118.97 
QB 3.85 
HA 4.45 
H 8.45 
A5 
QB 1.37 
N 127.51 
HA 4.62 
H 8.51 
P6 
HA      4.42 
QB      2.32 
QG 1.99 
HD2     3.66 
HD3     3.82 
D7 
N 120.77 
HB3 2.68 
HB2 2.75 
HA 4.64 
H 8.59 
T8 
QG2 1.19 
N 115.09 
HA 4.31 
H 8.21 
R9 
QG 1.71 
QB 1.80 
N 125.02 
QD 3.23 
HA 4.60 
H 8.38 
P10 
HA      4.40 
HD3     3.82 
HD2     3.61 
QB      2.28 
QG      1.98 
A11 
QB 1.37 
N 126.24 
HA 4.58 
H 8.63 
P12 
HB 4.24 
HA      4.41 
QB      2.30 
QG      2.00 
HD3     3.81 
HD2     3.66 
G13 
N 110.04 
QA 3.99 
H 8.67 
S14 
N 115.56 
QB 3.91 
HA 4.53 
H 8.26 
T15 
QG2 1.21 
N 116.14 
HB 4.23 
HA 4.38 
H 8.35 
A16 
QB 1.35 
N 128.52 
HA 4.59 
H 8.42 
P17 
HB      4.24 
HA      4.42 
QG 2.03 
QB      2.22 
HD3     3.83 
HD2     3.65 
P18 
HA      4.41 
QG 2.03 
QB      2.27 
HD2     3.65 
HD3     3.82 
A19 
QB 1.38 
N 124.77 
HA 4.59 
H 8.55 
H20 
N 117.66 
QB 3.22 
HA 4.68 
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H 8.55 
H20 C-term 
N 122.17 
H 8.06 
QB 3.16 
HA 4.59 
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Figure S5 - 1H-NMR assignments of the 15N-MUC1-4TR-T3T15. The * labeling in the 
amino acid indicates glycosylation. 
Residue Atom  ppm 
G1 
H 8.45 
N 110.33 
QA 3.97 
V2 
QG2 0.99 
HA 4.34 
HB 2.12 
H 8.21 
N 120.36 
T3* 
H 8.80 
N 117.73 
QG2 1.28 
HA 4.68 
HB 4.33 
H3-GalNAc 3.99 
H2-GalNAc 4.20 
H5-GalNAc 4.10 
H6-GalNAc 3.67 
H1-GalNAc 4.89 
H4-GalNAc 4.03 
H8-GalNAc 2.03 
NH-GalNAc 7.65 
S4 
H 8.61 
N 116.46 
QB 3.85 
HA 4.47 
A5 
H 8.62 
N 126.47 
QB 1.41 
HA 4.53 
P6 
HG2 2.03 
HD2 3.84 
HA 4.42 
HD3 3.65 
QB 2.30 
HG3 1.90 
D7 
HB2 2.68 
HA 4.64 
HB3 2.76 
H 8.60 
N 120.93 
T8 
H 8.20 
N 115.08 
HA 4.29 
QG2 1.22 
R9 
H 8.39 
N 124.96 
HB3 1.72 
HA 4.58 
HD3 3.21 
HB2 1.82 
QG 1.36 
P10 
HG2 2.05 
HA 4.39 
QB 2.28 
HD2 3.83 
HD3 3.67 
HG3 1.83 
A11 
H 8.63 
N 126.32 
HA 4.58 
QB 1.39 
P12 
HG2 2.04 
HA 4.41 
QB 2.29 
HD2 3.81 
HG3 1.92 
G13 
H 8.67 
N 109.64 
QA 4.00 
S14 
H 8.25 
N 115.99 
QB 3.96 
HA 4.68 
T15* 
H 8.76 
N 114.41 
QG2 1.27 
HA 4.61 
HB 4.36 
H3-GalNAc 3.89 
H2-GalNAc 4.09 
H5-GalNAc 3.98 
H8-GalNAc 2.05 
H1-GalNAc 4.93 
H4-GalNAc 3.94 
H6-GalNAc 3.89 
NH-GalNAc 7.88 
A16 
H 8.46 
N 125.37 
QB 1.34 
HA 4.57 
P17 
HG2 2.02 
HA 4.41 
QB 2.32 
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HG3 1.92 
P18 
HG2 1.92 
HA 4.41 
QB 2.33 
HG3 1.92 
A19 
H 8.54 
N 124.71 
QB 1.34 
HA 4.58 
H20 
H 8.39 
N 118.14 
QB 3.19 
HA 4.64 
H20 C-term 
HB3 3.12 
HA 4.45 
HB2 3.21 
H 8.02 
N 122.31 
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Figure S6 -  1H-NMR assignments of the 15N-MUC1-4TR-T3S14T15. The * labeling in the 
amino acid indicates glycosylation and # labeling indicates the amino acid perturbated with 
the neighboring glycosylation. 
Residue  Proton  ppm 
G1 
H 8.443 
N 110.311 
QA 3.965 
V2 
H 8.195 
N 120.683 
HA 4.323 
HB 2.107 
QG2 0.998 
T3* 
H 8.796 
N 117.735 
HA 4.688 
HB 4.320 
QG2 1.252 
H2-GalNAc 4.090 
H1-GalNAc 4.977 
H4-GalNAc 3.969 
H3-GalNAc 3.915 
HN-GalNAc 7.652 
H8-GalNAc 2.044 
H6-GalNAc 3.782 
H5-GalNAc 4.024 
S4 
H 8.610 
N 116.534 
HA 4.492 
HB3 3.871 
HB2 3.805 
A5 
H 8.620 
N 126.387 
HA 4.550 
QB 1.413 
P6 
HA 4.432 
QB 2.317 
HD3 3.840 
HD2 3.680 
HG3 2.054 
HG2 1.974 
D7 
H 8.596 
N 120.901 
HA 4.636 
HB3 2.747 
HB2 2.675 
T8 
H 8.200 
N 115.115 
QG2 1.202 
HA 4.288 
R9 
H 8.386 
N 125.077 
HA 4.58 
HD3 3.255 
QB 1.818 
QG 1.709 
HD2 3.207 
P10 
HA 4.410 
HG3 2.034 
HG2 1.901 
QB 2.302 
HD3 3.845 
HD2 3.662 
A11 
H 8.577 
N 126.278 
HA 4.571 
QB 1.401 
P12 
HA 4.40 
HG3 2.040 
HG2 1.821 
QB 2.278 
HD3 3.839 
HD2 3.630 
G13 
H 8.534 
N 109.165 
HA3 4.064 
HA2 3.977 
S14* 
H 8.505 
N 116.234 
HA 4.824 
HB3 4.073 
HB2 3.877 
H2-GalNAc 4.134 
H1-GalNAc 4.884 
HN-GalNAc 7.841 
H8-GalNAc 2.034 
H3-GalNAc 3.895 
H6-GalNAc 3.762 
H5-GalNAc 4.024 
H4-GalNAc 3.974 
T15* 
H 8.992 
N 113.750 
HA 4.611 
HB 4.295 
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QG2 1.252 
HN-GalNAc 7.787 
H2-GalNAc 4.102 
H8-GalNAc 2.032 
H3-GalNAc 3.868 
H6-GalNAc 3.727 
H5-GalNAc 4.006 
H4-GalNAc 3.977 
H1-GalNAc 5.008 
A16 
QB  1.383 
HA  4.582 
H 8.543 
N 124.368 
P17 
HA 4.407 
HG3 2.038 
HG2 1.950 
QB 2.293 
HD3 3.824 
HD2 3.680 
P18 
QB 2.358 
HD3 3.824 
HD2 3.632 
HG3 2.047 
HG2 1.921 
HA 4.420 
A19 
H 8.524 
N 124.641 
QB 1.356 
HA 4.557 
H20 
H 8.353 
N 118.226 
QB 3.156 
HA 4.621 
H20 C-Term 
H 8.019 
N 122.703 
HA 4.463 
HB3 3.230 
HB2 3.106 
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Figure S7 - 1H-NMR assignments of the 15N-MUC1-4TR-T3S4T8S14T15. The * labeling in 
the amino acid indicates glycosylation and # labeling indicates the amino acid perturbated 
with the neighboring glycosylation. 
Residue Proton ppm 
G1 
H 8.472 
N 110.209 
QA 3.966 
V2 
H 8.206 
N 120.637 
HA 4.333 
HB 2.112 
QG1 0.992 
T3* 
H 8.876 
N 117.646 
HA 4.683 
HB 4.351 
QG2 1.324 
HN-GalNAc 7.707 
H4 3.894 
H1 4.936 
H5 4.089 
H3 3.977 
H2 4.215 
H6 3.672 
H8 2.049 
T3* N-term 
H 8.798 
N 117.680 
HA 4.683 
QG2 1.294 
HB 4.313 
HN-GalNac 7.657 
H4-GalNAc 3.903 
H5-GalNAc 4.105 
H3-GalNAc 3.980 
H2-GalNAc 4.203 
H6-GalNAc 3.670 
H8-GalNAc 2.043 
S4* 
H 8.629 
N 116.779 
HA 4.508 
H 8.798 
N 116.258 
H3-GalNAc 4.114 
H2-GalNAc 4.214 
H8-GalNAc 2.077 
HN-GalNAc 7.846 
H1-GalNAc 4.882 
H6-GalNAc 3.641 
S4 
HA 4.683 
HB3 3.931 
HB2 3.791 
A5 
H 8.671 
N 126.794 
HA 4.508 
QB 1.429 
P6 
HA 4.414 
HG2 1.889 
HG3 2.040 
QB 2.298 
QD 3.839 
D7# 
H 8.608 
N 121.842 
HA 4.753 
HB3 2.811 
HB2 2.654 
D7 
H 8.594 
N 121.079 
HA 4.648 
HB3 2.794 
HB2 2.689 
T8* 
H 8.756 
N 114.351 
HA 4.543 
HB 3.756 
H2-GalNAc 4.170 
H4-GalNAc 3.942 
H3-GalNAc 3.984 
H6-GalNAc 3.670 
H5-GalNAc 4.090 
HN-GalNAc 7.885 
H1-GalNAc 4.850 
H8-GalNAc 2.043 
T8 
H 8.220 
N 115.218 
HA 4.333 
QG2 1.202 
R9# 
H 8.446 
N 121.946 
HA 4.526 
QD 3.245 
HB2 1.863 
QG 1.418 
HB3 1.746 
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R9 
H 8.414 
N 125.079 
HA 4.613 
QD 3.284 
QB 1.814 
QG 1.381 
P10 
HA 4.385 
HG2 1.889 
HG3 2.030 
QB 2.285 
QD 3.846 
A11 
H 8.606 
N 126.471 
HA 4.543 
QB 1.394 
P12 
HA 4.401 
HG2 1.840 
HG3 2.038 
QB 2.278 
QD 3.853 
G13 
H 8.532 
N 109.155 
HA3 4.071 
HA2 3.948 
S14* 
H 8.508 
N 116.270 
HB3 4.071 
HB2 3.913 
HA 4.858 
HN-GalNAc 7.784 
H4-GalNAc 3.870 
H1-GalNAc 4.834 
H5-GalNAc 4.099 
H3-GalNAc 3.993 
H2-GalNAc 4.206 
H6-GalNAc 3.688 
H8-GalNAc 2.032 
T15* 
H 9.005 
N 113.673 
HB 4.313 
QG2 1.259 
HA 4.646 
HN-GalNAc 7.836 
H4-GalNAc 3.898 
H1-GalNAc 4.891 
H3-GalNAc 4.109 
H2-GalNAc 4.195 
H5-GalNAc 3.989 
H6-GalNAc 3.679 
H8-GalNAc 2.072 
A16 
H 8.545 
N 124.478 
QB 1.342 
HA 4.549 
A19 
H 8.532 
N 124.655 
QB 1.352 
HA 4.556 
P17 
HA 4.443 
HG3 2.051 
HG2 1.955 
QB 2.313 
QD 3.839 
P18 
HA 4.403 
HG3 2.042 
HG2 1.895 
QB 2.301 
QD 3.828 
H20 
H 8.432 
N 117.979 
HA 4.674 
HB3 3.221 
HB2 3.170 
H20 C-term 
H 8.061 
N 122.519 
HA 4.473 
HB3 3.231 
HB2 3.126 
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2.5 Methods  
2.5.1 NMR experiments 
2.5.1.1 Assignment of (glyco)peptide 
All NMR experiments were recorded on a Bruker Avance 600 MHz 
spectrometer equipped with a triple channel cryoprobe head. The 1H NMR 
resonances of the peptides were completely assigned through standard 2D-TOCSY 
(30 and 80 ms mixing time) and 2D-NOESY experiments (400 ms mixing time). 
Solution conditions used for the NMR characterization studies were 1-3 mM 
(glyco)peptide, 25 mM perdeuterated Tris-d11 in 90:10 H2O/D2O, 7.5mM NaCl and 
1mM DTT, uncorrected pH 7.4. The assignments were accomplished either at 278K 
or 298K. The resonance of 2,2,3,3-tetradeutero-3-trimethylsilylpropionic acid 
(TSP) was used as a chemical shift reference in the 1H NMR experiments (δ TSP = 
0 ppm). Peak lists for the 2D-TOCSY and 2D-NOESY spectra were generated by 
interactive peak picking using the Computer Aided Resonance Assignment 
(CARA) software78. 
 
2.5.1.2 Saturation Transfer Difference (STD) 
Samples for STD-experiments were prepared in perdeuterated 25 mM Tris-
d11 in deuterated water, 7.5 mM NaCl and 1 mM DTT, uncorrected pH 7.4.  STD-
NMR experiments were performed at 298 K in the presence of UDP, MnCl2 with 
peptide (or GalNAc-O-Me) and GalNAc-Ts, the concentrations of each 
intervenient are described in the legend of the respective experiment.   
The STD-NMR spectra were acquired on a Bruker Avance 600 MHz 
spectrometer equipped with a triple channel cryoprobe head with 1920 transients in 
a matrix with 64k data points in t2 in a spectral window of 12335.53 Hz centered 
at 2819.65 Hz. An excitation sculpting module was employed to suppress the water 
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proton signals. Selective saturation of the protein resonances (on resonance 
spectrum) was performed by irradiating at −1 ppm using a series of Eburp2.1000-
shaped 90° pulses (50 ms, 1 ms delay between pulses) for a total saturation time of 
2.0 s. For the reference spectrum (off resonance), the samples were irradiated at 
100 ppm. Proper control experiments were performed with the ligands in the 
presence and absence of the protein to optimize the frequency for protein saturation 
(−1 ppm) and to ensure that the ligand signals were not affected. However, all 
glycopeptides, when irradiated at -1 ppm in the absence of protein, showed residual 
saturation on the aliphatic methyl groups in the STD-NMR spectra.  This 
nonspecific saturation was considered, by subtraction, when quantifying the STD-
NMR data in the presence of transferase. A blank STD experiment with only the 
protein was also recorded. The subtraction of this protein STD spectrum allowed 
eliminating the signal background of the protein. The STD-NMR total intensities 
were normalized with respect the highest STD-NMR response. The STD response 
of each amino acid corresponds to the average of STD percentages of all amino 
acid proton resonances that were measured with sufficient accuracy. The signal of 
the anomeric proton as well as the Hα protons of the Ala aminoacids of 
glycopeptides could not be analyzed in the STD-NMR spectra due to their close 
proximity to the HDO resonance. Some resonances from Gly and Pro overlapped 
and could not be discriminated. 
 
2.5.1.3 19F-NMR experiments 
19F-NMR experiments were carried out to monitor the 19F reporter 
(CF3)2COCH2- selectively introduced at the SH- group of the mutants T375C from 
both constructs of the WT GalNAc-T2 and the F104S mutant. The 19F experiments 
of GalNAcT2-19F and F104S-19F constructs were recorded at distinct conditions in 
absence and presence of MnCl2, UDP or UDP-GalNAc and peptide. The UDP or 
UDP-GalNAc and MnCl2 were added in an excess of 1.5 times of the protein 
concentration while peptide was in a 1.1:1 peptide:protein molar ratio.  Higher 
concentrations of UDP or UDP-GalNAc (500 µM), MnCl2 (500µM) and peptide 
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(protein:peptide molar ratio 1:2.2) did not induce higher 19F chemical shift 
perturbations. The 19F-NMR experiments were recorded on a Bruker Avance III 
600 MHz spectrometer equipped with a a 19F,1H SEF dual probe optimized for 
direct 19F detection. The 19F-NMR experiments were acquired at 298 K using a 
acquisition of 640 scans in a matrix with 8k data points in a spectral window of 
11295.2 Hz centered at (CF3)2CHOH -45174.9 Hz. The signal of 1,1,1,3,3,3-
hexafluoro-2-propanol was used as a chemical shift reference (δ = -75.7 ppm).  
Samples for 19F-NMR were prepared in 25 mM Tris-d11 in 90:10 H2O/D2O, 
uncorrected pH 7.5.    
 Trace elements of the 3-Bromo-1,1,1-trifluoroacetone reactive used 
for protein labelling (δ CF3COCH2Br = -83.3 ppm) were also present. In 
addition, the trifluoroacetic acid (TFA) used in the synthesis of peptides can 
be seen in 19F-NMR spectra in the presence of the peptide (δ TFA = -75.4 
ppm). 
In addition, to monitor the glycosylation event of MUC5Ac in presence 
of GalNAcT2-19F and F104S-19F, two 1H-NMR spectra were recorded before 
and after addition of UDP-GalNAc. All conditions contained MnCl2.    
 
2.5.1.4 NMR Glycosylation Assay 
Glycosylation of 15N-MUC1-4TR by recombinant GalNAc-Ts was 
monitored by collecting a series of 1H/15N-HSQCs experiments using a 600-MHz 
Bruker Avance III spectrometer equipped with a 5mm inverse detection triple-
resonance z-gradient cryogenic probe. All NMR experiments were performed at 
298 K. The spectra were acquired with 2048 × 128 points and 4 scans.  The spectral 
widths were 9615.4 Hz for 1H and 1946.2 Hz for 15N. The central frequency for 1H 
was set on the solvent signal and on the center of the amide region for 15N. The time 
between each experiment was approximately 10 min. Spectra were processed with 
the Bruker TopSpin 3.5 software. The volumes of the peaks in the 1H/15N-HSQC 
spectra corresponding to the glycosylated and non-glycosylated forms of MUC1-
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4TR were quantified by using the Mnova v.9.0 software. The ratio of the peak 
volumes for glycosylated residues to the total volume of peaks for both 
glycosylated and non-glycosylated forms was plotted versus time or sites. 
All samples were prepared in 200 µL buffer (25 mM Tris-d11, 7.5 mM NaCl, 
1 mM DTT, 150 µM MnCl2, in H2O:D2O 90:10) at pH 6.3. The relationships 
between 15N-MUC1-4TR and GalNAc-Ts were kept between WT enzymes and the 
corresponding mutants. Depending on the experiments, different amounts of UDP-
GalNAc were used. For the experiments where an excess of UDP-GalNAc was 
added, the ratio between UDP-GalNAc and each glycosylation site was set to 40/1 
(UDP-GalNAc/MUC1-4TR). In the step-by-step experiments, controlled amounts 
of UDP-GalNAc were added to glycosylate 4, 8, 10, 14 and 20 sites of MUC1-4TR 
using the required amount of enzyme to glycosylate all accessible acceptor sites. In 
most of the cases, 24 h were enough to achieve the exhaustive glycosylation of 
MUC1-4TR. The “endpoint” products of MUC1-4TR after glycosylation by 
GalNAc-T2/T3 and GalNAc-T4 were purified using HPLC as described below. 
Glycosylated MUC1-4TR, with GalNAc attached only to T3 and T15 sites, and 
MUC1-4TR-T3T15 were obtained using the D458R mutant and stopping the 
GalNAc transfer by adding EDTA (0.5 mM).  
 
2.5.1.5 Percentage of glycosylation of individual residues 
These values were determined by the calculating the peak volumes for 
glycosylated and non-glycosylated residues in 1H/15N-HSQC spectra. Relative 
glycosylation values were defined as the ratio of the volume of the glycosylated 
peak to the total volume of glycosylated and non-glycosylated peaks. 
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2.5.1.6 Combined chemical shift perturbation (CSP) 
The Δδcomb was calculated for each backbone NH groups of MUC1-4TR 
using the equation 2.5.1. A column plot was created with the Δδcomb values. Once 
again, the cut-off was calculated to identify the amino acids with higher 
perturbation after glycosylation. 
 
∆𝛿𝑐𝑜𝑚𝑏 = √((∆𝛿𝐻)2 + (
𝜔𝐻
𝜔𝑁
∆𝛿𝑁)2     Equation 2.5.1 
 
where Δ𝛿𝐻 is the 1H chemical shift difference for the signal with and without 
glycosylation, Δ𝛿𝑁 is the 15N chemical shift difference for the signal with and 
without glycosylation, and the 𝜔𝐻/𝜔𝑁 is the quotient between the gyromagnetic 
constant of the proton and the gyromagnetic constant of the nitrogen atom.  
With the values of Δ𝛿𝑐𝑜𝑚𝑏 obtained for each amino acid after glycosylation, 
a column plot was performed.  
 
2.5.2 Overexpression and Purification of 15N-MUC1-4TR 
A construct containing 4 repeats of 20 amino acids of the conserved sequence 
GVTSAPDTRPAPGSTAPPAH (MUC1-4TR) of the N-terminal domain of MUC1 
was synthetized by NZYtech. MUC1-4TR was sub-cloned in the expression vector 
pHTP-KSI, produced by NZYTech, to yield MUC1-4TR construct (Figure 2.5.1). 
The MUC1-4TR construct concomitantly contains a fusion protein KSI tag, a His 
tag and a TEV protease recognition sequence (Glu-Asn-Leu-Tyr-Phe-Gln↓Gly). 
The arrow indicates the cut site of TEV enzyme. 
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Sequence: 
MGHTPEHITAVVQRFVAALNAGDLDGIVALFADDATVEDPVGSEPRSGTAAI
REFYANSLKLPLAVELTQEVRAVANEAAFAFTVSFEYQGRKTVVAPIDHFRF
NGAGKVVSIRALFGEKNIHACQAMGSSHHHHHHSSGPQQGLRENLYFQGVT
SAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTA
PPAHGVTSAPDTRPAPGSTAPPAH 
Figure 2.5.1 - pHTP-KSI expression vector and KSI-MUC1-4TR sequence. This sequence 
consists of KSI-tag (blue), a His-tag (green), a TEV site (Tobacco Etch Virus) (red) and the 
amino acid sequence of MUC1-4TR (underlined). 
 
One single colony of the transformed E. coli cells (BL21 DE3) was 
inoculated and incubated in 10 mL of sterile LB medium with 50 μg/mL of 
kanamycin and left to grow overnight at 37 ºC at 220 rpm (pre-inoculum). The 
culture of pre-inoculum (10 mL) was then inoculated in 2 L of M9 minimal media 
with 50 µg/mL of kanamycin and let to grow. Protein expression was induced at 
OD600nm = 0.6 with a final concentration of 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG), overnight at 25ºC. To harvest cell was centrifuged 
at 6000 rpm for 15 minutes, at 4 ºC in an Avanti J-26 XPI Beckman Coulter with 
the rotor JA-10. The harvested cells of 1 L of culture were re-suspended (40 mL) 
in 10 mM phosphate buffer (pH 7.4) with 150 mM of NaCl and 1 mM of β-
mercaptoethanol, ruptured by sonication with 10 cycles of 1 min with 80% of 
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amplitude, in a Hielscher Ultrasound Technology (UP100H). After sonication, the 
cell lysate was centrifuged at 10000 rpm for 15 minutes, the pellet was recovered 
and solubilized in 50 mL of solubilization buffer (phosphate buffer (10 mM), 150 
mM NaCl, 8M Urea, β-mercaptoethanol (1 mM) (pH=7.4)) overnight at room 
temperature with agitation. Before the purification, the solution was centrifuged at 
10000 rpm, at 4 ºC for 15 minutes. The supernatant was loaded onto a Ni-NTA-
agarose column (QIAGEN) previously equilibrated with the solubilization buffer 
with 10 mM Imidazole. The resin was washed with a buffer containing 10 mM 
phosphate at pH 7.4, 150 mM NaCl and 50 mM imidazole, during the wash MUC1-
KSI refolds. MUC1-KSI was eluted with a gradient with buffer containing 10 mM 
phosphate at pH 7.4, 150 mM NaCl and 1 M imidazole (during 70 mL), with the 
flow 3 mL/min. To remove the imidazole, a desalting step (5 HiTrapTM desalting 
columns) against phosphate buffer (10 mM) with NaCl 150 mM and β-
mercaptoethanol 1 mM was performed. 
To obtain MUC1-4TR without KSI (fusion protein) and His-tag, the MUC1-
KSI was digested with TEV protease (Tobacco Etch Virus), overnight at room 
temperature, in the same buffer, after desalting chromatography with 500 µM of 
EDTA (Ethylenediaminetetraacetic acid) and TEV protease (1:100 (w/w)). 
Since after digestion, no aromatic amino acids were present, the last step to 
obtain pure MUC1-4TR employed a reversed-phase chromatography (AKTA 
Prime Plus GE HealthCare), using a C18 column (Purospher® STAR RP-18 end 
capped 5μm column (HPLC-Cartridge) with the detector placed at 220 nm, 230 nm 
and 254 nm. To purify MUC1-4TR were used as buffer (A) water/TFA (99.9:0.1, 
v/v), and (B) acetonitrile. The column and system were first equilibrated in 90% of 
buffer A and 10% of buffer B, then the sample was injected, and the elution 
recorded using a gradient from 10-40% of acetonitrile (B), with a flow of 2 mL/min 
for 40 minutes. All peaks with absorbance at 220 nm were collected. At the end the 
column was washed with 100% of acetonitrile.  
Pure MUC1-4TR was lyophilized and stored at 4 ºC. The purity of the protein 
was confirmed by 1H/15N-HSQC experiments. The yield of expression/purification 
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was estimated by 1H-NMR analysis and using 2,2,3,3-tetradeutero-3-
trimethylsilylpropionic acid (TSP) as a chemical shift reference (δ TSP = 0 ppm). 
 
2.5.2.1 Purification of the glycosylated products 
To purify MUC1-4TR glycosylated products, different buffers (A, 
water/TFA 99.9:0.1, v/v) and (B, acetonitrile) were used. The column and system 
were first equilibrated in 90% of buffer A and 10% of buffer B (20 min), then the 
sample was injected, and the elution recorded using a gradient from 10-30% of 
acetonitrile (B), with a flow of 2 mL/min for 70 minutes. All peaks with absorbance 
at 220 nm were collected and analyzed by 1H/15N-HSQCs and MALDI-TOF/TOF. 
At the end, the column was washed with 100% of acetonitrile. 
 
2.5.3 Mass spectrometry: MALDI-TOF/TOF 
An Autoflex III MALDI-TOF/TOF spectrometer (Bruker Daltonics) was 
used in linear mode with the following settings: 5000-40000 Th window, linear 
positive mode, ion source 1: 20 kV, ion source 2: 18.5 kV, lens: 9 kV, pulsed ion 
extraction of 120 ns, high gating ion suppression up to 1000 Mr. Mass calibration 
was performed externally with protein 1 standard calibration mixture (Bruker 
Daltonics) in the same range as the samples. Data acquisition was performed using 
FlexControl 3.0 softweare (Bruker Daltonics), and peak peaking and subsequent 
spectra analysis was performed using FlexAnalysis 3.0 software (Bruker 
Daltonics). 
 
2.5.3.1 Sample preparation  
Dried droplet preparations were spotted following the standard Dried Droplet 
application method (0.5 μL sample + 0.5 μL matrix (sinapinic acid, 10 mg/ml in 
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[70:30] Acetonitrile:Trifluoroacetic acid 0.1%)) onto a GroundSteel massive 384 
target (Bruker Daltonics). The preparations were desalted using ZipTip® C4 micro-
columns (Millipore) (2 μL sample) with elution using 0.5μL SA (sinapinic acid, 10 
mg/ml in 70:30 acetonitrile:trifluoroacetic acid 0.1%) matrix onto a GroundSteel 
massive 384 target (Bruker Daltonics).   
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 Chapter 
3  
 The conformational and interaction features of 
glycolipid with TOLL-like receptors and accessory 
proteins.  
The work presented in this chapter has been performed within the framework 
of the TOLLERANT EU project, in close collaboration with Dr. Francesco Peri, 
University of Milano-Bicocca, Milano, Italy. Alberto Minotti and Florent Cochet 
(PhD students) were responsible for the synthetic aspects, while Fabio Facchini 
and Stefania Enza Sestito (PhD students) performed the in vitro assay with cells. 
Dr. David Andreu (Pompeu Fabra University, Barcelona Biomedical Research 
Park, Spain) provided the antimicrobial peptides. Furthermore, in collaboration 
with Dr. Alba Silipo, University of Naples Federico II, Napoli, Italy, Mateusz 
Pallach (PhD student) was responsible for the extraction, isolation and 
characterization of the natural LPSs.  
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3.1 Introduction 
The immune system can be described as a set of molecules, cells and tissues 
responsible for conferring protection against external aggressions. In particular, 
against antigens that are strange to the body, whether a microorganism or 
macromolecule, and various internal injuries, or modified tumor cells. Thus, 
immunity can be defined as a set of defense mechanisms that our body has to protect 
itself from attacks and to maintain the immune homeostasis. The immune system 
under normal conditions does not show any kind of response to host cells 
(immunological tolerance).1–3 
There are two types of immune responses that complement each other. Innate 
immune response is the first line of attack to pathogens, recognizing only molecular 
patterns stored in microorganisms, the so-called Pathogen-Associated Molecular 
Patterns (PAMPs) and the danger-associated molecular patterns (DAMPs), derived 
from host cells with changes in homeostasis. The cells that are part of this kind of 
immunity are phagocytic cells (neutrophils, macrophages), dendritic cells (DCs), 
natural killer (NK) cells, and biological barriers (as epithelia).4  The adaptive 
immune system acts latter on the immune response. In contrast to innate immune 
responses, adaptive ones are stimulated by an immunogen (substance that is capable 
of trigger an immune response). In this case, the response magnitude and efficacy 
is usually increased after each exposure, including the development of antibodies 
memory. Therefore, innate immunity initiates the responses to directly kill 
pathogens, and, if not enough to clear it, the antigen-specific adaptive immune 
responses are triggered to provide a second layer of protection.4 
Toll-like receptors (TLRs) are mainly expressed on innate immune cells and 
play an important role in the cellular pathogen recognition and consequent immune 
responses. TLRs belong to the family of pattern recognition receptors (PRRs) and 
participate in immune surveillance by detecting PAMPs.5,6 This recognition triggers 
the activation of phagocytic cells that can lead to the internalization of the 
microorganism, as well as to cytokines and inflammatory mediators release, 
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resulting in an inflammatory process.1,3 Structurally, the TLRs have a single 
transmembrane helix that connects the extracellular ligand-binding domain to the 
intracellular signaling domain. 
 In humans, TLRs comprise a gene family of 10 receptors with various 
functions, including defense against a variety of diseases such as infections, 
cancers, autoimmune, inflammation, etc. Among the TLR family members, Toll-
Like Receptor 4 (TLR4) was the first receptor to be identified and characterized in 
humans. 7 TLR4 is expressed at the surface of innate immune cells (macrophages, 
DCs) and specifically recognizes bacterial endotoxins, i.e., lipopolysaccharides 
(LPS) or its truncated version lipooligosaccharides (LOS), the main molecular 
components of gram-negative bacteria cell walls.8 LPS (or endotoxin) was 
confirmed as the first agonist ligand of TLR4. LPS is provided by the cell wall of 
Gram-negative bacteria and recognized by a cascade of receptors, including the 
cluster differentiation antigen 14 (CD14), TLR4, and the myeloid differentiation 
protein (MD-2). The recognition of LPS starts with the binding of LPS aggregates 
to the LPS binding protein (LBP), followed by the transfer of LPS monomers to 
CD14. After that, CD14 presents LPS monomers to MD-2, triggering the formation 
of the TLR4-MD-2 complex.  The process concludes with the formation of the 
activated (TLR4.MD-2.LPS)2 dimer, which has a key role in starting the 
inflammatory cascade (Figure 3.1). In fact, the receptor dimerization induces the 
recruitment of adapter proteins to the intracellular TIR domain of TLR4, promting 
the activation of NF-κB (Nuclear Factor Kappa B) and Interferon Regulatory Factor 
3 (IRF3) and the triggering of cytokines secretion. 9–11 
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Figure 3.1- Scheme of Toll-Like Receptor 4–associated proteins that are involved in LPS 
sensing. 
 
Modulation of innate immunity receptors by agonists and antagonists with 
synthetic small molecules able to modulate this activity represents a powerful tool 
to study the TLR4 receptor system. These molecules display pharmacological 
interest as antisepsis and anti-inflammatory agents (antagonists) or as vaccine 
adjuvants (agonists).12,13  
A classification for TLR4 modulators is based on the effect they have on the 
TLR4 pathway. These modulators can act as antagonists, when they are able to 
inhibit the LPS-triggered TLR4 activation, or as agonists, when they stimulate the 
activation of TLR4 pathway. To modulate the activation of TLR4 pathway, these 
molecules can interact with one or more receptors or co-receptors of the pathway, 
interfering at different stages of the signaling.  
For TLR4 antagonists, the greatest effort has been made to treat septic shock 
and potentially all the pathologies due to the deregulated activation of TLR4 
pathway, including asthma, cardiovascular disorders, diabetes, obesity, metabolic 
syndromes, autoimmune disorders, neuroinflammatory disorders, neuropathic pain, 
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central nervous system disorders such as amyotrophic lateral sclerosis and 
Alzheimer disease, psychiatric diseases, skin inflammations (dermatitis), psoriasis, 
and some tumors.13  A second motivation for the discovery of TLR4 ligands has 
been the development of new agonists that could be employed as vaccine adjuvants: 
molecules that elicit a controlled immune response.14,15  
LPS and derivates, LOS or mimics, are amphiphilic molecules with low sub-
micromolar/nanomolar values of critical micellar concentration (CMC) in aqueous 
solutions, thus showing a propensity to aggregate in the concentration range 
relevant for biological responses. CMC values for E. coli LPS of 1.3 - 1.6 µM have 
been measured by fluorescence correlation microscopy.16 Nevertheless, as for any 
amphiphilic system, monomers are also present in dynamic equilibrium. The key 
question of what is the biologically active unit of endotoxins, whether large or small 
aggregates or monomers, has been amply debated in the literature.17–19 The first 
steps of LPS recognition, as binding to LBP and CD14, are almost certainly 
influenced by the size and 3D shape of LPS aggregates. However, the binding of 
single LPS molecules to receptors (CD14 and MD-2) is the basis of sensitive and 
selective of endotoxin molecular recognition by the (TLR4/MD-2/lipid A)2 
activated complex.20–23 
This work aims to study the interaction of a synthetic small molecule with 
antagonist of TLR4 properties with antimicrobial peptides and the characterization 
of the supramolecular structures formed in water solution of natural LPS or mimetic 
of Lipid A (synthetic molecules) by NMR and Electron Microscopy. 
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3.2 The interaction of Lipid A mimics with 
antimicrobial peptides 
Antimicrobial peptides (AMP) are known to bind to and neutralize LPS, 
interacting with endotoxin. However, it was observed that neutralization of LPS by 
AMP is associated with a drastic change of the LPS aggregate-type, from a cubic 
to a multilamellar shape, increasing the size of the aggregate and thus leading to the 
inhibition of the binding of endotoxin to LBP and other mammalian proteins.24  
Based on this premises, we herein focused on investigating the possibility 
that AMPs could interact with a simple LPS glycomimetic, the anionic 
monosaccharide FP7 (Figure 3.2), which has been described as a TLR4 
antagonist,25 and could modulate its antagonist activity on TLR4. 
 
 
Figure 3.2 - Chemical structure of FP7, a synthetic diacylated glucopyranose derivative 
active as TLR4 antagonist. 
 
3.2.1 AMPs enhances FP7 antagonist activity in HEK-Blue hTLR4 cells 
The effect of FP7 and antimicrobial peptides (AMPs) co-administration was 
first investigated in HEK-Blue hTLR4 cells, i.e., HEK293 cells stably transfected 
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with human TLR4, MD-2, and CD14 genes. Furthermore, HEK-Blue hTLR4 cells 
display a secreted embryonic alkaline phosphatase (SEAP), produced upon 
activation of NF-kB, as reporter gene. Thus, the LPS binding event causes TLR4 
dimerization, myddosome formation, and NF-kB activation, leading to SEAP 
production and secretion. FP7 (Figure 3.2) has been reported previously as a TLR4 
antagonist.25 These results were further confirmed by inhibiting the LPS-stimulated 
TLR4 activation, in a dose-dependent manner, providing a IC50 of 2.5 µM. 
Remarkably, no antagonist effects were detected for the AMPs administered alone 
on the same cell line, at the concentration range used (Figure 3.3).  
 
 
Figure 3.3 - Effect of AMPs 1-6 administration on LPS-stimulated TLR4 signal in HEK-
Blue hTLR4 cells. HEK-Blue hTLR4 cells were pre-treated with the indicated 
concentrations of AMPs 1-6 and stimulated with LPS (100 ng/mL) after 30 minutes. Data 
were normalized to stimulation with LPS alone. Data represent the mean of percentage ± 
SEM of at least 3 independent experiments. N.S. No stimulated with LPS.  
 
However, when FP7 was co-administered (1:1 stoichiometric ratio) with 
AMPs (Table 3.1), different results were obtained. The AMPs 2-5 poorly improved 
FP7 antagonist activity (IC50 around 1.1 - 1.5 μM), while AMPs 1 and 6 exhibited 
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stronger activity (IC50 0.56 μM and 0.18 μM respectively) (Figure 3.4). On the other 
hand, AMP 1 and AMP 6 efficiently improved the TLR4 antagonist activity of FP7 
in HEK-Blue hTLR4 cells, in a 0 to 10 μM concentration range. 
 
Table 3.1 - Sequences of the anti-microbial peptides. 
AMP Name Sequence 
 
1 CA(1-8)M(1-8) KWKLFKKIGIGAVLKVLTTGLPALIS-amide 26 
2 CA(1-7)M(2-9) KWKLFKKIGAVLKVL-amide 27 
3 
[K6(Me3)]CA(1-
7)M(2-9) 
KWKLFK(Me3)KIGAVLKVL-amide 28 
4 
    Nα-Oct-CA(1-
7)M(2-9) 
Octanoyl-KWKLFKKIGAVLKVL-amide                     29 
5 CA(1-7)M(5-9) KWKLFKKVLKVL-amide 27 
6 LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 30 
 
 
Figure 3.4  - Dose-dependent inhibition of LPS-stimulated TLR4 signal in HEK-Blue 
hTLR4 cells by FP7/AMPs co-administrations. Activities of FP7/AMPs administrations on 
LPS-stimulated TLR4 signal in HEK-Blue hTLR4 cells. 
 
Treatment IC50 LPS (µM)
FP7 2.5
FP7 + AMP 1 0.56
FP7 + AMP 2 1.18
FP7 + AMP 3 1.51
FP7 + AMP 4 1.32
FP7 + AMP 5 1.54
FP7 + AMP 6 0.18
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The cytotoxic effects of the co-administration were also tested to exclude the 
possibility that the activity increase was related with cytotoxic activity. The toxicity 
of all co-administrations was evaluated by a MTT test, which permitted showing 
the absence of significant toxicity even at the highest concentration tested (10 µM) 
(Figure 3.5).  
 
 
Figure 3.5 - MTT assay of FP7/AMPs co-administrations in HEK-Blue hTLR4 cells. 
Cells were treated with the six co-administrations used in the other assays; the bars 
represent the cell viability estimated by using 10 µM of compounds, equivalent to the 
maximum concentration used previously. Data are normalized with PBS and represent the 
mean of percentage ± SEM of at least 3 independent experiments. 
 
To exclude the hypothesis that the effects of AMPs in the activity of FP7 
could be due to a neutralizing effect on LPS, additional experiments were 
performed. The addition of phytohemagglutinin (PHA), in a dose-dependent 
manner, stimulated TLR4 activation in HEK-Blue hTLR4 cells, when co-
administered with FP7 and LL37. PHA-L induces the activation of TLR4 as 
agonist, but with a lower potency than LPS.31 The treatment with FP7 alone 
inhibited TLR4 activation in a dose-dependent way, as expected. In addition, the 
co-administration with LL37 showed enhancement of FP7 antagonism activity 
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(Figure 3.6), suggesting that this effect is, at least in part, independent from an LPS 
neutralizing effect. 
 
 
Figure 3.6 - Dose-dependent inhibition of PHA-stimulated TLR4 activation by FP7 and 
FP7/AMP6. Cells were treated with increasing concentrations of compounds and 
stimulated with PHA-P (5 µg/mL). The results represent normalized data with positive 
control (PHA-P alone). Concentration-effect data were fitted to a sigmoidal 4 parameter 
logistic equation to determine IC50 values and represent the mean of percentage ± SEM of 
at least 3 independent experiments. The IC50 values are shown Table. 
 
3.2.2 LL-37 (AMP6) enhances FP7 antagonist activity in human PBMC 
HEK-Blue hTLR4 cell is a model. Thus, the capacity of LL-37 to improve 
FP7 antagonist activity in human monocytes was also investigated. Human 
Peripheral Blood Mononuclear Cells (h)PBMCs were isolated from buffy coats, 
pre-incubated with increasing concentrations (0.1-10 μM) of FP7 or FP7/LL37 
(1/1) and stimulated with LPS (100 ng/mL). As expected, FP7 induced the 
reduction in the production of IL-1β. The addition of LL37 to FP7 produced a much 
more powerful inhibitory response, decreasing the production of IL-1β already at 
the lowest dose of 1 μM. (Figure 3.7). 
The conformational and interaction features of glycolipid with TOLL-like receptors and 
accessory proteins 
 
 
 188 
 
Figure 3.7. LL-37 (AMP6) potentiation of FP7 antagonist activity in human PBMCs. 
PBMCs isolated from buffy coats were preincubated with FP7 or FP7/AMP6 mix for 30 
minutes and then stimulated with LPS (100 ng/mL). IL-1β production was quantified after 
one night’s incubation. Data represent the mean ± SEM of at least three independent 
experiments. 
 
3.2.3 NMR and TEM analysis of glycolipid/peptide interaction 
The characterization of the interaction between the synthetic TLR4 
antagonist FP7, and these two synthetic anti-microbial peptides, CA(1-8)M(1-18) 
and LL37 was studied by NMR experiments. Nuclear magnetic resonance (NMR) 
spectroscopy has become a powerful tool to investigate structural features, 
dynamics and interactions of biomolecules in solution, at atomic resolution. 
 
3.2.3.1 NMR analysis from the AMP point-of-view 
The effect of binding can be successfully traced by the perturbations 
observed on characteristic NMR parameters (e.g. chemical shifts, line widths, and 
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signal intensities) of either partner. The titration of CA(1-8)M(1-18) (AMP1) 
peptide with FP7 (Figure 3.8) permitted to observe clear perturbation of the signals 
of the lateral chains of the hydrophobic aminoacids upon addition of the FP7 
glycolipid. The experimentally observed reductions in intensity (Figure 3.8), due to 
specific line broadening of these signals, probably arise from the changes in the 
transverse relaxation times of these signals, a clear indication of the existence of a 
binding event. Additional variations in the amide region were also observed (Figure 
3.8). This dramatic change likely arises from the existence of interaction between 
CA(1-8)M(1-18) peptide and the FP7 glycolipid. 
 
 
Figure 3.8- Left) 1H-NMR of CA(1-8)M(1-18) (300 μM) with upon addition of FP7.  A: 
CA(1-8)M(1-18)  alone;  B: FP7 (10 μM);  C: FP7 (20 μM);  D: FP7 (30 μM);  E: FP7 (40 
μM); F: FP7 (60 μM); G: FP7 (80 μM); H: FP7 (140 μM); I: FP7 (200 μM); J: FP7 (300 
μM); I-Right) Intensity (%) of the Hε- Trp2 of CA(1-8)M(1-18)  as a function of the [FP7]/[ 
CA(1-8)M(1-18)] molar ratio. The samples have 10 % DMSO in PBS 100 mM pH=5.5 in 
H2O/D2O 90:10 at 310K, 64 scans. 
 
The interaction of the second anti-microbial peptide, LL37 (AMP6) with 
FP7 was also investigated by using 1H-NMR (Figure 3.9). Once more, the existence 
of broadening of the peptide NMR resonance signals upon addition of FP7 
permitted to deduce the existence of a molecular recognition phenomenon. 
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Figure 3.9 - Left) 1H-NMR of LL37 (300 μM) with upon addition of FP7.  A: LL37 alone;  
B: FP7 (10 μM);  C: FP7 (30 μM);  D: FP7 (80 μM);  E: FP7 (140 μM); F: FP7 (200 μM); 
G: FP7 (300 μM); H: FP7 (400 μM); I: FP7 (600 μM); J: FP7 (900 μM);  Right) Intensity 
(%) of the Hε-Gln22 of LL37 peptide as a function of [FP7]/[LL37]. The samples have 10 
% DMSO in PBS 100 mM pH=5.5 in H2O/D2O 90:10 at 310K, 64 scans. 
 
The DOSY (Diffusion Order SpectroscopY) experiments on the CA(1-
8)M(1-18) peptide showed a strikingly low diffusion co-efficient, far from its 
small/medium molecular weight, strongly suggesting that the peptide is aggregated 
(Figure 3.9 -I and Table 3.2). This experimental evidence was also deduced by 
transmission electron microscopy (TEM) negative staining analysis (Figure 3.9 -
II). Indeed, filament-like shapes were observed for the peptide alone. 
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Figure 3.9 – I) DOSY spectrum Black: CA(1-8)M(1-18) (300µM) Red: : CA(1-8)M(1-18) 
(300µM) FP7 (80µM). Green : CA(1-8)M(1-18) (300µM) FP7 (200µM). II) Transmission 
Electron Microscopy - Negative Staining Analysis. CA(1-8)M(1-18) peptide at 2.5mg/ml. 
nominal magnification of 30,000 X (0.36nm/pixel). 
 
Table 3.2 - CA(1-8)M(1-18) peptide (300µM) diffusion data values. 
 D/m2s-1 
CA(1-8)M(1-18) 2.29x10-10 
CA(1-8)M(1-18) + FP7 2.29x10-10 
 
However, the diffusion co-efficient remains unchanged in the presence of 
FP7 (Figure 3.9 and Table 3.2). The interaction of FP7 with CA(1-8)M(1-18) 
peptide (in excess), does not show a large effect in the average size of the CA(1-
8)M(1-18) aggregates. As for CA(1-8)M(1-18), DOSY experiments were recorded 
for LL37 (Figure 3.10 -I and Table 3.3) upon addition of FP7 Lipid. The same result 
was observed in this case. The diffusion co-efficient is not affected in the presence 
of FP7 (Figure 3.10 -I and Table 3.3).  
 
DMSO
CA(1-8)M(1-18)
I II
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Figure 3.10 – I) DOSY spectrum. Black: LL37 (300µM) Red: LL37 (300µM) FP7 (200µM). 
II) Transmission Electron Microscopy.  Negative Staining Analysis. Left: LL37 peptide at 
45mg/ml. nominal magnification of 30,000 X (0.36nm/pixel). 
 
Table 3.3 - LL37 peptide (300µM) diffusion data values. 
 D/m2s-1 
LL37 1.78x10-10 
L37 + FP7 1.78 x10-10 
 
However, as also deduced for AMP1, the DOSY of LL37 showed a small 
diffusion co-efficient, far from that expected for the small/medium molecular 
weight. Again, this fact strongly suggests that there is aggregation of the peptide. 
This hypothesis was confirmed with the corresponding TEM analysis (Figure 3.10 
-II). 
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3.2.3.2 NMR analysis from the FP7 point-of-view 
The process was also monitored by looking at NMR signals of the 1H signals 
of the FP7 glycolipid upon addition of the peptide (Figure 3.11). In this case, the 
dramatic reduction of the intensity of the NMR signals of the aliphatic chains 
permitted to deduce that the interaction with CA(1-8)M(1-18) peptide involved the 
lipid chains (Figure 3.11). Three alternative hypotheses could be invoked to explain 
these data. The peptide could act as linker between different FP7 aggregates (Figure 
3.12) and/or deform the FP7 micelle  (Figure 3.13) or the peptide could participate 
in the formation of large aggregates (Figure 3.14), behaving as a large molecule, as 
earlier described by us for MD2.25 
 
 
Figure 3.11- 1H-NMR of FP7 (500 µM) with upon addition of CA(1-8)M(1-18) peptide.  A: 
FP7 alone  B: CA(1-8)M(1-18) (10 µM) C: CA(1-8)M(1-18) (30 µM)  D: CA(1-8)M(1-18) 
(50 µM)  E: CA(1-8)M(1-18) (90 µM) F: [CA(1-8)M(1-18) (170 µM). The sample has 10% 
DMSO in Buffer PBS 100mM pH=5.5 in H2O/D2O 90:10 at 310K, 560 scans, DS=4. 
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Figure 3.12 - Cartoon showing the possibility that the AMP act as linker between different 
FP7 aggregates 
 
 
Figure 3.13 - Cartoon showing the possibility that the AMP changes the shape of FP7 
aggregates 
 
 
Figure 3.14 - Cartoon showing the possibility that the AMP aggregation and the aggregate 
behaves as a large molecule. 
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Indeed, FP7, being an amphipathic molecule, forms aggregates or micelles 
in water solution, as previously demonstrated by DOSY.25 Thus, the existence of 
FP7 aggregation and formation of micelles of very diverse size was demonstrated. 
However, they show the same morphology when analyzed by negative staining 
TEM (Figure 3.15, Left) or by cryogenic transmission electron microscopy (Cryo-
TEM) (Figure 3.15, Right).  
 
 
Figure 3.15 - Transmission Electron Microscopy - Negative Staining Analysis. Left: FP-7 
at 2.5mg/ml. nominal magnification of 10,000 X (1.1nm/pixel) Right:  Transmission 
Electron Microscopy - cryo-TEM of FP7 alone (2.5 mg/mL) with a nominal magnification 
of 30000X (0.36 nm/pixel). The samples have 10% DMSO in PBS 100 mM pH=5.5. 
 
In contrast to the case with the antimicrobial peptides, the DOSY experiment 
of FP7 in the presence of CA(1-8)M(1-18) peptide (Figure 3.16) induced clear 
perturbations in the diffusion behavior of FP7. Under substoichiometric ratios 
([CA(1-8)M(1-18)]/[FP7]=0.06) of the peptide, an increase in the diffusion 
coefficient was evident. This effect could be, in principle, due to changes either in 
the size (Figure 3.12) or shape (Figure 3.12) of the lipid. Thus, TEM with Negative 
Staining Analysis (Figure 3.17) and Cryo-TEM (Figure 3.18) were employed to 
obtain the required morphological information. The presence of the CA(1-8)M(1-
18) peptide induced formation of aggregates between different FP7 micelles, thus 
1000nm
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supporting the hypothesis outlined in Figure 3.12. The peptide is linking various 
FP7 micelles, displaying peanut-shaped structures. This fact suggests the presence 
of fusion events (indicated in red in the Figure 3.17 and Figure 3.18).  
 
 
Figure 3.16 - DOSY spectrum.  Black: FP7 (500µM) Red: FP7 (500µM) and CA(1-8)M(1-
18) (30µM)  
 
Table 3.4 - FP7 Lipid (500µM) diffusion data values. 
 D/m2s-1 
FP7 5.01x10-11 
FP7 + CA(1-8)M(1-18) 3.16 x10-11 
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Figure 3.17 - Transmission Electron Microscopy - Negative Staining Analysis. Left: FP7 
Lipid (320 μM) with CA(1-8)M(1-18) peptide  (80 μM) in H2O and DMSO 10%, nominal 
magnification of  10000 X (0.36 nm/pixel) Right : FP7 Lipid   (320 μM) with CA(1-8)M(1-
18) peptide  (80 μM) in PBS 100 mM pH=5.5 with DMSO 10%, nominal magnification of  
20000 X (0.36 nm/pixel)  
 
 
Figure 3.18 - Transmission Electron Microscopy - Cryo-TEM FP7 Lipid (320 μM) with 
CA(1-8)M(1-18) peptide  (80 μM) in PBS 100 mM pH=5.5 with DMSO 10%, nominal 
magnification of  30000 X (0.36 nm/pixel) 
 
As well as for the CA(1-8)M(1-18) peptide, the 1H-NMR of FP7 upon 
addition of LL37 (Figure 3.19) showed that the aliphatic chains are clearly involved 
in the binding event, since they broaden significantly in the presence of the peptide. 
 
 
Peptide 
FP7 micelle 
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Figure 3.19 - 1H-NMR of FP7 (500 µM) with upon addition of LL37 peptide.  A: FP7alone. 
B: LL37 (10 µM) C: LL37 (20 µM) D: LL37 (30 µM) E: LL37 (50 µM) F: LL37 (90 µM). 
The sample has 10% DMSO in Buffer PBS 100mM pH=5.5 in H2O/D2O 90:10 at 310K, 320 
scans, DS=4. 
 
DOSY experiments showed that, upon addition of LL37 peptide (Figure 3.20 
and Table 3.5), there were clear perturbations of the diffusion of FP7. The peptide 
causes a decrease in the diffusion coefficient, although the observed perturbation is 
smaller compared to that in the presence of CA(1-8)M(1-18) peptide.   
The TEM analysis showed that the effect of LL37 is different to that of CA(1-
8)M(1-18) in the presence of FP7 micelles. In this case, a dramatic change in the 
shape, from spheres to cylinders, was induced when LL37 was present. Long 
entangled cylindrical micelles are now displayed in the cryo-TEM image (Figure 
3.21). 
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Figure 3.20 - DOSY spectrum. Black: FP7 (500µM) Red: FP7 (500µM) and LL377 (10µM) 
Green FP7 (500µM) and LL377 (50µM) 
 
Table 3.5 - FP7 Lipid (500µM) diffusion data values. 
 D/m2s-1 
FP7 6.31x10-11 
FP7 + [LL377]=10µM 5.0x10-11 
FP7 + [LL377]=50µM 3.98 x10-11 
 
 
Figure 3.21 - Transmission Electron Microscopy. Cryo-TEM. FP7 Lipid (588 μM) with 
LL37 peptide (400 μM) in PBS 100 mM pH=5.5 with DMSO 10%, nominal magnification 
of 30000 X ((0.36 nm /pixel). 
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NMR and TEM experiments clearly showed an effect of either CA(1-8)M(1-
18)  or LL37 on FP7 aggregation state. NMR shows addition of either AMP to FP7 
to cause the formation of larger aggregates, as revealed by the reduction in the 
intensities of FP7 aliphatic chain 1H NMR signals and the decrease of FP7 diffusion 
coefficient in DOSY. Cryo-TEM images confirm these data and clearly show that, 
upon peptide addition, FP7 micellar aggregates undergo a change in size and 3D 
shape from spherical to rod-like cylindrical. 
In the end, although the NMR experiments have been performed at a 
concentration two orders of magnitude higher than that at which FP7 displays 
biological activity, they provide a valuable indication on the ability of these 
antimicrobial peptides to affect FP7 aggregation state in aqueous environment.  
 
3.3 Design of new TLR4 antagonists based on FP7 
FP7 monosaccharide structure is a proper structural scaffold for designing 
new active antagonists on TLR4.32 Substitution of phosphates with carboxylates 
was proposed to provide new molecules that could maintain their activity on TLR4. 
Thus, the newly proposed FP15 and FP18 molecules (Figure 3.22) display two 
carboxylic groups at C1 and C4, which are obviously in the form of β-carboxylated 
anions at neutral pH and therefore could mimic the two negative phosphates of the 
FP7 molecule.  
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Figure 3.22 - Chemical structure of FP15 and FP18 compounds. 
 
The powerful antagonist Eritoran contains saturated and unsaturated 
lipophilic chains attached at the C3 and C2 positions of the glucosamine moieties. 
Thus, FP15 was designed to display aliphatic chains at C3 (C14) and oleic chains 
at C2 (C18, cis-9). On the order hand, FP18 displays a myristic moiety at C3 (C14) 
and an aliphatic chain of 5 carbons at C2, finalizing with a 19F-containing para-
phenyl group. 
As already described above, FP7 aggregates in aqueous media. Thus, to 
investigate the behavior of FP15 and FP18 in solution, Cryogenic Transmission 
Electron Microscopy (Cryo-TEM) methods were employed (Figure 3.23).  The 
detailed inspection of the cryo-TEM data for FP15 allowed showing that this 
glycolipid displays a different aggregation behavior in solution to that of FP7.  
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Figure 3.23 - Cryogenic Transmission Electron Microscopy (Cryo-TEM) of FP15 (7 
mg/mL) nominal magnification of 40,000 X (0.26 nm/pixel). 
 
FP15 mainly generates circular and homogeneous small unilamellar vesicles 
(SUV), although with rather different size distributions, from 10 to 110 nm. 
Moreover, it was possible to detect the presence of fusion events (as highlighted in 
the zoomed picture in Figure 6, dark red squares) as well as the existence of open 
bilayers. Indeed, the use of vitrified samples allowed trapping the potentially un 
structures associated with the formed intermediates in the solubilization process of 
the vesicles. 
According to the Cryo-TEM data, FP18 forms more heterogeneous structures 
than FP15. In this case, (Figure 3.23) it was possible to observe the presence of 
circular Small Unilamellar Vesicles (SUV, a vesicle of a single bilayer and small 
size) with different sizes, between 16 – 110 nm, as well as circular and amorphous 
Large Unilamellar Vesicles (LUV) (vesicle of a single bilayer of larger size) with 
sizes ranging from 200 – 700 nm. In addition, FP18 forms Multivesicular Vesicles 
(MVV, vesicles of the bilayer that are not arranged in a concentric manner, red 
arrows in Figure 3.23),33 as well as Multilamellar  Vesicles (MLV, vesicles made 
of concentric layers of the bilayer,33 red squares in Figure 3.23). 
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Figure 3.23 – Cryogenic Transmission Electron Microscopy - Cryo-TEM of FP15 (7 
mg/mL) nominal magnification of 40000 X (0.36 nm/pixel). 
 
Besides vesicles, in the Cryo-TEM of FP18, it was possible to see long and 
numerous entangled structures (Figure 3.23 down), which are probably formed by 
wormlike micelles.34 
Therefore, these experimental data show that these compounds are able to 
form vesicles/liposomes displaying a double layer. This fact can be a good starting 
point to use these them for drug delivery issues.  
 
3.4 Characterization of natural LPSs/MD-2 interaction 
Natural LipoPolySaccharides (LPSs), as amphiphilic molecules, form 
aggregates in aqueous environments above a critical concentration (CMC). At 
higher LPS concentrations, the amphiphilic aggregates form nearly spherical 
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supramolecular aggregate structures, which can be multilamellar or non-lamellar, 
depending on the physicochemical environment.35 The aggregation process of LPS 
from Escherichia coli serotype 026:B6 has been described by Santos et al.,36 with 
an apparent critical micellar concentration (CMCa) value of 14 µg/mL. 
 
3.4.1 LPS from Bradyrhizobium BTAi-1 Δshc 
Rhizobia are Gram-negative bacteria that can establish a symbiotic 
relationship with legumes.37 Their abilities to fix nitrogen from natural sources hold 
promise as a viable alternative to the use of industrial N-fertilizers in agriculture.38 
Furthermore, the lipid A of rhizobial LPS, characterized by a peculiar lipid and 
sugar composition and by the presence of very long-chain fatty acids (VLCFA), is 
important for their adaptation to the intracellular life.39 
In this chapter, in the framework of our EU project TOLLERANT, we have 
focused our study on the mutant LPS from Bradyrhizobium BTAi-1 Δshc, where the 
hopanoid biosynthesis pathway have been removed (Figure 3.24).  
 
 
 
Figure 3.24 -. Chemical structure of the LPS components from Bradyrhizobium 
BTAi-1 Δshc. 
OPS 1
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3.4.1.1 NMR experiments 
The 1H-NMR of LPS from Bradyrhizobium BTAi-1 Δshc in presence of the 
accessory MD-2 protein (Figure 3.25) permitted to observe clear perturbation of 
the signals at 2.04 and 1.41 ppm. However, other 1H NMR signals from the could 
not be analyzed due to extensive overlapping with the signals from hMD-2. The 
experimentally observed reductions of intensity (Figure 3.25), due to specific line 
broadening of these signals, probably arise from the changes in the transverse 
relaxation times of these signals, an indication of the existence of a binding event. 
 
 
Figure 3.25 - 1H-NMR spectra. Green: 1H-NMR of 60uM of hMD-2, Blue: 1H-NMR 
of 0.9 mg/mL of LPS from Bradyrhizobium BTAi-1 Δshc; Red: 1H-NMR of 0.9 mg/mL of 
LPS from Bradyrhizobium BTAi-1 Δshc in presence of 60μM of MD-2; The spectra were 
acquired in deuterated phosphate buffer at pH 7.5, 298 K, 64 scans. 
 
We have previously demonstrated, using DOSY measurements, that FP7 
forms aggregates or micelles in water solutions, with a small diffusion coefficient 
value. Fittingly, the interaction of this molecule with MD-2 makes the diffusion 
coefficient significantly faster, indicating that the initial aggregate is indeed 
disrupted.25 The same behavior was observed herein for the LPS from 
Bradyrhizobium BTAi-1 Δshc (Figure 3.26 and Table 3.6). The diffusion coefficient 
increases one order of magnitude, strongly suggesting that the presence of MD-2 
LPS Free
LPS +MD-2
MD-2
2.04
1.41
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perturbs the aggregation process of the LPS, providing a supramolecular entity of 
smaller size (Figure 3.27). 
 
 
Figure 3.26 -  DOSY spectrum  Black: DOSY of 0.9 mg/mL of LPS from 
Bradyrhizobium BTAi-1 Δshc Green : DOSY of 0.9 mg/mL of LPS from Bradyrhizobium 
BTAi-1 Δshc in presence of 60μM of MD-2; The spectra were acquired in deuterated 
phosphate buffer at pH 7.5, 298 K, 64 scans, 32 points and d20 = 500 ms and p30 = 5 ms. 
 
Table 3.6. Diffusion coefficient value 
 D/m2s-1 
0.9 mg/mL LPS from Bradyrhizobium BTAi-1 Δshc 
5.781x10-
12 
0.9 mg/mL LPS from Bradyrhizobium BTAi-1 Δshc + MD-2 
60uM 
2.09x10-11 
 
 
Figure 3.27 - Schematic representation of the putative processes that take place 
before and after addition of MD-2, based on the DOSY experimental data. 
 
 
LPS + MD-2 
LPS alone 
LPS
hMD-2
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A similar behavior has been previously described by Tobias et. al.40 for the 
interaction of the LPS from Salmonella minnesota Re595 with the LPS-binding 
Protein (LBP) and the bactericidal/permeability-increasing protein (BPI) by 
sedimentation, light scattering, and fluorescence analyses. Shortly, they also 
reported that the presence LBP promoted the disaggregation of the LPS 
supramolecular structure. 
 
3.4.1.2 Cryo-Electron Microscopy 
It is important to note that the attempt of Cryo-EM with Salmonella 
minnesota Re595 LPS, it was impossible to freeze the samples. 
 
3.4.2 LPS from Acetobacter pasteurianus 
Acetobacter pasteurianus is an aerobic Gram-negative bacterium used in the 
production process of a Japanese black vinegar called kurozu. Consumption of this 
vinegar is believed to carry health benefits as recently recommended as a health 
drink in Japan.41 Since oral administration of LPS has been reported to modulate 
immune responses,42 the LPS-like components in kurozu might be responsible for 
the beneficial health effects of kurozu. However, recent studies with the separated 
LPS from A. pasteurianus showed that it only displays weak TLR4-stimulating 
activity in comparison with that of the E. coli analogue.43  
After extraction and isolation, the LPS from A. pasteurianus, the molecule 
was further characterized using extensive analytical methods, including chemical 
modifications, MS, MALDI, MS/MS, NMR. Finally, the chemical structure of the 
different components of the molecule were fully characterized (Figure 3.28). 
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Figure 3.28 - Structure of the different LPS components of the LPS from A. 
pasteurianus. 
 
3.4.2.1 NMR experiments 
The presence of MD-2 provided alterations in the 1H-NMR signals of the 
LPS from A. pasteurianus (Figure 3.29), especially at the anomeric proton signals 
of the OPS part. (Figure 3.29). Unfortunately, it was not possible to obtain non-
ambiguous information about the acyl chains, due to the presence of MD-2 signals 
in this region of the spectrum.       
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Figure 3.29 - Up: 1H-NMR spectra. Green: 1H-NMR of 60μM of MD-2, Blue: 1H-
NMR of 0.9 mg/mL of LPS from A. pasteurianus; Red: 1H-NMR of 0.9 mg/mL of LPS from 
A. pasteurianus in presence of 60μM of MD-2; The spectra were acquired in deuterated 
phosphate buffer at pH 7.5, 298 K, 64 scans. Down: “Epitope mapping” where red 
represents the protons with more attenuation and yellow less perturbation. 
 
From a structural perspective, the OPS domain is rather distant from lipid A 
fatty acid chains, which are known to act as the binding site for MD-2. However, 
we cannot discard the hypothesis that the observed perturbation at the anomeric 
signals is due the recognition of MD-2. The surface of MD-2 has hydrophobic and 
hydrophilic regions,44 that might be involved with additional transient interactions 
with the OPS, as schematized in Figure 3.30. 
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Figure 3.30 - Schematic representation of the intrinsic flexibility of the OPS together 
with the hypothetical contact-points with the MD-2 protein.   
 
The effect of MD-2 at A. pasteurianus LPS by DOSY experiments was 
different to that observed for the LPS from Bradyrhizobium BTAi-1 Δshc. In this 
case, the addition of MD-2 also induced clear perturbations of the diffusion 
coefficient of the LPS. However, now the diffusion coefficient decreased one order 
of magnitude, in contrast with the observations for the LPS from Bradyrhizobium 
BTAi-1 Δshc. This behavior is associated with an increase in size or a change in the 
shape of the supramolecular structure. (Figure 3.31 and Table 3.7). 
 
 
Figure 3.31 - DOSY spectrum  Black: DOSY of 0.9 mg/mL of LPS from A. pasteurianus  
Green : DOSY of 0.9 mg/mL of A. pasteurianus in presence of 60uM of MD-2; The spectra 
were acquired in deuterated phosphate buffer at pH 7.5, 298 K, 64 scans, 32 points and d20 
= 300 ms and p30 = 4 ms. 
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Table 3.7 - Diffusion coefficient value 
 
D/m2s-1 
0.9 mg/mL LPS from A. pasteurianus 
1.064x10-11 
0.9 mg/mL LPS from A. pasteurianus + MD-2 60uM 
5.175x10-12 
 
3.4.2.2 Cryo-Electron Microscopy 
The LPS from A. pasteurianus, being an amphipathic molecule, forms 
aggregates or micelles in water solution (Figure 3.32 up). The LPS from A. 
pasteurianus generates mainly circular and homogeneous micelles with a highly 
conserved size distribution close to 60 nm. Upon addition of MD-2, some micelles 
increased the size, while others lost their circular form. In fact, the results obtained 
with Cryo-TEM are in agreement with the reduction in the diffusion coefficient 
value observed in the DOSY experiments described above. 
 
 
Figure 3.32 - Cryogenic Transmission Electron Microscopy (Cryo-TEM) of LPS from A. 
pasteurianus (0.9mg/mL) nominal magnification of 40,000 X (0.26 nm/pixel). 
LPS from Acetobacterpasteurianus (0.9mg/mL)
60nm 62nm
LPS from Acetobacterpasteurianus (0.9mg/mL)  +  hMD-2 (60µM)
112nm104nm
105nm
72nm
62nm
58nm
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Therefore, according to the NMR data, both LPSs (from Bradyrhizobium 
BTAi-1 Δshc and A. pasteurianus) interact with MD-2 protein. However, the DOSY 
experiments also showed that the two LPS molecules show a different behavior in 
the presence of MD-2. This different performance could be due to the different 
structural features of the two molecules. The LPS from Bradyrhizobium BTAi-1 
Δshc possesses two very long-chain fatty acids (VLCFA), namely 32:0 (2,31-2OH) 
and 26:0 (25-OAc) (rest 2 times 14:0, 12:0, 12:1), whereas the LPS from A. 
pasteurianus does not (18:0 (3-OH), 16:0, 14:0(3-OH), 14:0). This LPS from 
Bradyrhizobium BTAi-1 Δshc showed the smaller diffusion coefficient (5.781x10-
12 m2/s), indicating the presence of much larger aggregates than in the case of the 
LPS from A. pasteurianus (1.064x10-11 m2/s). Only in this case, MD-2 is able to 
disrupt the supramolecular aggregates. 
 
3.5 Conclusions 
In this chapter, we have described the characterization of different features 
of the interaction of glycolipids with TOLL-accessory proteins. 
The interaction of the FP7 glycolipid, a TLR4 antagonist, with known 
antimicrobial peptides (CA(1-8)M(1-18)26 and LL3730) showed that the this co-
administration enhances the antagonist potency observed for isolated FP7. Thus, in 
pathologies where inflammation is exacerbated by bacterial infection, the 
combination of anti-TLR small molecules with AMPs, as discussed here for the 
TLR4 antagonist FP7 and peptides CA(1-8)M(1-18) and LL-37, may become a 
valuable and innovative therapeutic approach. 
The characterization of the aggregation of the different glycolipids, natural 
or mimetic, showed that each molecule displays very different types of aggregation, 
which are strongly related to the different chemical features of the molecules.  
Finally, the interaction of natural LPS (from Bradyrhizobium BTAi-1 Δshc 
and A. pasteurianus) with MD-2 showed that both LPSs interact with the protein. 
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However, the DOSY experiments and Cryo-EM showed that these two LPS present 
a different behavior in presence of MD-2. The LPS from Bradyrhizobium BTAi-1 
Δshc in presence of the protein underwent disaggregation. In contrast, this is not 
the case for the LPS from A. pasteurianus.  
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3.6 Methods 
 
3.6.1 NMR experiments 
All NMR experiments were recorded on a Bruker Avance III 800 MHz 
spectrometer equipped with a TCI cryoprobe and Bruker Avance III 600 MHz 
spectrometer equipped with a TBI probe. 
The 1H NMR resonances of the peptides (CA(1-8)M(1-18)  and LL37) were 
characterized through 2D-TOCSY (75 ms mixing time) and 2D-NOESY 
experiments (300 ms mixing time). The concentration of the compounds was set to 
500 µM (LL37) and 300 µM (CA(1-8)M(1-18) ) in perdeuterated PBS 100 µM in 
H2O/D2O 90:10 with 10% DMSO, uncorrected pH meter reading 5.5. The peptide 
characterization was accomplished either at 293 K. The resonance of 2,2,3,3-
tetradeutero-3-trimethylsilylpropionic acid (TSP) was used as a chemical shift 
reference in the 1H NMR experiments (δ TSP = 0 ppm). Peak lists for the 2D-
TOCSY and 2D-NOESY spectra were generated by interactive peak picking using 
the CARA software.45  
The DOSY spectra of FP7 were recorded at 310 K with the tdDOSYccbp.2D 
pulse sequence by acquisition of 256 scans, with a diffusion time of 300 ms, a 
gradient length of 2 ms, and a gradient ramp from 5 % to 95 % in 16 linear steps. 
Additions of the peptides to the solution were then performed and new DOSY 
spectra recorded up to a molar ratio of [CA(1-8)M(1-18) ]/[FP7]=0.06 and 
[LL37]/[FP7]=0.1. 
The DOSY spectra of the isolated CA(1-8)M(1-18)  and LL37 peptides as 
blank were recorded at 310 K by acquisition of 128 scans, with a diffusion time of 
250 ms, a gradient length of 1.5 ms, and a gradient ramp from 5 % to 95 % in 16 
linear steps. Additions of the FP7 to the solution were then performed and new 
DOSY spectra recorded up to a molar ratio of [FP7]/[CA(1-8)M(1-18) ]=0.667 and 
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[FP7]/[LL37]=0.667. FP7 samples were prepared by diluting the stock solution of 
FP7 (50 mM in DMSO) with the PBS buffer 100 mM pH=5.5, with a final 10 % 
DMSO ratio. Peptide samples were prepared by dissolving the solid molecules in 
DMSO (20 mM stock solution).  
The 1H NMR experiments were recorded with an concentration of the 
compounds was set to 0.9 mg/mL (LPS from Acetobacter pasteurianus) and 1 
mg/mL (LPS from Bradyrhizobium BTAi-1 Δshc)) in perdeuterated PBS 50 mM in 
D2O, uncorrected pH meter reading 7.5, with 64 scans.  
DOSY spectra of LPS were recorded at 298 K with the ledbpgppr2s pulse 
sequence by acquisition of 64 scans, with a diffusion time of 500 ms (for LPS from 
Acetobacter pasteurianus) or 300 ms (for LPS from Acetobacter pasteurianus), a 
gradient length of 4 ms (in both cases), and a gradient ramp from 5% to 95 % in 32 
linear steps. Was used the same conditions for acquisition of the sample in presence 
of MD-2.  
 
3.6.2 Expression and Purification of MD-2 protein 
MD-2 was expressed  in Pichia pastoris, in the laboratory of Prof. Peri by 
Lenny Zaffaroni (University of Milano-Bicocca, Milano, Italy) as previously 
described.46 The MD-2 was purified by affinity chromatography (TALON Cobalt). 
A 0.5 M solution of Tris HCl pH 7.5 and 1.5 M NaCl was added to the medium to 
a final concentration of 50 mM Tris HCl and 150 mM NaCl. The Pichia medium 
containing MD-2 was incubated with 5 mL of TALON Cobalt resin (Clontech) 
previously equilibrated with the 50 mM of Tris buffer at pH 7.5, 150 mM NaCl 
overnight at 4 ºC with slow agitation. The resin was washed with 50 mL of 50 mM 
of Tris buffer at pH 7.5, 150 mM NaCl. MD-2 and eluted with 1 M imidazole in 
1.5 mL fractions, which were analyzed for protein concentration and by SDS-
PAGE. The buffer of fractions containing MD-2 were was exchange by means of 
several cycles of dilution-ultrafiltration (Vivaspin Turbo 15, 3.000 Dalton 
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molecular weight cut-off, Sartorius Stedim Biotech, Germany) to 50 mM PBS in 
deuterated water, at pH 7.5. The purity of the protein was confirmed with SDS-
PAGE electrophoresis and the yield of the purification was approximately 3 mg per 
litter of initial culture. 
 
3.6.3 Transmission Electron Microscopy 
The samples of FP7 and the antimicrobial peptides were prepared with 90 % 
of PBS 100mM in H2O and 10 % of DMSO, and 16% DMSO in the cases of FP15 
and FP18. Negative staining samples were applied to glow-discharged carbon-
coated copper grids and stained with 2 % (w/v) NANOVAN. Digital micrographs 
were taken at room temperature in low dose mode radiation on a Jeol transmission 
electron microscope operated at 100 kV and equipped with an orius camera. For 
cryo-microscopy studies the samples were vitrified on Quantifoil 2/2 grids, using 
vitrobot (FEI) and were analyzed at nitrogen liquid temperature with a TEM 
operated at 200 kV in low-dose conditions. Micrographs were taken at low radiation 
dose on a JEM-2200FS/CR transmission electron microscope JEOL, Japan) 
operated at 200 kV and equipped with an   UltraScan4000 SP (4008x4008 pixels) 
cooled slow-scan CCD camera (GATAN, UK). The samples of FP7 and the 
antimicrobial peptides were prepared with 90 % of PBS 100mM in H2O and 10 % 
of DMSO, and 16% DMSO in the cases of FP15 and FP18. And the samples of 
natural LPSs were prepared with PB (50mM) pH 7.5. 
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Final Remarks 
Besides the specific conclusions detailed in each of the chapters, the global 
conclusions are highlighted here: 
Within this work, we have provided experimental evidences that the catalytic 
events mediated by GalNAc-Ts follow induced-fit-mechanism, for which the 
presence UDP-GalNAc is essential. The long-range glycosylation preference of 
GalNAc-Ts is based on the existence of a very small flexible linker that provides 
rotational capacity to the lectin domain. On the other hand, for the short-range 
glycosylation, there is in the catalytic domain a binding site that is responsible for 
the binding of the neighboring GalNAc residue. All the GalNAc-Ts (GalNAc-T2, 
-T3 and -T4) studied herein glycosylate in a highly-ordered form the MUC1 
substrate, and the MUC1 TR domains are fully O-glycosylated in a stepwise 
manner. The interplay between the lectin and the catalytic domains is essential for 
the catalysis of all the glycosylation sites of MUC1. 
Additionally, we have also been studying different molecular recognition 
features related to innate immunity processes. We have characterized the 
supramolecular structures of a variety of natural and synthetic molecules, TLR4- 
agonists or -antagonists, by using a combination of NMR and biophysical methods. 
In particular, the co-administration of the so-called FP7 glycolipid, a TLR4 
antagonist, with antimicrobial peptides (CA(1-8)M(1-18) and LL37) enhances the 
antagonist potency observed for isolated FP7. Moreover, the characterization of the 
aggregation of different glycolipids have shown the possibility of existence of very 
different types of aggregation, which are strongly related to the different chemical 
features of the molecules.  
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